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Natural IgM secretion in health and disease: genetic control and role in type 1 diabetes 
 
Abstract 
Germline-encoded autoreactive natural antibodies (NAbs) of the IgM isotype are secreted 
and circulate as a result of basal immune system stimulation, and constitute an important first 
line of defense against microorganism invasion, bridging the innate and the adaptive immune 
responses. NAbs are mostly secreted by positively selected B1a cells, and have been 
claimed to have a protective role against autoimmunity. Nevertheless, NAbs binding to cell 
surface self-antigens could have implications in the initiation of autoimmunity. 
Article I focused on the genetic control of NAbs secretion in healthy mice. Importantly, 
interferon regulatory factor 4 (Irf4), a transcription factor required for plasma cell 
differentiation and antibody secretion, was identified as the most probable candidate for the 
control of homeostatic serum IgM levels in the mouse.   
Type 1 diabetes (T1D) is a complex autoimmune disease that develops spontaneously in 
humans and is pathogenically similar in the non-obese-diabetic (NOD) mouse model. B cells 
are necessary in the NOD diabetogenic process, and the presence of anti-pancreatic beta 
cell antibodies is the earliest manifestation of T1D. 
Article II revealed that NOD peritoneal cavity B1a cells are more prone to spontaneously 
secrete NAbs that recognize pancreatic beta cell autoantigens, which could promote T1D 
either by enhancing professional antigen presentation of islet antigens, by activating the 
complement cascade or by directly promoting beta cell damage and self-antigens release. 
The studies reported in article III have explored these possibilities and have proven that 
NAbs of NOD B1a cells origin could bind and directly induce oxidative stress on pancreatic 
beta cells. Moreover, these studies have shown that NOD B1a cells have a lower threshold 
for innate-like stimulation and have established a link between NOD B1a cells properties, 
NAbs specificities and impact of IgM binding on beta cells physiology. Finally, article IV 
provides evidence that early treatment with antibodies that evoke NOD B1a cells proliferation 
and differentiation into IgM secreting cells correlates with T1D precipitation. 
In conclusion, this thesis has shown that Irf4 is a critical player in the genetic network that 
controls IgM secretion in healthy individuals, and that in the NOD mouse model of T1D, a 
lower threshold for innate like stimulation of peritoneal cavity B1a cells contributes to a 
naturally increased state of B1a cells activation and autoreactive IgM secretion, determining 
the initiation and/or contributing to the fueling of beta cells autoimmunity.  
 
Keywords: Autoimmunity, autoreactive natural antibodies of the IgM isotype, B1a cells, 
genetic control, innate immune system, interferon regulatory factor 4, non-obese-diabetic 












































Secreção de IgM natural na saúde e na doença: controlo genético e papel na diabetes tipo 1 
 
Resumo 
Os autoanticorpos naturais (NAbs) da classe IgM existem no organismo na ausência de 
imunização e constituem uma primeira linha de defesa fundamental contra infecções. Os 
NAbs são secretados maioritariamente por células B1a e a sua ligação a autoantigénios na 
superfície celular pode ter implicações para a iniciação de autoimunidade. O trabalho 
descrito no artigo I focou-se na compreensão do controlo genético da secreção de NAbs em 
murganhos saudáveis. Este estudo identificou o interferon regulatory factor 4 (Irf4), um factor 
de transcrição necessário para a diferenciação de plasmócitos e secreção de anticorpos, 
como o candidato mais provável para o controlo da homeostasia dos níveis de IgM 
circulante no murganho.   
A diabetes tipo 1 (T1D) é uma doença autoimune complexa que se desenvolve 
espontaneamente nos humanos e que tem uma patogenia semelhante no murganho NOD 
(non-obese-diabetic). Os linfócitos B são necessários para o processo diabético do NOD, em 
que a presença de anticorpos anti-células beta pancreáticas é uma das manifestações mais 
precoces. O artigo II revelou que as células B1a da cavidade peritoneal do NOD têm uma 
elevada predisposição para secretarem NAbs que reconhecem autoantigénios de células 
beta pancreáticas e que podem promover o desenvolvimento de T1D quer pelo aumento da 
apresentação de autoantigénios, quer pela activação da cascata do sistema de 
complemento, quer pela indução directa de danos nas células beta pancreáticas. A 
investigação descrita no artigo III provou que os NAbs secretados por células B1a do NOD 
têm a capacidade de se ligarem e induzirem stress oxidativo nas células beta do pâncreas. 
Estes estudos revelaram ainda que as células B1a do NOD têm um limiar reduzido para 
activação inata e estabeleceram uma relação entre as propriedades das células B1a do 
NOD, as especificidades dos NAbs e o impacto da ligação de IgM na fisiologia das células 
beta. Finalmente, o artigo IV evidenciou que a indução de proliferação e diferenciação das 
células B1a em células secretoras de IgM contribui para o início da T1D.  
Esta tese demonstrou que o Irf4 é um factor de transcrição com um papel fundamental no 
controlo da secreção de IgM em animais saudáveis e que, no murganho NOD, as células 
B1a da cavidade peritoneal têm um menor limiar para estimulação inata, que contribui para 
o seu estado de activação e para a secreção de IgM autoreactiva, determinando a iniciação 
e/ou contribuindo para a progressão da diabetes tipo 1.  
 
Palavras-chave: Autoanticorpos naturais da classe IgM, autoimunidade, células B1a, 
células beta pancreáticas, controlo genético, diabetes tipo 1, interferon regulatory factor 4, 
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Chapter I. General Introduction 
 
1. Immune surveillance by natural IgM  
 
The study of antibodies started in 1900, when Paul Ehrlich discovered that animals could be 
immunized against diphtheria and that the resulting animal antisera could be used to protect 
children against this disease (Ehrlich, 1900a; Ehrlich, 1900b). Ehrlich assumed that 
molecules in the sera of infected animals recognized and eliminated bacterial particles and 
he predicted that the immune system would not only eliminate microbial invaders, but would 
also inhibit the growth of tumors, by providing antibodies against malignant cells (Ehrlich, 
1902). These theories were explored by Burnet, seven decades later, who first defined the 
immune surveillance concept as “an evolutionary necessity” (Burnet, 1970), and nowadays it 
is well established that nature has created an effective immune program in which antibodies 
are main players in mediating critical immune functions in vertebrates. 
 
 
1.1. Innate and adaptive immune responses 
 
An immune reaction is composed of an inherited, unspecific, immediate response and of a 
secondary one, which is adaptive and as so specific, that includes the generation of memory 
cells. The recognition system of the innate response works through a set of germ-line 
encoded pattern recognition receptors (PRRs), prominently toll-like receptors (TLRs) 
(Medzhitov, 2001). These receptors recognize specific patterns of antigens, termed 
pathogen-associated molecular patterns (PAMPs), like carbohydrates on glycoproteins and 
glycolipids, and repetitive structures as those found in bacterial lipopolysaccharide (LPS)  
and nucleic acids (Akira, Uematsu, & Takeuchi, 2006; Hemmi et al., 2000; Janeway & 
Medzhitov, 2002; Lund, Sato, Akira, Medzhitov, & Iwasaki, 2003; Medzhitov & Janeway, 
2000; Pasare & Medzhitov, 2005). Importantly, some of the factors released by damaged or 
dying cells, termed damage-associated molecular pattern molecules or DAMPs, also interact 
with TLRs, meaning that TLR activation may occur even in the absence of invasion by 
pathogens (Rubartelli & Lotze, 2007). As an example, TLR4 is part of the receptor for the 
bacterial product LPS, but also responds to the endogenous cellular molecule 70 kilodalton 
heat shock protein (Hsp70) and to the extracellular breakdown products of hyaluron, while 
TLR9 binds to DNA unmethylated CpG sequences that, although in different proportions, are 
found in all living creatures (Matzinger, 2002). This extremely important recognition system 
guarantees that a rapid immune response may be initiated upon the detection of structures 
that are most likely involved in primary cell stability and cell preservation mechanisms.  
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TLRs are expressed on various immune cells, including macrophages (Hausmann et al., 
2002; Kim et al., 2009), dendritic cells (DCs) (Iwasaki & Medzhitov, 2004), B cells (Genestier 
et al., 2007), T cells (Kulkarni, Behboudi, & Sharif, 2011), and even on non-immune cells 
such as epithelial cells (Abreu, Fukata, & Arditi, 2005). The expression of TLRs is not static, 
but rather is modulated rapidly in response to pathogens, a variety of cytokines, and 
environmental stimuli. Furthermore, TLRs may be expressed extra- or intracellularly. While 
certain TLRs (TLRs 1, 2, 4, 5, and 6) are expressed on the cell surface, others (TLRs 3, 7, 8, 
and 9) are found almost exclusively in intracellular compartments such as endosomes, and 
their ligands require internalization to the endosome before signaling is possible (Akira et al., 
2006). TLR stimulation recruits adaptor proteins containing a  Toll/Interleukin-1 receptor 
(TIR) domain, such as myeloid differentiation factor 88 (MyD88) and TIR-domain-containing 
adapter-inducing interferon-β (TRIF) (Akira & Takeda, 2004), resulting in the triggering of 
downstream signaling cascades that rapidly induce the expression of genes involved in the 
inflammatory and immune responses. As an example, MyD88 signaling pathway modulates 
the activation of the transcription factor nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-B), mitogen-activated protein (MAP) kinases and the transcription 
factor interferon regulatory factor 5 (Irf5), leading to the production of pro-inflammatory 
cytokines (Akira et al., 2006; Takaoka et al., 2005).  While the activation of the TRIF 
signaling pathway induces type-I interferon (IFN) production and pro-inflammatory signals, 
leading to DCs maturation, expression of co-stimulatory molecules, and IFN-/ secretion 
(Akira et al., 2006; Hoebe et al., 2003; Hoshino, Kaisho, Iwabe, Takeuchi, & Akira, 2002; 
Kaisho, Takeuchi, Kawai, Hoshino, & Akira, 2001; Yamamoto et al., 2003). Upon TLR 
activation the source of infection can be immediately eliminated by macrophage and DC 
mediated phagocytosis (Blander & Medzhitov, 2004) or neutralized by immunoglobulins of 
the IgM isotype, secreted mostly by B1a and marginal zone B cells (Genestier et al., 2007). 
Furthermore, activated antigen-presenting cells (APCs) contribute to the initiation of the 
adaptive immune response by migrating from the site of stimulation to the regional lymph 
nodes, where they express co-stimulatory molecules and present antigens to naïve CD4+ T 
cells, inducing their activation (Akira, Takeda, & Kaisho, 2001; Medzhitov, Preston-Hurlburt, 
& Janeway, 1997). Consequently, the interaction of activated CD4+ T cells with B cells in the 
germinal centers (GC) determines the increase of the B cell receptor (BCR) affinity for the 
cognate antigen by somatic hypermutation of their variable region (V) exons and change of 
their immunoglobulin (Ig) heavy chain (IgH) class by Ig class switch recombination from IgM 
to IgA, IgE or IgG. GC B cells with high-affinity and class-switched BCRs can then develop 
either into memory B cells or antibody-secreting plasma cells, fundamental components of 
protective adaptive immunity (LeBien & Tedder, 2008; Oracki, Walker, Hibbs, Corcoran, & 
Tarlinton, 2010; Radbruch et al., 2006). Therefore, the innate response triggered upon TLR 
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activation is a key element in inflammation as well as in the initiation of adaptive immunity 
against invading pathogens (Akira et al., 2006). 
 
 
1.2. Natural IgM bridges the innate and the adaptive immune system 
 
Antibodies of the IgM isotype perform a wide range of actions in the immune system having 
an important role in the primary defense mechanisms as suggested by the high 
concentration of IgM found in human cord blood, germ free mice and healthy individuals in 
the absence of immunization  (Avrameas, 1991; Casali & Schettino, 1996; Coutinho, 
Kazatchkine, & Avrameas, 1995; Pereira et al., 1986; Tlaskalová-Hogenová et al., 1992). 
These so denominated “natural antibodies” (NAbs) are characterized by low antigen affinity, 
relatively high avidity and polyreactivity, providing the organism with a first line of defense 
against the invasion by foreign microorganisms (Boes, Prodeus, Schmidt, Carroll, & Chen, 
1998). NAbs are mainly encoded by germline V gene segments and have a low percentage 
of nontemplated nucleotide (N)-additions. This lack of somatic mutations results in a 
restricted repertoire of reactivities and consequently NAb recognize phylogenetically 
conserved structures, such as nucleic acids, heat shock proteins, carbohydrates, and 
phospholipids (Carmack, Shinton, Hayakawa, & Hardy, 1990; Gu, Förster, & Rajewsky, 
1990; Kantor & Herzenberg, 1993; Hardy & Hayakawa, 1994).  
Natural IgM has been claimed to bridge the innate and the adaptive immune system, since 
the binding of IgM to previously unfamiliar antigens may mediate their direct neutralization 
and also contribute to the mounting of affinity-matured IgG responses to T cell-dependent 
antigens (Ehrenstein, O’Keefe, Davies, & Neuberger, 1998). Importantly, antigen-IgM 
complexes potently induce the activation of the complement pathway (Brown et al., 2002), an 
event that is central to the initiation of the adaptive immune response (Fearon & Locksley, 
1996; Klaus, Humphrey, Kunkl, & Dongworth, 1980; Pepys, 1972). In fact, a single IgM 
pentamer can trigger the classical pathway of complement activation as efficiently as a 
thousand molecules of IgG (Cooper, 1985). Therefore, naturally secreted IgM is able to 
primarily defend the organism against pathogens to which it is unspecific, while sustaining 
the first steps of an antigen directed specific immune response.  
 
 
1.3. Natural IgM regulates the homeostasis of the B cell compartment 
 
Natural IgM has also an important role in the regulation of B cell homeostasis, by controlling 
their longevity and turnover, as elegantly demonstrated in studies performed on the S- 
mouse, which lacks circulating but not B cell membrane bound IgM (Notley, Baker, & 
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Ehrenstein, 2010). It is well established that BCR signaling is an essential component for B 
cell survival (Fuentes-Pananá, Bannish, & Monroe, 2004), however while the reduction on 
basal BCR signaling observed in S- mice results in impaired mature B cell survival and 
increased turnover in the spleen, enhanced B cell subsistence is observed in the peritoneal 
cavity (Notley et al., 2010). As a consequence of these and possibly other regulatory features 
of natural IgM, follicular B cell (FO) numbers are reduced in the S- mouse (Baker & 
Ehrenstein, 2002), while peritoneal B1 cells (Boes, Esau, et al., 1998; Ehrenstein et al., 
1998) and splenic marginal zone B cell (Mz) numbers are increased (Baker & Ehrenstein, 
2002). These observations allow presuming that different B cell subpopulations have distinct 
thresholds for BCR responsiveness and survival. 
 
 
1.4. Natural IgM and autoimmunity 
 
Natural IgM has been shown to bind apoptotic cells/debris and contribute to the clearance of 
autoantigens from the organism through C1q binding mechanisms (Chen, Park, Patel, & 
Silverman, 2009; Ogden, Kowalewski, Peng, Montenegro, & Elkon, 2005; Quartier, Potter, 
Ehrenstein, Walport, & Botto, 2005). Since apoptotic cells provide a potential source of 
immunogens for the development of autoreactivity, this property has been associated with a 
protective role for natural IgM against autoimmunity in several models of systemic lupus 
erythematosus (SLE) (Manson, Mauri, & Ehrenstein, 2005). Nevertheless, it is still 
controversial whether IgM would always provide the organism with this shielding effect. 
Given that a high proportion of natural IgM is self-reactive (Casali & Notkins, 1989; Hardy, 
Carmack, Li, & Hayakawa, 1994; Kantor & Herzenberg, 1993), it is reasonable to expect that 
the binding of IgM to a surface self-antigen could directly mediate apoptosis of the target cell 
(Brändlein et al., 2003; Varambally et al., 2004) or result in the activation of the complement 
cascade, which in turn would contribute to a pathogenic autoantibody response. 
Furthermore, it has been claimed that highly abundant IgM autoantibodies can rescue the 
development of autoreactive follicular and marginal zone B cells, by masking tolerogenic self-
antigens (Ferry, Crockford, Leung, & Cornall, 2006). Hence, it is plausible that, in certain 
instances, natural autoreactive IgM would have a role in the predisposition to autoimmunity. 
 
 
2. Genetic control of natural IgM secretion 
 
The capacity for immunoglobulin secretion is acquired in the process of terminal B-cell 
differentiation to plasma cells (Calame, Lin, & Tunyaplin, 2003) and requires the expression 
of the transcription factor interferon regulatory factor 4 (Irf4) (Klein et al., 2006), a member of 
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the interferon-regulatory factor family (Mamane et al., 1999) that is required for lymphocyte 
proliferation (Mittrücker et al., 1997) and has an inhibitory role on interferon-induced 
transcription (Yamagata et al., 1996). Irf4 expression is restricted to cells of the immune 
system (Marecki & Fenton, 2002; Pernis, 2002), playing a critical role in both early 
(Mittrücker et al., 1997) and late B-cell differentiation (Klein et al., 2006). Moreover, the role 
that Irf4 plays in the differentiation of plasma cells is complex, highly regulated, and 
interdependent on the sequential expression of several transcription factors that are also 
crucial for the generation of antibody secreting cells (Figure I.1). 
 
 
Figure I.1 IRF4 upregulation initiates the differentiation of mature B cells into antibody 
secreting plasma cells 
 
The co-expression of MITF, BCL6 and PAX5 maintains naïve B cells in a resting state while, upon B 
cell stimulation, the activation of the REL/NF-B pathway initiates the transcription of IRF4 and 
consequently induces the expression of BLIMP1 and XBP1, leading resting B cells to a plasma cell 
fate. Induction: (); Inhibition: (    ). 
 
 
2.1. IRF4 plays a central role in the differentiation of plasma cells and in antibody 
secretion  
 
Irf4 transcription is induced by antigen receptor or mitogen stimulation (Sciammas et al., 
2006), is dependent on the binding of complexes of the transcription factors Rel/NF-B to 
two kappa-light-chain-enhancer of activated B cells (B) elements located in the Irf4 
promoter (Grumont & Gerondakis, 2000) and is repressed by the microphthalmia-associated 
transcription factor (Mitf), which is highly expressed on naive B cells, antagonizing the 
process of terminal B cell differentiation (L. Lin, Gerth, & Peng, 2004). When expressed, the 
IRF4 transcription factor binds to a motif in the Ig light (IgL) chain gene enhancers E3’, E2-4, 
and E3-1, playing an essential role in immunoglobulin production (Eisenbeis, Singh, & Storb, 
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1995). Also, IRF4 directly downregulates the expression of Bcl6 (B-cell leukemia/lymphoma-
6), a transcription factor that is necessary for the germinal center events to occur (Saito et 
al., 2007), inhibiting its repression effect on Prdm1 (the gene encoding B lymphocyte inducer 
of maturation program 1 or BLIMP1). BLIMP1 is a master regulator of terminal B cell 
differentiation whose upregulation represses the expression of paired box gene 5 (Pax5), 
allowing the transcription of genes in the immunoglobulin joining segments (IgJ)   as well as 
in the IgH chain and IgL chain loci (K.-I. Lin, Angelin-Duclos, Kuo, & Calame, 2002; Shaffer, 
Peng, & Schlissel, 1997; Singh & Birshtein, 1996; Rinkenberger, Wallin, Johnson, & 
Koshland, 1996). Pax5 expression is required  to maintain B-cell identity (Cobaleda, 
Schebesta, Delogu, & Busslinger, 2007), it directly represses the transcription of components 
of the antibody-secreting-cell pathway such as  genes encoding for IgJ (Rinkenberger et al., 
1996) and Xbp1 (X-box binding protein-1) (Reimold et al., 1996), which are crucial for 
immunoglobulin secretion and plasma cell development  (Reimold et al., 2001; Shaffer et al., 
2004). Once upregulated, Prdm1 also inhibits Bcl6 (Tunyaplin et al., 2004), and induces the 
expression of Irf4  (Kallies et al., 2004; Sciammas & Davis, 2004) and OBF1, a B 
lymphocyte-specific transcription factor (Shaffer et al., 2002; Shaffer et al., 2004) that 
regulates the transcription and recombination of IgL chain  genes (Casellas et al., 2002). 
Furthermore, the switch to expression of mRNA that encodes the secreted form of the µ IgH 
chain requires BLIMP1 (Shapiro-Shelef et al., 2003). Thus, Irf4 upregulation initiates a 
cascade of events that culminate in the differentiation of plasma cells and in antibody 
secretion (Figure I.1). Importantly, in the context of this thesis (article I), we have identified 
Irf4 as the most probable candidate for the control of homeostatic serum IgM levels in the 
mouse. In this work we have demonstrated that, in the absence of deliberate stimulation, 
BALB/c mice have significantly higher levels of circulating IgM when compared to C57BL/6. 
Further, by performing a genome-wide screen and quantitative trait loci (QTL) analysis on a 
C57BL/6xBALB/c F2 generation, we have identified a region on mouse chromosome 13 that 
contained a locus (loci) controlling IgM serum levels. Importantly, this genomic region 
encompassed the Irf4 locus, and we were able to correlate higher levels of serum IgM with 
increased differentiation of IgM secreting B cells and Irf4 expression.  
 
 
3. B1a cells, the main natural IgM secretors 
 
Different B cell subsets have been characterized in the mouse coelomic cavities and spleen, 
based on multiple surface markers, origin and functions (Table I.1).  
B1 cells are enriched in the peritoneal and pleural cavities, express low surface levels of 
B220 and CD11b and are classically subdivided into CD5+ B1a and CD5- B1b subsets 
(Herzenberg, 2000).  Although commonly overlooked, a subset of CD11b-CD5+ peritoneal 
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B1c cells has also been recently described (Hastings, Gurdak, Tumang, & Rothstein, 2006). 
B1a cells derive from fetal liver precursors and spontaneously secrete natural autoantibodies 
of the IgM isotype (NAbs) (Hayakawa, Hardy, Herzenberg, & Herzenberg, 1985; Herzenberg, 
2000), while B1b cells are generated from neonatal bone marrow progenitor cells (Stall, 
Wells, & Lam, 1996) and can rapidly respond to exogenous antigens (Martin, Oliver, & 
Kearney, 2001; Ochsenbein et al., 1999). The less studied B1c population appears earlier in 
ontogeny and is believed to contain both B1a and B1b progenitors (Ghosn, Yang, Tung, 
Herzenberg, & Herzenberg, 2008) and cells that have not yet fully differentiated into the 
typical CD11b+ B1 phenotype (Hastings et al., 2006). Importantly, CD19+CD11b-CD5- B2 
cells with an intermediate functional phenotype between peritoneal B1b and splenic B2 cells 
are also present in the peritoneal cavity (Hastings, Tumang, Behrens, & Rothstein, 2006). 
B1 cells characterized by the CD11b-IgMhighB220lowCD5+ surface phenotype that 
spontaneously secrete natural antibodies (Holodick, Tumang, & Rothstein, 2010) and that 
respond quickly to innate stimulation (Fischer et al., 2001) are also found in the spleen, 
although in lower frequencies and with extensive differences when compared to their 
peritoneal counterparts (Tumang, Hastings, Bai, & Rothstein, 2004; Wells, Kantor, & Stall, 
1994). However, the spleen is mostly enriched for conventional or B2 cell sub-populations 
that include FO B cells and the less abundant Mz B cells. Splenic B2 cells arise 
predominantly during adult life (Carey, Moffatt-Blue, Watson, Gavin, & Feeney, 2008) and 
while CD23+CD21- FO B cells are the main players in the adaptive humoral immune 
response, the IgMhighCD23-/lowCD21high Mz B cells, along with B1 cells, are part of the natural 
immune system response, acting as a first and rapid line of defense against bacterial 
pathogens (Martin & Kearney, 2002). 
 
 
3.1. B1a cells are functionally different from conventional B cells 
 
Conventional B cells are predominantly generated in adult life, from bone marrow precursors, 
through a process of negative selection which ensures that only non-autoreactive B cells exit 
to the periphery (D. Nemazee, 2000; Seagal & Melamed, 2003). So, during development, B 
cells that react with self-antigens are removed in the bone marrow by mechanisms that 
include anergy (Brink et al., 1992; Goodnow, Crosbie, Jorgensen, Brink, & Basten, 1989; 
Hartley et al., 1991), receptor-editing, particularly on the Ig light chain (Casellas et al., 2001; 
D. Nemazee, 2000; Yachimovich, Mostoslavsky, Yarkoni, Verbovetski, & Eilat, 2002), and 
clonal deletion (D. A. Nemazee & Bürki, 1989; D. Nemazee & Buerki, 1989). In contrast, B1a 
cells develop mostly early in ontogeny and are positively selected through their BCR (Ferry 
et al., 2006; Hayakawa et al., 1999). The BCRs of B1a cells are encoded by a relatively 
restricted set of light and heavy chain rearrangements, including heavy chains that lack N 
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region insertions at the V (Variable)-D (Diverse) and D (Diverse)-J (Joining) gene segment 
junctions. These phenomena contribute to the maintenance of a limited and germ line 
programmed repertoire (Kantor, Merrill, Herzenberg, & Hillson, 1997; Rowley, Tang, Shinton, 
Hayakawa, & Hardy, 2007) throughout adult life, when B1a cells are predominantly 
maintained by their “self-renewing” properties. In fact, it has been shown that adult B1a cells 
are able to repopulate the peritoneal cavity of allotype-congenic mice and irradiated mice as 
efficiently as fetal liver progenitors, while the same was not observed when B cell progenitors 
from the bone marrow were transferred to the same recipients (Förster & Rajewsky, 1987; 
Hayakawa, Hardy, Stall, Herzenberg, & Herzenberg, 1986).  
 
 
Table I.1 Principal features of the predominant B cell subsets in the peritoneal cavity 
and spleen of the mouse 
 
The location, origin, type of selection, cell surface phenotype and function of peritoneal cavity B1a, 
B1b, B1c and B2, and of splenic B1, marginal zone (Mz) and follicular (FO) B cells are summarized. 
 
 
B1a cells differ functionally from conventional B cells in several ways. A distinctive property 
of B1a cells is the ability to spontaneously secrete IgM in the absence of specific 
immunization or T cell help (Casali & Schettino, 1996). Therefore, the maintenance of a 
restricted repertoire of B1a cells throughout life warrants a stable reactivity pattern of 
circulating natural IgM. Additionally, “resting” B1a cells present antigen to T cells more 
efficiently than conventional B cells, strongly promoting T cell proliferation, cytokine secretion 
and the differentiation of naive (Foxp3–CD4+) T cells into type 1 helper T cells (Th1) and type 
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17 helper T cell (Th17) pro-inflammatory cells, in marked contrast to conventional antigen-
presenting B cells which favor the differentiation of naive (Foxp3–CD4+) T cells into Foxp3+ 
regulatory T cells (Zhong et al., 2007). Furthermore, B1a cells display evidence of tonic 
signaling in a “steady” state, namely due to the constitutive activation of signal transducer 
and activator of transcription 3 (STAT3) (Karras et al., 1997), extracellular signal-regulated 
kinase (ERK) and nuclear factor of activated T-cells (NF-AT) (S.-C. Wong et al., 2002). The 
activation of these molecules occurs normally after BCR stimulation (Healy et al., 1997; 
Sutherland, Heath, Pelech, Young, & Gold, 1996; Wang, Kurosaki, & Corey, 2007), and has 
been shown to have implications for cell growth, proliferation and differentiation (Marshall, 
1995; Peng, Gerth, Ranger, & Glimcher, 2001; Tarakhovsky, 1997). Thus, it can be 
hypothesized that their steady state level of activation on B1a cells has implications on the 
activity of this cell subset in the absence of external immunization. 
  
 
3.2. BCR signaling on B1a cells physiology 
 
BCR signaling has a double-edged sword role in B1a cell physiology. While robust BCR 
stimulation induces proliferation in conventional B cells, the same stimulus induces weak 
proliferative responses in mature B1a cells (Martin & Kearney, 2001). Conversely, during 
development, B1a cells positive selection requires strong BCR engagement by self-antigen 
and a certain degree of BCR signaling is also critical for B1a cells survival (Ahearn et al., 
1996; Casola et al., 2004; Hayakawa et al., 1999; Leitges et al., 1996;  Rickert, Rajewsky, & 
Roes, 1995; Tsukada, Rawlings, & Witte, 1994). Thus, positively selected B1a cell 
subpopulation has a naturally high autoreactive potential that is heavily compensated by the 
incapacity to respond to BCR stimulation.  
Surface expressed CD5 controls B1a cell proliferation upon BCR engagement (Bikah, Carey, 
Ciallella, Tarakhovsky, & Bondada, 1996) and it has been speculated that this molecule does 
so by recruiting the tyrosine phosphatase Src homology phosphatase-1 (SHP-1), an 
intracellular negative regulator, to the BCR complex (Tarakhovsky, 1997). CD22 and Siglec-
G are two members of the sialic acid–binding immunoglobulin-like lectin protein family 
(Siglec) that are expressed in a B cell–restricted way and are able to inhibit BCR signaling 
through mechanisms which are also thought to be SHP-1 dependent (Crocker, Paulson, & 
Varki, 2007; Jellusova, Wellmann, Amann, Winkler, & Nitschke, 2010; Nitschke, 2009). In 
fact it has been shown that B1a cells and serum autoreactive IgM accumulate in mice that 
carry mutations on the Shp-1 (O’Keefe, Williams, Davies, & Neuberger, 1996; Shultz et al., 
1993; Sidman, Shultz, Hardy, Hayakawa, & Herzenberg, 1986), Cd22  or Siglec-G genes 
(Hoffmann et al., 2007). On the other hand, several studies have clearly shown that BCR 
signaling is essential for B1a cells survival. Actually, mice deficient on CD19, CD21, Bruton's 
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tyrosine kinase (Btk) or protein kinase C β (PKCβ) have virtually no B1a cells in their 
peritoneal cavities (Tsukada, Rawlings, & Witte, 1994). These mice models share a deficient 
BCR activation signaling pathway since CD19 and CD21 proteins amplify IgM-mediated 
signaling (Carter & Fearon, 1992; Fearon & Carter, 1995), while Btk and PKCβ are activated 
upon BCR cross-linking (Leitges et al., 1996; Rawlings & Witte, 1995). Thus, it could be that 
CD5, SHP-1, CD22 and/or Siglec-G keep the threshold of the antigen receptor mediated 
activation of B1a cells at a level insufficient to induce their proliferation, but sufficient to 
provide signals that promote the survival of B1a cells. On the other hand, the expression of 
CD19 and CD21 might be essential for the amplification of survival signals mediated by the 
Btk/PKCβ signal transducing pathway (Tarakhovsky, 1997). 
The expression of CD5 on B1a cells has a dual regulatory role. While down-modulating the 
B1a cell responsiveness to BCR mediated signaling (Bikah et al., 1996), and by this way 
controlling the production of a potentially autoreactive antibody repertoire, CD5 favors the 
secretion of interleukin-10 (IL10) by this cell subset (Gary-Gouy et al., 2002). In fact, B1a 
cells are major secretors of IL10 (O’Garra et al., 1992), a cytokine that contributes to the 
balance of type 1 and type 2 helper T cell (Th1/Th2) responses, that inhibits pro-
inflammatory cytokine production by monocytes and macrophages, and that controls the 
proliferation of antigen-specific CD4+ T cells by suppressing the antigen presenting capacity 
and decreasing co-stimulatory molecule expression by professional antigen-presenting-cells 
(DiLillo, Matsushita, & Tedder, 2010). Thus, through the secretion of IL10, B1a cells 




3.3. B1a cells response to innate-like stimulation 
 
CD5 expressing B1a cells respond poorly to BCR stimulation, but their activation status, 
proliferation, antibody secretion capacity and migration is strongly influenced by the gut 
microflora modifications and by innate-like stimulation through TLR (Alam et al., 2011; Alam, 
Valkonen, Palagani, et al., 2010; Genestier et al., 2007; Gururajan, Jacob, & Pulendran, 
2007; Ha et al., 2006). B1a cells express several TLRs, which play a central role as sensors 
of infection and inducers of innate and adaptive immune responses (Kiyoshi Takeda, Kaisho, 
& Akira, 2003). Additionally, peritoneal B1 cells express CD9 (Won & Kearney, 2002) a 
membrane protein of the tetraspanin superfamily that is known to regulate cell motility 
(Hemler, 2005), and high levels of α4, α6, and β1 integrins  that are involved in cell adhesion. 
Importantly, it has been shown that TLR stimulation of peritoneal B1 cells results in 
proliferation, differentiation to antibody secreting cells and the coordinated downregulation of 
integrin-CD9, resulting in a rapid and efficient mobilization of these cells from the peritoneal 
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cavity to other lymphoid organs (Ha et al., 2006). B1 cell migration from the peritoneal cavity 
was also shown to be reduced in germ-free mice, when compared with mice kept under 
specific pathogen free conditions that harbor a diverse gut microbiota (Ha et al., 2006). So, it 
is feasible that TLR signals control B1 cell recruitment and participation not only in acute 
responses, but also in steady-state conditions for the maintenance of immune system 
homeostasis. 
Further, B1a cells are involved in the production of gut IgA, that is generated through a 
primitive T independent and follicular-independent pathway, and play an important role in the 
regulation of bacterial communities in the intestine (Fagarasan et al., 2002; Fagarasan, 
Kinoshita, Muramatsu, Ikuta, & Honjo, 2001; Macpherson et al., 2000; Suzuki et al., 2004). It 
is thus tempting to speculate that B1 cells surveying the abdominal cavity may be sensing 
the gut microbiota through TLRs, which are constantly contributing to their functional status. 
Importantly, TLRs can recognize both exogenous (PAMPs) and endogenous (DAMPs) 
molecules. Therefore, it can be speculated that peritoneal cavity B1a cells TLRs stimulation 
could occur either by gut derived microbial signals or ligands resulting from damaged or 
dying cells, and be instrumental in their secretory functions. 
 
 
3.4. B1a cells across animal species 
 
Notably, human B1a cells, with the capacity for spontaneous IgM secretion, efficient T cell 
stimulation, and tonic intracellular signaling, have recently been identified in both the 
umbilical cord and the adult peripheral blood. These cells are largely CD5+ and were 
characterized according to their cell surface phenotype as CD20+CD27+CD43+CD70- cells 
(Griffin, Holodick, & Rothstein, 2011). Thus, studies of B1a cells in mice may provide insight 
on human B1a cells properties and immunological roles, since they widely share cell surface 
markers and functional properties.  
CD5+ B cells have also been described in cattle, sheep, pigs, rabbits and chickens, where 
important species-related differences were found.  In contrast with the relative low numbers 
(15–30%) of CD5 expressing B cells existing within the human (Griffin et al., 2011), mouse 
(chapter VI, article III) and pig B cell populations (Wilson & Wilkie, 2007), CD5 is expressed 
at low levels on all B-cells in the rabbit (Raman & Knight, 1992), chicken (Koskinen, Göbel, 
Tregaskes, Young, & Vainio, 1998) and cattle (Naessens, 1997), while in sheep the 
percentages of CD5+ B cells may vary tremendously between animals and within the same 
individual in time (16-82%) (Chevallier et al., 1998). 
In cattle and sheep CD5+ B cells share important characteristics with murine B1a cells. 
Namely, they express low levels of IgD (Naessens, 1997), have a similar tissue distribution 
and express CD11b on their surface (Naessens & Williams, 1992). Also, rabbit CD5+ B cells 
12 
 
express a restricted repertoire of variable genes of Ig heavy chain (VH) and have been 
suggested to be functionally homologous to murine B1a cells (Becker, Suter, & Knight, 1990; 
Knight & Becker, 1990). On the other hand, functional analysis of CD5 expressing cells has 
shown that this cell surface marker cannot be used to discriminate B1 and B2 cell 
subpopulations in pigs (Wilson & Wilkie, 2007). Finally, chicken B cells largely resemble 
mouse B1a cells, in that they have a generalized expression of CD5, are generated during a 
limited period of time (in the bursa of Fabricius) and are maintained by self-renewal in adult 
life (Pink, 1986). Although these reports clearly show that B1a cells are present across 
animal species, further studies are needed to better understand the properties of this B cell 
subpopulation in these and other species. 
 
 
4. Mechanisms of immune tolerance 
 
The immune system has a remarkable capacity to maintain a state of equilibrium. The 
discrimination of self and non-self-antigens is critical for the mounting of immune responses 
against invading microorganisms while preventing autoimmunity. In healthy individuals, the 
absence of immune response against self-antigens is known as immune tolerance or self-
tolerance (Daniel, Nolting, & von Boehmer, 2009; Waldmann, 2010). During development, 
lymphocytes with receptors capable of recognizing self-antigens are constantly being 
generated. Before immunization, the maintenance of the pool of naïve B cells (Fuentes-
Pananá et al., 2004; Lam, Kühn, & Rajewsky, 1997) and T cells (Brocker, 1997; Kirberg, 
Berns, & von Boehmer, 1997; Rooke, Waltzinger, Benoist, & Mathis, 1997; Takeda, 
Rodewald, Arakawa, Bluethmann, & Shimizu, 1996) is dependent on antigen receptor–
mediated signals. Thus, avoiding autoimmune reactions to continuously presented self-
antigens requires effective mechanisms for preventing and terminating lymphocyte 
responses (Daniel et al., 2009; Waldmann, 2010) (Table I.2). 
 
 
4.1. Immune tolerance in the B cell compartment 
 
4.1.1 Conventional B cells 
 
During adult life, B lymphocyte lymphopoiesis occurs mainly in the bone marrow where the 
development of self-reactive B cells has been shown to be controlled by the mechanisms of 
clonal deletion (D. A. Nemazee & Bürki, 1989; D. Nemazee & Buerki, 1989), anergy 
induction (Brink et al., 1992; Goodnow et al., 1989; Hartley et al., 1991) and receptor-editing 
(D. Nemazee, 2000; Casellas et al., 2001; Yachimovich et al., 2002). 
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In transgenic mice systems, antigen specific B cells can develop in the absence of their 
corresponding antigen, accumulate in peripheral lymphoid organs and produce antigen 
specific immunoglobulins. On the other hand, when the antigen to which B cells react to is 
present in the system, specific B cells and antibodies are absent from the periphery from the 
same transgenic mice. Further, B cells bearing a low level of membrane immunoglobulin with 
the referred antigen specificity are found in the bone marrow of these transgenic mice, 
suggesting that clonal deletion of autoreactive cells occurs in the pre-B-cell to B-cell 
transitional stage of B-cell development (Brink et al., 1992; D. A. Nemazee & Bürki, 1989; D. 
Nemazee & Buerki, 1989). 
In the presence of soluble antigens, BCR down-regulation may be induced in developing B 
cells, which are rendered anergic and may exit to the periphery (Goodnow et al., 1989). This 
was verified in Ig-transgenic mice expressing hen-egg lysozyme (HEL)-specific BCRs, where 
conventional B cells matured and populated the usual microenvironments in peripheral 
lymphoid tissues in the absence of the antigen, and could be stimulated by HEL to produce 
antibody or to enhance proliferation responses to LPS stimulation in vitro. Conversely, when 
soluble HEL was encountered in vivo as a self-antigen, B cells expressing HEL-specific 
BCRs were rendered tolerant. Importantly, clonal deletion of Ig-transgenic B cells expressing 
HEL-specific BCRs occurred when HEL was recognized as a membrane-bound self-antigen 
(Brink et al., 1992). 
In response to self-antigens, developing B lymphocytes can also modify their receptors 
through secondary Ig gene rearrangements in a process called receptor editing. This 
mechanism was observed in mice transgenic for the 3–83 antibody where, in the absence of 
its specific antigen, B cells in the periphery were numerous and expressed almost exclusively 
transgene-encoded BCRs (Tiegs, Russell, & Nemazee, 1993). However, when cognate 
antigen was introduced in the system, peripheral B cells were reduced in number, and lacked 
self-reactivity. These peripheral B cells retained the expression of the 3–83 Ig heavy chain, 
but not the 3–83 Ig light-chain. Furthermore, transgenic B cells in the bone marrows of 
antigen-expressing mice, expressed high levels of recombination activating genes (Rag-1 
and Rag-2) mRNA, and manifested rearrangements at their endogenous Ig light-chain loci. 
These findings suggest that autoantigen binding by immature bone marrow B cells could re-
induce or prolong Ig light-chain gene rearrangements, allowing a cell to alter its autoreactive 
specificity and escape death (Tiegs et al., 1993). Independent evidence for receptor editing 
was obtained from transgenic mice carrying IgH+L chain genes specific for double-stranded 
DNA (ds-DNA) (Gay, Saunders, Camper, & Weigert, 1993).  
Immature B cells, the end products of central B cell maturation, exit the bone marrow, 
migrate to the spleen and develop through transitional stages into mature B cells.  Different 
selective pressures that contribute to the maintenance of immune tolerance in the B cell 
compartment occur in this stage of differentiation. While BCR simulation of early transitional 
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B cells leads to their arrest in an unresponsive state (Goodnow et al., 1988) or cell death 
(Norvell, Mandik, & Monroe, 1995), as transitional B cells progress towards the mature stage 
they gain sensitivity to positive selection pressures, being rescued from BCR induced 
apoptosis by T-cell help signals (Chung, Sater, Fields, Erikson, & Monroe, 2002). Thus, late 
transitional B cells that were not eliminated by negative selection pressures, resemble the 
mature B cells that they give rise to, which are activated and proliferate upon BCR 
stimulation (Niiro & Clark, 2002; Harwood & Batista, 2008).  
Furthermore, studies using the monoclonal B cell receptor 3369 mouse line, specific for the 
thymocyte Thy glycoprotein, have demonstrated that the strength of BCR crosslinking 
induced by low-dose self-antigen in the spleen may influence the progression of naive 
immature B cells. In fact, the default maturation pathway of transitional B cells into follicular B 
cells may be altered by an increase in the strength of BCR signaling which preferentially 
directs B cells to mature into the marginal-zone B cell subset (Wen et al., 2005). 
 
 
4.1.2. B1a cells 
 
The use of transgenic mice systems has shown that during fetal and neonatal life the 
presence of self-antigen influences positively the fate of B1 cells (Hayakawa et al., 1999; 
Ferry et al., 2006). When the VH3609 µa heavy chain transgene, specific for the thymocyte 
Thy glycoprotein, was introduzed into the C.B17 (µb) background, the mice generated had 
high IgM anti-thymocyte autoantibody (ATA) serum titers detectable as early as at 1 week of 
age. Transgenic peritoneal cavity CD5+ B1a cells secreted high levels of ATA, while 
transgene positive B2 cells in the spleen did not. CD5+ transgenic B cells were also present 
in the spleen, as a minor fraction, and contributed with some ATA secretion. In the same 
study, the sequencing of the mRNA obtained from hybridomas of sorted B cell sub-
populations has shown that while CD5- B2 cells had a diverse light chain usage, CD5+ cells 
with ATA specificity used preferentially canonical V21C light chains that lacked nucleotide 
additions. Furthermore, mice resulting from the cross of VH3609 µa transgenic mice with 
antigen-deficient Thy-1- mice were deprived from ATA secreting B1a cells, proving that the 
presence of self-antigen is essential in the development of this B cell subset (Hayakawa et 
al., 1999). The antigen dependent positive selection of peritoneal cavity B1a cells was also 
suggested in an anti-erythrocyte BCR transgenic model of autoimmune hemolytic anemia 
(Okamoto et al., 1992), and was later validated by studies using transgenic mice carrying 
HEL specific B cell receptors (Ferry et al., 2006).  
At present there are two alternative hypotheses to explain the origin of CD5+ B1a cells. The 
lineage hypothesis, first proposed by the Herzenberg laboratory, holds that B1a pre-
committed precursors exist in fetal tissues, such as the liver and the omentum (Hayakawa et 
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al., 1985; Kantor & Herzenberg, 1993; Kantor, Stall, Adams, Herzenberg, & Herzenberg, 
1992). On the other hand, the specificity hypothesis (Cong, Rabin, & Wortis, 1991; 
Haughton, Arnold, Whitmore, & Clarke, 1993) proposes that any naïve B cell may be induced 
to become CD5 positive by antigen-induced surface lg cross-linking. The later hypothesis is 
supported by the fact that, under some circumstances, B2 cells can assume a B1a-like 
phenotype, that includes the expression of CD5 (Wortis, Teutsch, Higer, Zheng, & Parker, 
1995). However, this phenotype switch rarely occurs under normal circumstances (Hamilton 
& Kearney, 1994; Kantor & Herzenberg, 1993) and several studies have demonstrated the 
existence of different progenitors for the B1 and the B2 cell lineages (de Andrés et al., 2002; 
Fossati, Kumar, & Snoeck, 2010; Tung, Mrazek, Yang, Herzenberg, & Herzenberg, 2006). 
Consequently, the physiological relevance of the specificity hypothesis is currently 
questioned, while the lineage hypothesis is generally accepted. 
B1a cells are generated mostly during fetal development and neonatal life (Hayakawa et al., 
1999), and their maintenance in adult life is mainly assured by their self-replenishment 
capacity (Förster & Rajewsky, 1987; Hayakawa et al., 1986). Although widely accepted, this 
assumption has some inherent contradictions, since the decline of the ability to generate B1a 
cells during ontogeny is relative rather than absolute. Early studies have shown that adult 
bone marrow cells can, to a limited extent, give rise to B1a cells in the peritoneal cavity and 
spleen of severe combined immunodeficient (SCID) mice or of lethally irradiated allotype-
congenic mice recipients (Huang, Henry, Iacomini, Imanishi-Kari, & Wortis, 1996; Iacomini & 
Imanishi-Kari, 1992; Kantor et al., 1992; Thomas-Vaslin, Coutinho, & Huetz, 1992). 
Moreover, the early precursors of B1a and B1b cells have recently been identified as Lin-
CD45Rlow-negCD19+ cells in the mouse fetal liver and fetal bone marrow, and clearly 
distinguished from the CD45R+CD19- B2 cell progenitors in the adult bone marrow (de 
Andrés et al., 2002; Tung et al., 2006). Although less abundant, the CD45Rlow-negCD19+ B1 
cell precursors have also been shown to persist in the bone marrow after birth (Montecino-
Rodriguez, Leathers, & Dorshkind, 2006), and have been suggested to be mostly originated 
from kit- common lymphoid progenitors (kit-CLP) (Fossati, Kumar, & Snoeck, 2010). 
Interestingly, kit-CLP have lower expression levels of Rag genes and terminal 
deoxynucleotidyl transferase (TdT), in comparison with CLP (Harman, Northrup, & Allman, 
2008; Kumar, Fossati, Israel, & Snoeck, 2008), which could favor the usage of germline 
encoded IgH Variable, Diverse, and Joining (VDJ) gene sequences on bone marrow 
originated B1 cells. 
Although common B1 precursors exist in the adult bone marrow, a more efficient 
reconstitution was observed in the B1b than in the B1a peritoneal cavity compartment at this 
stage. This observation suggested that differences in the fetal and adult microenvironment 
could influence the fate of B1 cell progenitors (Herzenberg, 2000; Tung et al., 2006). Later 
studies, from the Herzenberg laboratory, have suggested that CD138 and Major 
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Histocompatibility Complex of Class II (MHC-II) expression would help to better characterize 
the early-stage bone marrow B lineage progenitors previously defined. This suggestion came 
from the observation that the B2 progenitor subset is enriched in CD138high cells, while 
CD138- cells constitute around 90% of the neonatal subset that gives rise to B1a cells and 
CD138int cells constitute roughly 50% of the adult precursor subset that predominantly gives 
rise to B1b cells. Moreover, MHC-II is expressed in the B2 cell lineage progenitors and 
mature cells but only in B1a and B1b mature B cells. The functional correlates of this pattern 
of CD138 and MHC-II expression on B cell precursors requires further investigation (Tung et 
al., 2006). 
More recently the Carsetti laboratory has claimed that, before birth, fetal liver B1a precursors 
may migrate to the spleen, giving origin to peritoneal cavity B1a cells during adult life 
(Rosado et al., 2009). This finding is sustained by studies from the same laboratory showing 
that adult asplenic and splenectomized mice have a reduced number of peritoneal cavity B1a 
cells (Wardemann, Boehm, Dear, & Carsetti, 2002). 
Independently of their origin, B1a cells persist from early life and continuously give rise to 
IgM autoantibodies which, if in abundance, may directly bind antigens on the cell surface and 
mediate cellular damage (Brändlein et al., 2003; Varambally et al., 2004). Additionally, by 
masking tolerogenic self-antigens, natural IgM of B1a cell origin may rescue the development 
of autoreactive conventional B2 cells and predispose to autoimmunity in the later cell 
compartment (Ferry et al., 2006). 
Importantly, the maintenance of peripheral immune tolerance in the positively selected B1a 
cell subset is guaranteed by the expression of regulatory molecules, such as CD5, SHP-1, 
CD22 and Siglec-G, which keep the BCR mediated activation of B1a cells below the levels 
necessary to induce their extensive proliferation and autoantibody secretion, thus preventing 
autoimmunity (Bikah et al., 1996; Hoffmann et al., 2007; O’Keefe, Williams, Davies, & 
Neuberger, 1996; Tarakhovsky, 1997). 
 
 
4.2. Immune tolerance in the T cell compartment 
 
In normal physiological conditions, tolerance mechanisms which avoid autoreactivity in the T 
cell compartment are present both centrally, in the thymus, and in the periphery. During 
thymic development, the affinity/avidity of the recognition of self-antigens presented in the 
context of Major Histocompatibility Complex (MHC) molecules is essential for T cell 
maturation. If the self-peptide-MHC molecule complex expressed on cortical epithelial cells is 
recognized with low/moderate affinity/avidity the T cells are positively selected and further 
mature (Ashton-Rickardt & Tonegawa, 1994; Kisielow & Miazek, 1995; Surh & Sprent, 1994). 
Yet, if the affinity/avidity to self-peptide-MHC molecule complex is high, the self-reactive T 
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cells are negatively selected and apoptosis is induced (Ashton-Rickardt & Tonegawa, 1994). 
The negative selection of thymocytes is mostly mediated by self-peptide presenting bone 
marrow-derived dendritic cells in the thymic medulla (Surh & Sprent, 1994; Viret, Barlow, & 
Janeway, 1999). Finally, the absence of recognition of the self-peptide-MHC molecule 
complex leads to T cells death by neglect (Janeway & Bottomly, 1994; Kisielow & von 
Boehmer, 1995; Surh & Sprent, 1994).  
The presence of peripheral autoreactive T cells in healthy individuals has suggested that 
central tolerance is not the only barrier against autoreactivity (Lohmann, Leslie, & Londei, 
1996; Semana, Gausling, Jackson, & Hafler, 1999). In fact, peripheral tolerance mechanisms 
that deal with autoreactive T cells that have escaped negative selection in the thymus have 
been described. They include T cell-intrinsic mechanisms that act directly on the responding 
cell, such as ignorance, immune deviation and apoptosis, and T cell extrinsic mechanisms 
that evoke additional cell subsets such as tolerogenic dendritic cells and regulatory T cells 
(Walker & Abbas, 2002). Clonal ignorance occurs when T cells are irresponsive to self-
antigens either because the self-antigens are anatomically sequestered or presented in the 
absence of co-stimulatory signals needed to trigger the immune response (Zinkernagel, 
1996). Immune deviation has been suggested to avoid T cell autoimmunity, by balancing the 
CD4+ T cell responses between Th1, which have been associated with many cases of 
autoimmunity (Bradley et al., 1999), and Th2 which have been linked with downregulation of 
autoimmunity in experimental autoimmune encephalomyelitis (EAE) and type 1 diabetes 
(T1D) experimental models (Bradley et al., 1999; Young et al., 2000). Activation induced cell 
death (AICD) of autoreactive T cell clones in the periphery may also occur upon repetitive 
encounter with self-antigen, and both the ligation of the Fas death receptor to its ligand 
(Watanabe-Fukunaga, Brannan, Copeland, Jenkins, & Nagata, 1992) and the cytotoxic T-
lymphocyte antigen 4 (CTLA-4) protein, a negative regulator of T cell activation, have been 
suggested to have an important role in this mechanism (Colucci, Bergman, Penha-
Gonçalves, Cilio, & Holmberg, 1997; Tivol et al., 1995). Specialized subsets of dendritic cells, 
named tolerogenic DCs, may also cross-present self-antigens and mediate the suppression 
of antigen-specific T cell immune responses through the deletion of self-reactive T cell clones 
(Bonifaz et al., 2002; Mukhopadhaya et al., 2008) or via the induction of regulatory T cells 
(Gregori, 2011; Maldonado & von Andrian, 2010). Regulatory T cells are characterized by the 
expression of CD4+CD25+FoxP3+ (Sakaguchi, 2005) and, being engaged in the dominant 
control of self-reactive T cells, give an important contribute to the maintenance of 







Table I.2 Major immune tolerance mechanisms taking place in the B and T cell 
compartments of the mouse 
 
The location and the main immune tolerance mechanisms taking place in the mouse B and T 
lymphocyte compartments are represented. 
 
 
5. Immune tolerance failure and autoimmunity 
 
The primary function of the immune system is to confer protection of the organism against 
infection. However, the maintenance of normal immune function is a very intricate process, 
and the failure to establish and maintain tolerance to self-antigens results in autoimmunity.   
The phenomenon of autoimmunity was first described by Paul Ehrlich in 1899, who 
introduced the term “horror autotoxicus” to describe the reluctance of the organism to 
produce toxic autoantibodies (Himmelweit, 1957). Importantly, autoimmunity and 
autoimmune diseases are distinct phenomena. A certain degree of autoimmunity is a built-in 
feature of the immune system and can be shown in healthy individuals (Ermann & Fathman, 
2001), while autoimmune diseases are the result of aberrant genetic, environmental, and 
pathogenic factors that, over variable periods of time, lead to a dysfunction of the immune 
system characterized by inflammation and attack on the body’s own organs, tissues, and 
cells (Ermann & Fathman, 2001; Marrack, Kappler, & Kotzin, 2001). Among the genetic 
markers of predisposition to autoimmune disease are specific sets of genes for the MHC 
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molecules that both shape and regulate the specificity of the adaptive immune response. In 
addition, genetic variability in a number of other genes that are important in the regulation of 
immune responses has been associated with the development of autoimmune diseases. The 
genetic makeup of humans and mice determines not only how the immune system deals with 
antigenic challenges from the environment, but also how the immune system is regulated to 
remain tolerant towards self. Certain environmental conditions, such as an infection, failure of 
regulatory mechanisms and/or an inappropriate immune response to crossreactive self -
antigens, may condition the onset of autoimmune disease, leading to self-antigen attack, 
organ damage and dysfunction (Ermann & Fathman, 2001). 
Autoimmune diseases (AID) exhibit a spectrum of clinical features that range from local or 
organ-specific to systemic diseases. According to their principal clinical-pathologic features, 
each AID can be classified in two main groups: (1) systemic autoimmune diseases, in which 
the autoimmune response is directed to antigens which are not organ-specific and thus is a 
more generalized condition, such as the case of systemic lupus erythematosus (Lipsky, 
2001) and rheumatoid arthritis (RA) (Feldmann, 2001); and (2) organ specific autoimmune 
diseases, as is the case of autoimmune thyroiditis (Weetman, 2001) and type 1 diabetes 
(Gershwin & Shoenfeld, 2011; Wucherpfennig & Eisenbarth, 2001). 
Several of the mechanisms involved in the removal, inactivation or regulation of self-reactive 
lymphocytes, conferring the property of immune tolerance or self-tolerance, are now 
understood as described above. However, the conditions under which, and the mechanisms 
by which, this self-tolerance can break down, giving rise to autoimmunity manifestations and 
autoimmune diseases remain less clear. 
 
 
6. Type 1 diabetes in Portugal and in the Western World 
 
The urgency to identify the subtle factors contributing to type 1 diabetes (T1D) onset and 
progression is compelled by recent statistics indicating that the number of T1D new cases is 
rising tremendously in European Societies. According to the 2010 Annual Report of the 
Portuguese National Observatory of Diabetes (Observatório Nacional da Diabetes, 2010), 
the prevalence of diabetes in Portugal for the year of 2009 was of 12.3% (983*103 patients) 
for people between 20 and 79 years of age, corresponding to 7,3% of the total population. 
Furthermore, incidence studies over the last 7 years have allowed to estimate that around 
500 new cases per 100 000 inhabitants arise in our country each year. Of these, roughly 
90% are patients with type 2 diabetes and a bit less than 10% are cases of type 1 diabetes. 
However, T1D incidence is rising, due to yet unknown causes, and since 2000 the number of 
new cases per year doubled in children and young people till the age of 19, being its current 
prevalence in this age group of 0.12%. Importantly, the Portuguese picture of type 1 diabetes 
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mimics its general evolution in Europe, where the number of T1D new cases in children 
under the age of five is increasing by more than 5% each year and where is predicted that, 
by 2020, the T1D incidence in this age group has doubled (Patterson, Dahlquist, Gyürüs, 
Green, & Soltész, 2009). 
Type 1 diabetes is a complex autoimmune disease, contributed by multiple genetic and 
environmental factors that results in the selective destruction of insulin secreting beta cells 
from the pancreatic islets of Langerhans (Yang & Santamaria, 2003). The absence of insulin 
secretion in this disease leads to persistent high blood glucose levels which results in 
general tissue damage and severe complications affecting mostly the kidneys, the eyes, the 
peripheral nerves and the vascular system. In almost all the so-called “developed countries” 
diabetes is the major cause of blindness, renal failure and lower limb amputation and one of 
the leading causes of death due to its implications in coronary disease and cardiac failure 
(Gordon, 2004; Putaala et al., 2011; Tong et al., 2008). 
Beyond the suffering that diabetes provokes in patients and relatives, there are also serious 
economic implications to diabetic people (salary loss, high expenses on medicines, 
prolonged sick leave) and the society in general (high costs with health care services, lower 
productivity of the working population). As an example, the use of drugs for diabetes therapy 
(dosage/1000 inhabitants/day) in Portugal experienced a 49% raise between 2000 and 2009 
and the predicted increase on the sales for these medicines will quadruple by 2020, reaching 
858*106 euros. The total costs associated with diabetes in 2009 were equivalent to 0.9% of 
the Portuguese Gross Domestic Product, and represented 9% of the money spent on Health 
in Portugal reflecting well the tremendous impact that this disease has on our economy 
(Observatório Nacional da Diabetes, 2010). 
 
 
6.1. Type 1 diabetes in veterinary species 
 
In veterinary medicine, diabetes is one of the most frequently diagnosed endocrine disorders 
in cats and dogs that, although rarely, can also be detected in the equine veterinary practice. 
While in cats (Rand, 1999) and horses (Durham, Hughes, Cottle, Rendle, & Boston, 2009) 
the most commonly diagnosed diabetes cases are of the non-insulin-dependent type 2, type 
1 diabetes marked by the presence of pancreatic beta cell reactive autoantibodies (Davison, 
Herrtage, Steiner, Williams, & Catchpole, 2003; Elie & Hoenig, 1995; Hoenig & Dawe, 1992), 
is the most frequent form of disease in dogs. Interestingly, in both humans, dogs and mice, 
the major genetic determinants of type 1 diabetes are the major histocompatibility complex 
alleles on the leukocyte antigen genes (Hattori et al., 1986; Kennedy et al., 2006; She, 1996). 
Thus, the research effort put on the understanding of mouse type 1 diabetes pathogenesis 
may benefit both humans and veterinary animal species, particularly the dog. 
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7. The NOD mouse model of type 1 diabetes 
 
Type 1 diabetes develops spontaneously in humans and other animal species and the 
pathogenic events leading to its development are largely represented in the non-obese-
diabetic (NOD) mouse, an insightful experimental model for the study of this autoimmune 
disease (Castaño & Eisenbarth, 1990). The genetic architecture of T1D in the NOD mouse 
and human patients reveals a combination of apparently normal alleles at numerous loci that 
in isolation afford only a small degree of disease susceptibility, but together set in motion a 
series of immunological events that lead to islet inflammation and overt diabetes. Although 
strongly contributed by genetic elements, environmental factors, such as the composition of 
the gut microbiota (Alam et al., 2011) or the exposition to certain viral infections (Horwitz et 
al., 1998; Hyöty & Taylor, 2002; Jun & Yoon, 2001; See & Tilles, 1995; Serreze, Ottendorfer, 
Ellis, Gauntt, & Atkinson, 2000; Yang & Santamaria, 2003) may also help to trigger the type 1 
diabetes disease process.  
 
 
7.1. Type 1 diabetes pathogenic events in the NOD mouse 
 
T1D pathogenesis in the NOD mouse is influenced by a variety of defects that interfere with 
the establishment or maintenance of T cell tolerance (Choisy-Rossi, Holl, Pierce, Chapman, 
& Serreze, 2004; Kreuwel et al., 2001; Lesage et al., 2002), and can be tracked back to 
around 3 to 5 weeks of age, when antigen-presenting-cell mediated priming of autoreactive T 
cells in the pancreatic lymph nodes and the recruitment of mononuclear cells into the 
pancreatic islets of Langerhans lead to the inflammation phenomena termed as insulitis.  The 
clinical signs of diabetes, due to massive beta cell loss, arise only from 12 weeks onwards on 
this mouse model and are determined by the selective destruction of insulin secreting beta 
cells by autoreactive cytotoxic T cells (Yang & Santamaria, 2003). In fact, it has been 
proposed that diabetogenesis in the NOD requires two checkpoints temporally distinct: (1) 
initial targeting of islet beta cells and (2) later conversion of nondestructive insulitis into a 
diabetogenic inflammatory process (André et al., 1996). This two-step model is supported by 
the gender comparison of type 1 diabetes development in the NOD where, although all mice 
develop insulitis, the occurrence of diabetes is much higher in females (60-80%) than males 
(20-30%) (Lampeter, Signore, Gale, & Pozzilli, 1989).  
Cytotoxic T cells are the effectors of pancreatic beta cell destruction (Yang & Santamaria, 
2003). Nevertheless, several factors have been shown to be involved in T1D pathogenesis. 
In particular, studies on NOD.Igµ.null mice, completely deficient in B cells, have clearly 
demonstrated the requirement of this lymphocyte sub-population for the diabetic autoimmune 
process. In fact, NOD.Igµ.null mice have normal numbers of T cells but have a delay in the 
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onset and a reduction in the severity of insulitis and are strongly protected from type 1 
diabetes development (Akashi et al., 1997; Serreze et al., 1996). Further, the reconstitution 
of NOD.Igµ.null mice with NOD B cells restores T1D susceptibility (Serreze et al., 1998). It 
has been previously demonstrated that T lymphocytes from diabetic NOD donors can 
efficiently transfer disease to neonatal recipients depleted of B lymphocytes (Bendelac et al., 
1988). Thus, once generated, diabetogenic T lymphocytes can mediate destruction of 
pancreatic beta cells in the absence of B lymphocytes. Together these reports suggest that B 
lymphocytes play an essential role in the initial development and/or activation of beta cell 
autoreactive T cells in the NOD mouse. 
 
 
7.2. B cells are important players on type 1 diabetes pathogenesis 
 
Intense investigation on the role that B cells play in NOD type 1 diabetes has shown that B 
cells capacity to present antigen to T cells is a determinant factor in disease progression. 
NOD mice with functionally competent macrophages, dendritic cells and T cells, but with a 
MHC-II deficient B cell compartment were shown to be resistant to the development of 
autoimmune diabetes. Importantly, the pancreas of these mice presented rare foci of peri-
insulitis, suggesting that MHC-II mediated antigen presentation by NOD B cells serves to 
overcome a checkpoint in T cell tolerance to islet beta cells, after their initial targeting has 
occurred (Noorchashm et al., 1999). In addition, the introduction of a mutant IgM heavy chain 
transgene allowing the restoration of B cells on NOD.Igµ.null mice, but not the recovery of 
circulating antibodies, was only partially able to restore T1D. Importantly, this transgenic 
construct had a fixed heavy chain reactive to the hapten (4-hydroxy-3-nitrophenyl) acetyl but 
maintained the potential for selection of a diversity of light chains. Therefore, in theory, albeit 
at lower levels, these transgenic B cells could still present the relevant diabetes related 
autoantigens to the autoreactive T-cells (F. S. Wong et al., 2004). Furthermore, NOD BCR 
specificity has been proven as a determinant factor of B cells pathogenicity in T1D. In fact, 
NOD mice carrying transgenic (Tg) VH genes with different potential for insulin binding have 
different disease outcomes. While VH125.Tg.NOD that produce a repertoire in which 1-3% of 
mature B cells are insulin specific develop accelerated diabetes, VH281.Tg.NOD mice, with 
limited insulin binding capacity, are partially protected from T1D (Hulbert, Riseili, Rojas, & 
Thomas, 2001). Consistently, the presence of a fixed BCR due to the introduction of 
transgenic Ig molecules specific for the disease irrelevant antigen hen egg lysozyme (HEL) 
retards the onset of diabetes in NOD mice (Silveira et al., 2002). One of the important 
aspects of the function of B cells as APCs is the ability to concentrate antigen many fold by 
virtue of the antigen specificity of their BCR (Rock, Benacerraf, & Abbas, 1984). Thus, these 
studies prove that the antigen presenting function and BCR specificity of B cells have an 
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important role in T1D pathogenesis. However, they also leave open the possibility that beta 
cell reactive autoantibodies may be a part of autoimmune diabetes initiation. 
 
 
7.3. Natural IgM and B1a cells role on type 1 diabetes development 
 
The earliest manifestation of diabetogenesis is the presence of islet-related autoantibodies, 
both in pre-diabetic patients and in the NOD mouse (Leslie, Lipsky, & Notkins, 2001). These 
autoreactive immunoglobulins, of the IgG isotype, recognize beta cell antigens (insulin,  
glutamate decarboxilase (GAD), islet cell antigen 512 (IA-2)) (Bingley et al., 1997; Kaufman 
et al., 1992; L. Yu et al., 2000), and are believed to be bystander products of the disease, 
resulting from the ongoing autoimmune process (Leslie et al., 2001). Thus, it is generally 
accepted that in the stage of cytotoxic beta cell destruction, the exposure of conventional B 
cells to high loads of beta cell related autoantigens would lead to the preferential activation of 
B cells with autoreactive potential. The long-sustained interactions between autoreactive T 
and B cells would then condition the repertoire of autoantibodies typical of pre-diabetic 
patients, where the beta cell destruction is already in progress, though clinical signs are not 
yet present. 
The work presented in the articles II, III and IV of this thesis focuses on the role that 
autoreactive antibodies play in T1D pathogenesis in the NOD mouse. Our studies were 
encouraged by previous research showing that, before the development of insulitis, 
antibodies of the IgM isotype bound to pancreatic beta cells surface may be found in the 
NOD mouse while such antibodies were not detected in non-diabetic C57BL/6 controls 
(Shieh, Cornelius, Winter, & Peck, 1993). Also, analysis of spleen hybridomas, produced in 
the absence of immunization, has revealed that the NOD has more spontaneously active B 
cells when compared to non-diabetes-prone strains. Additionally, this study has shown that 
the NOD mouse has more cells naturally secreting insulin reactive antibodies with natural 
IgM properties. This reactivity pattern was detectable already at 4 weeks of age and was 
maintained throughout life (Thomas, Kendall, & Mitchell, 2002). Consistently, in situ 
hybridization studies by Holmberg and colleagues have clearly shown that NOD mice 
maintain in adult life the neonatal bias for expression of D-proximal variable genes of Ig 
heavy chain (VH), and thus exhibit an antibody repertoire biased to germline-encoded 
specificities (Andersson, Ekstrand-Hammarström, Eriksson, Overmo, & Holmberg, 1994; 
Leijon, Freitas, & Holmberg, 1993). 
Together these findings suggest that the genetic background of NOD mice determines 
developmental abnormalities that may favor the generation of B cells that secrete anti-insulin 
natural antibodies. They also supported our work hypothesis that natural antibodies with 
pancreatic autoantigen specificity are therefore produced in the NOD from early life and bind 
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to beta cells, possibly having a triggering effect in the diabetogenic cascade of events that 
lead to specific beta cell destruction. 
Most of the antibodies of the IgM isotype arise from spontaneously secreting B1a cells, 
independently of germinal center reactions, exogenous stimuli or T cell help (Casali & 
Schettino, 1996). Importantly, B1a cells have a high potential for autoreactivity and have 
been shown to be critical for autoantibody development and autoimmune symptoms in the 
New Zealand Black (NZB) and New Zealand Black/ New Zealand White F1 (NZB/W) mouse 
models of systemic lupus erythematosus (Steinberg, Smathers, Frederiksen, & Steinberg, 
1982; Murakami, Yoshioka, Shirai, Tsubata, & Honjo, 1995). Moreover, B1a cells have been 
recently proven to be necessary for the insulitis onset in the DO11 x RIP-mOVA transgenic 
mouse model of T1D, where diabetes is mediated by cytotoxic T cells recognizing pancreatic 
beta cells antigens (Ryan et al., 2010). Also, in the 125Tg mouse, B1a cells prevail as anti-
insulin IgM secretors while B2 cells with the same specificity are anergized (Rojas, Hulbert, & 
Thomas, 2001). Evidence that B1a cells are augmented in the peripheral blood of T1D 
patients (Gyarmati, Szekeres-Barthó, Fischer, & Soltész, 1999) and that B1a cells are 
naturally increasingly activated in the NOD strain (Alam, Valkonen, Ohls, Törnqvist, & 
Hänninen, 2010), further suggest that B1a cells may be involved in the diabetogenic 
autoimmune process. These data justified our effort to investigate whether natural antibodies 
with the ability to bind to pancreatic beta cells are produced by NOD B1a cells and have an 
impact on beta cell physiology upon binding. 
In the article II, published in the context of this PhD thesis, we were able to determine that 
NOD peritoneal cavity B1a cells are more prone to spontaneously secrete IgM that 
recognizes pancreatic autoantigens and we set out the hypothesis that soluble, islet-specific, 
natural antibodies could promote disease either by enhancing professional antigen 
presentation of islet antigens, by activating the complement cascade or by directly causing 
the initial tissue damage and islet cell antigens release.  
In the article III of this thesis we have investigated these hypothesis and we have established 
that IgM of NOD B1a cells origin could bind and directly induce stress responses on 
pancreatic beta cells. Moreover, we have determined that NOD B1a cells have a lower 
threshold for innate-like stimulation and we have established a link between NOD B1a cells 
properties, natural autoreactive specificities and impact of IgM binding on beta-cells 
physiology. Finally, the article IV of this thesis provides evidence that NOD B1a cells 
proliferation and differentiation into IgM secreting cells contributes to T1D onset.  
In summary, B1a cells carrying germ-line-encoded specificities recognizing self-antigens are 
an inherited component of the immune system that is selected during fetal life and secretes 
natural IgM, serving as an early line of defense against invading microorganisms. B1a cells 
are highly regulated by inhibitory molecules that, in healthy individuals, keep their 
autoreactive potential under control. Nevertheless, in certain autoimmune conditions, as type 
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1 diabetes, a lower threshold for innate like stimulation of B1a cells contributes to a naturally 
increased state of B1a cell activation and autoantibody secretion, determining the initiation 
and/or contributing to the fueling of autoimmunity.  
In this PhD thesis the genetic factors controlling IgM concentration in the serum of non-
manipulated healthy mice were investigated, as well as the role that B1a cells and natural 
antibodies play in autoimmunity, by studying their properties in the NOD mouse model of 





































Chapter II. Objectives 
 
Spontaneous, constitutive secretion of IgM is a key distinct characteristic of B1a cells that 
accounts, in large extent, for the circulating protective pool of natural antibodies in both mice 
and humans. However, B1a cells and the immunoglobulins that they produce are potentially 
autoreactive, so that regulation of natural antibody secretion is a crucial control mechanism 
in the immune system.  
This thesis main objective was to understand the role of natural IgM in health and disease. 
Thus, the studies were focused on:  
(1) Determining the genetic factors controlling natural IgM secretion in healthy mice; 
(2) Dissecting the natural antibody secretion profile and the properties of B1a cells in the 
non-obese-diabetic (NOD) mouse model of type 1 diabetes; 
(3) Investigating the impact of autoreactive IgM of B1a cell origin in pancreatic beta cells 













All mice used were females between 1 and 32 weeks of age, bred and maintained in either 
conventional or specific pathogen free (SPF) housing facilities at the Instituto Gulbenkian de 
Ciência. This study included C57BL/6, BALB/c, NOD, NOD.SCID, C57BL/6.H2g7 and 
NOD.H2b strains as well as mice from the genetic crosses F1 (C57BL/6 X BALB/c) and F2 
(C57BL/6 X BALB/c). Blood was collected from the facial vein and urinary glucose levels 
were measured weekly from 12 to 32 weeks of age with Diabur 5000 test stripes (Roche). 
Mice were considered to be diabetic after two consecutive positive measures of glycosuria. 
Euthanasia was performed by CO2 inhalation or cervical dislocation. The experimental 
protocols were approved by the competent Portuguese authority (Direcção Geral de 
Veterinária) and are in accordance with international regulations (U.S. Department of Health 
and Human Service, Office of Extramural Research, National Institutes of Health, Office of 
Laboratory Animal Welfare, 1985). 
 
 
2. Cell lines 
 
BCL1 cells (BALB/c-derived B lymphoma) were kindly provided by Dr. John F. Kearney, 
University of Alabama at Birmingham, and maintained in RPMI 1640 complete medium 
(supplemented with 10% heat inactivated fetal calf serum (FCS), 2 mM L-glutamine, 10 mM 
HEPES (pH 7.4), 50 mM 2-mercaptoethanol, 100 U penicillin and 100 mg/ml streptomycin, 
all from Life Technologies). 
 
 
3. Intra-peritoneal injection 
 
For the assessment of NIM-R7 impact on lymphocyte distribution we have performed 4 
weekly intra-peritoneal (IP) injections of 50 g of antibody diluted in 100 ml of RPMI 1640 
(Life Technologies) on NOD female mice starting at 5 weeks of age. Mice were euthanized 
one week after the last injection and the organs were taken for flow cytometry analysis. For 
the verification of the NIM-R7 effect on T1D development the same IP injections protocol was 










Genomic DNA was extracted from mouse tails with standard digestion/precipitation methods. 
Genotyping was performed using microsatellite DNA markers, polymorphic for the parental 
strains. Markers were chosen according to their chromosomal position, as given by the 
Broad Institute for Genome Research (USA), to cover uniformly the whole mouse genome at 
an average density of 20 cM. The genotypes for each locus were determined by DNA marker 
amplification using conventional PCR techniques. Amplification products were analyzed in 
4% agarose gels (Cambrex BioScience) with ethidium bromide (Sigma) and the allele size 
was determined using the Eagle Eye II video system (Stratagene).  
 
 
4.2. Genetic analysis 
 
Quantitative trait locus analysis was performed by using the normal model in the R/QTL 
software (Broman, Wu, Sen, & Churchill, 2003). This program calculates logarithm of odds 
(LOD scores) over intervals between linked markers, generating likelihood plots of genetic 
association with the phenotype across the genotyped chromosomal regions. The genome-
wide statistical significance of the results was empirically determined by performing 
permutation tests (Lander & Kruglyak, 1995) and the QTL confidence interval was calculated 
using the Bayesian method of R/QTL (Broman & Sen, 2009). 
 
 
4.3. RNA isolation and real-time PCR 
 
Total RNA from either sorted or cultured cells was obtained using the RNeasy Mini Kit 
(Qiagen) or the High Pure RNA Isolation Kit (Roche) following the manufacturer protocol for 
animal cells. RNA was converted to cDNA with a Transcriptor First Strand cDNA Synthesis 
Kit or a Transcriptor High Fidelity cDNA Synthesis Kit (both from Roche). The following 
TaqMan Gene Expression Assays with FAM-reporter (Applied Biosystems) were used: Irf4 
(Mm0051634-m1), Tlr2 (Mm00442346_m1), Tlr4 (Mm00445274_m1), Tlr6 
(Mm02529782_s1), Tlr7 (Mm00446590_m1), Tlr9 (Mm00446193_m1), Fas 
(Mm00433237_m1), Nos2 (Mm01309901_m1), Caspase 3 (Mm01195084_m1) and Ccl2 
(Mm00441242_m1). Gene expression quantification was performed in ABI Prism 7900HT 
(Applied Byosistems, Foster City, CA, USA). Relative quantification in each real-time PCR 
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reaction was obtained after normalization for mouse GAPDH (VIC/MGB probe) expression 
using the 2-CT analysis method (Livak & Schmittgen, 2001). 
 
 




Standard indirect ELISA was used to quantify total IgM and anti-insulin IgM in the serum. 
Total IgM, IgM with reactivity to a pool of T1D related autoantigens (AAg) and IL10 levels 
were measured in cell culture supernatants after TLR stimulation. Briefly, ELISA plates 
(Nunc) were coated with IgM, insulin only (Sigma) or a T1D AAg pool of insulin, IA-2 
(GenWay Biotech), GAD65 and GAD67 (United States Biologicals). Bound seric IgM was 
detected by goat anti-mouse IgM-HRP human adsorbed antibody or goat-anti-mouse-IgM-AP 
conjugated antibody (both from Southern Biotech.) and revealed respectively with the 
substrate o-phenylenediamine (Calbiochem, Gibbstown, NJ, USA) and H2O2 or the sigma 
phosphatase substrate. Optical densities were read in a spectrophotometer at 490 nm or 405 
nm. IgM concentrations were calculated against standard curves obtained  with either 
purified monoclonal IgM (clone 11E10, Southern Biotech.) or anti-insulin IgM kindly provided 
by Dr. JW Thomas, Vanderbilt University Medical Center (Thomas, Kralick, & Ewulonu, 
1997). IL10 concentration was determined with a mouse IL-10 ELISA MAX™ Deluxe kit 
(Biolegend) according to the manufacturer’s instructions.  
 
 
5.2. ELISPOT ASSAY 
 
The number of IgM-secreting B cells or B cells secreting IgM with reactivity to a T1D related 
AAg pool of insulin (Sigma) and GAD67 (United States Biologicals) or insulin, IA-2 (GenWay 
Biotech), GAD65 and GAD67 (United States Biologicals), to thyroiditis associated AAg 
(thyroglobulin and thyroperoxidase), to the sialitis related AAg muscarinic-3-receptor, to SLE 
associated AAg (ds-DNA, single stranded-DNA (ss-DNA) and histone) or to AAg typically 
recognized by B1a cells (phosphatidylcholine, phosphorylcholine and dextran) (Baumgarth, 
Tung, & Herzenberg, 2005) were determined by ELISPOT ASSAY.  
The plates were coated overnight at 4 ºC with goat anti-mouse IgM-human adsorbed 
(Southern Biotech.) or with the referred antigens diluted in coating buffer (0.05M Na2CO3). 
Cell dilutions were performed in RPMI 1640 complete medium and incubated overnight at 
37ºC. When specific IgM reactivity was being measured 1% Bovine Serum Albumin (BSA) 
was added to the RPMI 1640 complete medium. Non-adherent cells were thereafter removed 
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by flicking the plate followed by lysis with 0.1% Tween 20 in water. After extensive washing 
with PBS containing 0.05% Tween 20 the plates were incubated with goat anti-mouse IgM-
AP-conjugated antibody (Southern Biotech.), washed again and revealed with BCIP-AMP 
substrate (2.3 mM of 5-bromo-4-chloro-3-indolyl phosphate diluted in 2-amino-2-methyl-1-
propanol buffer, Sigma). After incubation overnight at 4 ºC and washing three times with 
distilled water, the traces of IgM-secreting cells appeared as blue spots that were counted 
under the microscope. 
 
 
5.3. Flow cytometry analysis 
 
Lymphocytes were isolated from peritoneal cavity by peritoneal lavages performed with PBS 
supplemented with 2% FCS or from spleen by straining through a nylon mesh. Single cell 
suspensions were then stained according to standard procedures. Fc-receptors unspecific 
binding was prevented by incubating the cells with unlabeled anti-mouse-Fc-block/CD16/32 
(clone 2.4G2, BD Pharmingen).  The following antibodies were used for staining: FITC or PE-
Cy7-anti-CD19 (clone 1D3), FITC or A647-anti-IgM (clone R33.24.12), PE-anti-CD23 (clone 
B3B4), Percp or PE-anti-CD5 (clone 53-7.3), Pacific-Blue, Cy5, or APC-anti-CD45R/B220 
(clone RA3-6B2), biotinylated or FITC-anti-CD11b/Mac-1 (clone M1/70), FITC-anti-CD21 
(clone 7G6), PE-anti-CD43 (clone S7), biotinylated-anti-CD86 (clone GL1), FITC-anti-CD62L 
(clone Mel14) and  biotinylated or PE-anti-Syndecan-1 (clone 281-2). Monoclonal NIM-R7 
(anti-p58) antibody (Parkhouse, Santos-Argumedo, Teixeiral, Henry, & Wawrzynczak, 1992) 
was biotinylated and used for staining. Biotinylated antibodies were revealed by FITC, PercP 
or APC-Cy7-streptavidin. Traceable latex beads (Beckman coulter) were added for counting 
cells. Stained cell suspensions were analyzed by flow cytometry either with a FACSCaliburTM 
(Becton Dickinson) or a FACS CYAN ADP (Dako Cytomation) and the data was respectively 




5.4. Cell purification 
 
Peritoneal or splenic B cell subpopulations were purified using the high speed cell sorter 
MoFlo (Dako-Cytomation, Berkeley, CA, USA) or the BD FACSAria III cell sorter (BD 






5.5. “Panama” Blot 
 
Global serum IgM repertoire was evaluated by the “Panama” Blot semi-quantitative 
immunoblotting technique that allows evaluation of antibody reactivities against large panels 
of antigens and has been described in detail elsewhere (Haury, Grandien, Sundblad, 
Coutinho, & Nobrega, 1994; Nobrega et al., 1993). Briefly, protein extracts were prepared 
and, following electrophoresis, the separated proteins were transferred onto nitrocellulose 
membranes that where then incubated with serum in miniblot incubation units (Immunetics). 
Goat anti-mouse IgM-AP conjugated secondary antibody (Southern Biotech.) was used and 
immunoreactivities were revealed with nitroblue tetrazolium (NBT) and bromo-chloro-
indolylphosphate (BCIP) substrates (Promega Corp.).  Quantitation of immunoreactivities 
was performed by densitometry in high resolution reflective mode. A second densitometry 
was performed after colloidal gold staining (Protogold, Biocell). The irregularities of  the 
electrophoretic migration were corrected by the superimposition of the two stainings and the 
intensity of reactivity development was adjusted to a standard serum. For all these 
procedures, specially developed macros using the software IGOR (Wavemetrics) were used. 
The adjusted reactivity profiles were divided into sections defined empirically for each protein 
extract and the intensity of the respective serum immunoreactivity was quantified as the 
mean optical density within these limits. A sample profile thus consisted of a list of reactivity 
measures, one for each section, and was analyzed by Principal Component Analysis. 
 
 
6. Cell biology 
 
6.1. Toll-like receptor stimulation 
 
Purified peritoneal B1a cells were cultured in RPMI 1640 complete medium with or without 1-
5 g/ml of purified LPS and with or without 0.5 M CpG (ODN 1826, Invivogen). On the 
second day of culture the cells were collected, counted and plated for ELISPOT ASSAY of 
anti-T1D AAg IgM secreting cells. Supernatants were taken for antibody and IL10 
quantification by ELISA at day 3 of culture. For proliferation analysis cells were pulsed in the 
last 6 hours of culture, harvested and 3H-thymidine (Perkin Elmer) incorporation was 
measured. Expression of cell activation markers after one day of stimulation was assessed 
by staining using biotinylated-anti-CD69 (clone H1.2F3), biotinylated-anti-CD86 (clone GL1), 
Alexa488-anti-CD25 (clone PC 61) and FITC or Percp-Streptavidin antibodies followed by 





6.2. In vitro transwell cultures  
 
Islets of Langerhans were isolated from the pancreas by collagenase type V digestion (1.4 
mg/ml, Sigma) followed by hand picking under a stereomicroscope. Islets were subsequently 
dissociated into single cell suspensions by simultaneous mechanical and dispase enzymatic 
treatment (5 mg/ml, Roche). Freshly dissociated cells were cultured in Ham’s F-10-glutamax 
medium (Gibco) supplemented with 10 mm glucose (Sigma), 0.5% BSA, 50 M 
isobutylmethylxanthine (Sigma), 50 units/ml penicillin and 50 g/ml streptomycin (Gibco). 24 
hours after, sorted B cells were added in transwells (0.4 M pore size, Millipore). After 24 
hours of co-culture beta cells were either collected for flow cytometry analysis or processed 
for RNA isolation. Alexa647-anti-IgM (clone R33.24.12) was used for staining of bound IgM 




7. Statistical analysis 
 
Statistical significant differences for the analyzed phenotypes were estimated by either 
Kruskal-Wallis or unpaired student’s t-test. Two-tailed tests with 95% of confidence interval 





















Chapter IV. Article I: Irf4 is a positional and functional candidate gene for the control 
of serum IgM levels in the mouse 
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Natural IgM are involved in numerous immunological functions but the genetic factors that 
control the homeostasis of its secretion and upholding remain unknown. Prompted by the 
finding that C57BL/6 mice had significantly lower serum levels of IgM when compared to 
BALB/c mice, we performed a genome-wide screen and found that the level of serum IgM 
was controlled by a QTL on chromosome 13 reaching the highest level of association at 
marker D13Mit266 (LOD score=3.54). This locus was named IgMSC1 and covered a region 
encompassing the interferon regulatory factor 4 gene (Irf4). The number of splenic mature B 
cells in C57BL/6 did not differ from BALB/c mice but we found that low serum levels of IgM in 
C57BL/6 mice correlated with lower frequency of IgM secreting cells in the spleen and in the 
peritoneal cavity. These results suggested that C57BL/6 mice have lower efficiency in late B 
cell maturation, a process that is highly impaired in Irf4 knockout mice. In fact, we also found 
reduced Irf4 gene expression in B cells of C57BL/6 mice. Thus, we propose Irf4 as a 
candidate for the IgMSC1 locus, which controls IgM homeostatic levels at the level of B cell 
terminal differentiation. 
 





Natural IgM play a significant role in the immunology of health and disease. IgM antibodies 
are involved in numerous immunological functions including protection against infection 
(Boes, Prodeus, Schmidt, Carroll, & Chen, 1998; Brown et al., 2002; Ochsenbein et al., 
1999), prevention of autoimmunity (Boes et al., 2000; Ehrenstein, Cook, & Neuberger, 2000), 
B cell homeostasis (Baker & Ehrenstein, 2002; Boes et al., 1998; Ehrenstein, O'Keefe, 
Davies, & Neuberger, 1998) and immunosurveillance against tumors (Brandlein et al., 2003; 
Vollmers & Brandlein, 2005). IgM biological roles also include opsonization of apoptotic cells, 
resulting in accelerated clearance by phagocytic cells (Peng, Kowalewski, Kim, & Elkon, 
2005). Many of the circulating IgM correspond to natural antibodies that exist prior to 
infection or immunization (Bos et al., 1987; Haury et al., 1997; Lacroix-Desmazes et al., 
1998). Natural IgM are polyreactive to evolutionary conserved structures (Boes, 2000) and 
bind efficiently to previously un-encountered antigen (Lydyard et al., 1990). These antibodies 
compensate their low antigen affinity with relatively high avidity and furthermore the 
effectiveness of the antigen-antibody interaction is enhanced by the high efficiency of IgM in 
engaging the complement pathway (Manson, Mauri, & Ehrenstein, 2005; Peng, et al., 2005). 
The preimmune Ig repertoire is thought to be composed by mature B cells either recirculating 
through follicles of secondary lymphoid organs (B2 cells), or joining compartments in specific 
locations as the marginal zone in the spleen (MZ B cells) and the pleural or peritoneal 
cavities (B1 cells) (Lacroix-Desmazes, et al., 1998). B2 and marginal zone B cell 
development is initiated in the bone marrow and completed in the periphery (Shapiro-Shelef 
& Calame, 2005; Srivastava, Quinn, Hazard, Erikson, & Allman, 2005) throughout life. B cells 
exported from the bone marrow maturate in the spleen (Chung, Silverman, & Monroe, 2003) 
into subsets that differ in their surface phenotype, anatomic localization,  and immunologic 
function (Martin & Kearney, 1999; Martin & Kearney, 2002; Oliver, Martin, Gartland, Carter, & 
Kearney, 1997) and that ultimately are able to differentiate into antibody-producing plasma 
cells, upon antigenic stimulation (Shapiro-Shelef & Calame, 2005). Most frequently primary 
antigen contact of mature naïve B cells leads to IgM production detectable in the serum. 
On the other hand, studies on germ-free or axenic mice suggest that in the absence of 
pathogens such stimulation is conveyed by the action of self-antigens, leading to production 
of natural antibodies (Holmberg et al., 1986; Pereira et al., 1986).  The B1 cell population, is 
derived almost exclusively from foetal liver (Herzenberg, 2000), is established early in 
ontogeny and is predominantly maintained by self-replenishment (Hardy & Hayakawa, 1994). 
These cells locate preferentially in the pleural and peritoneal cavities (Herzenberg, 2000) and 
spontaneously secrete natural Ig (Tumang, Frances, Yeo, & Rothstein, 2005) participating in 
relatively few antigen-stimulated antibody responses (Herzenberg, 2000). 
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The capacity for Ig secretion is acquired in the process of B cell terminal differentiation 
(Calame, Lin, & Tunyaplin, 2003), at the plasma cell stage and requires the expression of the 
transcription factor Irf4  (Klein et al., 2006), a member of the interferon regulatory factor (IRF) 
family (Mamane et al., 1999). Irf4 expression is induced by antigen receptor or mitogen 
stimulation (Sciammas et al., 2006) and is restricted to cells of the immune system (Marecki 
& Fenton, 2002; Pernis, 2002), playing a critical role in both early (Mittrucker et al., 1997) and 
late B cell differentiation (Klein, et al., 2006). Interestingly, Irf4 upregulation results in 
spontaneous differentiation of B cells into plasma cells and production of IgM in the absence 
of external stimuli (Lin, Gerth, & Peng, 2004).  
Several familiarity and genetic studies have indicated that heritable components control the 
serum levels of IgE, IgA, and IgG (Barbosa, Rao, & Morton, 1981; Borecki, McGue, Gerrard, 
Lebowitz, & Rao, 1994; Grundbacher, 1974) and identified a number of loci influencing total 
serum levels of these antibodies in humans (Barnes et al., 1996; Bleecker, Amelung, Levitt, 
Postma, & Meyers, 1995; Mansur, Bishop, Holgate, Markham, & Morrison, 2004). There is 
also convincing evidence for parent-offspring effects and genetic heritability in human serum 
IgM levels (Barbosa, et al., 1981; Borecki, et al., 1994; Grundbacher, 1974), as well as 
evidence for genetic control of natural IgM titres in mammals (Gobet, Cerny, Ruedi, 
Hengartner, & Zinkernagel, 1988), birds (Parmentier et al., 2004) and fish (Kachamakova et 
al., 2006). However, no linkage evidence for quantitative trait loci influencing serum IgM has 
been reported and the genetics of the homeostatic regulation of serum IgM remains largely 
unknown. Here, we characterized a total IgM serum phenotype in mouse inbred strains and 
performed a genome-wide screen that identified a region on mouse chromosome 13 that 
contained a locus (loci) controlling IgM serum levels. Searching for the cellular and genetic 
basis of serum IgM phenotype we correlated the level of serum IgM with the frequency of 





Serum IgM phenotype 
To investigate the genetic control of serum IgM we analyzed the IgM concentration in the 
serum of C57BL/6 and BALB/c inbred strains. We found that the serum IgM level was lower 
in C57BL/6 than in BALB/c mice, albeit the phenotype showed reduced penetrance (Figure 
IV.1). The F1 [C57BL/6 X BALB/c] generation showed an intermediate phenotype and a F2 
[C57BL/6 X BALB/c] progeny of 136 mice showed a phenotype spectrum, from low to high 
values, indicating that alleles controlling the phenotype were segregating in the cross (Figure 
IV.1). The serum IgM trait, measured as the logarithm of IgM concentration, was normally 
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distributed in the F2 [C57BL/6 X BALB/c] progeny required for quantitative trait locus (QTL) 
analysis (data not shown). 
 
 
Figure IV.1 Serum IgM levels in naive mice 
 
IgM serum concentration was measured in 8 C57BL/6 (black circles), 10 BALB/c (white circles), 7 F1 
[C57BL/6 X BALB/c] (black triangles) and 136 F2 [C57BL/6 X BALB/c] (white diamonds) mice by 
Indirect ELISA. Average concentrations are shown as horizontal bars.  
 
 
Genetic mapping of serum IgM phenotype 
We performed a QTL analysis for this trait scanning the genome with 100 microsatellite 
markers in the 136 F2 progeny. We found that a region in proximal mouse chromosome 13 
was linked to the serum IgM trait, with a 95% confidence interval between the markers 
D13MIT57 and D13MIT179, where the highest associated marker D13Mit266 reached a LOD 
score of 3.54 corresponding to an empirically estimated genome-wide p-value of 0.04. The 
chromosome 13 locus was named IgMSC1 (IgM-secreting cells locus 1) (Figure IV.2a) and 
covered a region encompassing the Irf4 gene. Although no other chromosomal region 
reached the level of genomic significance, suggestive LOD scores were detected in 
chromosome 7 at marker D7MIT318 (LOD 2.05) and in chromosome 9 at marker D9MIT53 
(LOD 2.02) that could represent additional loci controlling the serum IgM phenotype, albeit 
with a smaller genetic effect as compared to IgMSC1. To evaluate the IgMSC1 genetic effect 
in the serum IgM phenotype F2 mice were classified according to their genotype at the 
highest linked marker in the IgMSC1 locus (D13Mit266). This analysis shows that the 
IgMSC1 locus has an additive mode of action (Figure IV.2b) and controls a significant 
fraction of the phenotypic variance (15.5%). 
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Figure IV.2a Mapping the IgMSC1 locus 
 
LOD score curve for mouse chromosome 13 represents the likelihood for linkage of the serum IgM 
trait with the represented markers. Regions of significant linkage show LOD score above 3.0. The  x-
axis ticks represent the relative position of microsatellite markers along this chromosome, from left to 
right: D13Mit236, 4cM; D13Mit57, 9cM; D13Mit115, 11cM; D13Mit266, 16cM; D13Mit88, 21cM; 
D13Mit179, 30cM; D13Mit159, 47cM; D13Mit147, 49cM; D13Mit262, 68cM; and D13Mit78, 75cM. 
 
 
Figure IV.2b IgM serum trait control by the IgMSC1 locus 
 
The F2 (C57BL/6 X BALB/c) mice were classified according to their genotype as AA (BALB/c) AB 
(heterozygous) or BB (C57BL/6) at D13Mit266 and the mean trait value and the standard error are 
represented for each group. 
 
 
IgM secreting cells and serum IgM 
With the aim of determining the cellular basis of the IgM serum trait we started by counting 
the total number of B cells, sIgM+ B cells and IgM secreting cells in the spleen of C57BL/6 
and BALB/c adult mice. We found no significant differences in the total number of B cells or 
in the total number of mature sIgM+ B cells (data not shown), suggesting that regulation of B 
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cell spleen cellularity and B cell maturation in the spleen is similar in these strains. However, 
we also found that C57BL/6 have significantly lower number of IgM secreting cells in the 
spleen, offering an explanation for the observed lower serum IgM phenotype (Figure IV.3). 
 
 
Figure IV.3 Number of IgM secreting cells in the spleen correlates with serum IgM 
concentration 
 
The values represent results that were obtained by ELISA-Spot-Assay and indirect ELISA in individual 
C57BL/6 and BALB/c mice. 
 
 
Moreover, we purified B cell populations to show that the number of IgM secreting cells 
within splenic B cells was lower in C57BL/6, suggesting that these mice have less efficient 
plasma cell differentiation as compared to BALB/c mice (Figure IV.4a). These findings 
suggested that the cellular basis for the serum IgM trait resides in final steps of the peripheral 
B cell maturation and terminal differentiation in the spleen.  
It has been described that the B cell population (B1) localizing in the pleural and peritoneal 
cavities is an important source of natural IgM in the mouse (Herzenberg et al., 1986). To 
assess the contribution of peritoneal B cells to the observed phenotype we decided to 
characterize the population of B cells and IgM secreting cells in the peritoneal cavity of 
C57BL/6 and BALB/c mice. We found that C57BL/6 mice have a decreased number of IgM 
secreting cells in the peritoneal cavity when compared to the BALB/c strain (Figure IV.4b). 
Thus, the number of IgM secreting B cells in the peritoneal cavity may also contribute to the 
cellular basis of the serum IgM trait in these mouse strains. These data indicate that the 
reduced number of IgM secreting cells in the C57BL/6 mice is not specific of the spleen 




Figure IV.4 Decreased number of IgM secreting cell counting in purified splenic B cells 
and purified peritoneal cavity B cells in C57BL/6 mice 
 
(a) Number of IgM secreting cells in splenocyte B cells pooled from groups of 8 C57BL/6 (black bars) 
and 8 BALB/c (white bars) mice. The results represent the mean and standard deviation of triplicate 
samples assayed simultaneously. (b) Number of IgM secreting cells in peritoneal cavity B cells pooled 
from groups of 5 mice and representing the mean and standard deviation of two separate experiments 
assayed in triplicates. 
 
 
Irf4 gene expression 
The Irf4 gene is a key player in several stages of B cell development, namely in controlling 
plasma cell differentiation (Klein, et al., 2006; Mittrucker, et al., 1997) and co-localizes with 
IgMSC1 on chromosome 13. In principle, several genes in the region flanked by D13MIT115 
and D13MIT88 that encompass the highest linked marker in the IgMSC1 locus could mediate 
the observed IgM serum phenotype. Nevertheless, the Irf4 gene is the most plausible 
functional candidate in this interval as it was previously related to antibody secretion (Klein, 
et al., 2006; Mittrucker, et al., 1997). To ascertain whether the Irf4 gene could be involved in 
controlling the serum IgM trait, we quantified Irf4 RNA by real-time PCR in purified B cells 
from the spleen and the peritoneal cavity. We found that Irf4 expression was significantly 
reduced in splenic B cells and in peritoneal cavity B cells from the C57BL/6 (Figure IV.5). 
These data strongly suggest that Irf4 is a candidate gene to IgMSC1 and contributes to the 









Figure IV.5 Irf4 gene expression is decreased in purified B cells from the spleen and 
peritoneal cavity of C57BL/6 mice 
 
RNA of the Irf4 gene was quantified in purified B cells from spleens of 5 C57BL/6 (black bars) and 5 
BALB/c (white bars) adult mice or in purified B cells from pooled peritoneal cavity lavages of 5 
C57BL/6 (black column) or 5 BALB/c (white column) adult mice. The results represent the mean and 





In this work we used a mouse genome screen approach to search for genetic factors that 
control the IgM levels in the serum. We identified a major locus on mouse chromosome 13 
controlling the IgM serum concentration that we called IgM-secreting cells locus 1 (IgMSC1). 
Our results support a correlation of this phenotype with the number of IgM producing cells in 
the spleen and in the peritoneal cavity, leading us to hypothesize that the IgMSC1 controls 
IgM serum concentration by regulating the differentiation and/or maintenance of plasma cells 
both in the spleen and in the peritoneal cavity. It has been described that the serum anti-RBC 
IgM concentration is linked to the 40 to 49.5 cM region on chromosome 13 (Lee et al., 2004) 
and we show that gene(s) controlling natural IgM secretion are also localized in this 
chromosome. However, the anti-RBC locus (40-49.5 cM) and the IgMSC1 locus (9-30 cM) 
are somewhat apart on chromosome 13 raising the possibility that they would not correspond 
to the same genetic factor. We noted that the IgG serum concentration in C57BL/6 mice was 
significantly higher as compared to BALB/c and that IgMSC1 was not controlling levels of 
serum IgG in the genetic cross we analyzed (data not shown). This indicates that the genetic 
mechanisms that control IgM and IgG serum steady state levels have distinct and 
independent components.  
The IgMSC1 locus is tightly linked to the interferon regulatory factor 4 (Irf4) gene region on 
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mouse chromosome 13 and we showed that the relative expression of this transcription 
factor is reduced in C57BL/6 B cells isolated from the spleen and from the peritoneal cavity. 
Thus, we propose the interferon regulatory factor 4 as a candidate gene to mediate the 
IgMSC1 phenotypic effect.  
A series of recent studies have demonstrated critical functions for IRF-4 at several stages of 
B cell development, where it seems to preferentially limit clonal expansion and promote 
differentiation processes (Lu, Medina, Lancki, & Singh, 2003; Sciammas, et al., 2006). Irf4 is 
a member of the interferon-regulatory factor family of transcription factors characterized by a 
specific DNA-binding domain and the ability to either activating or repressing the transcription 
of interferon-inducible genes (Mamane, et al., 1999; Shapiro-Shelef & Calame, 2005). 
Expression of Irf4 is restricted to cells of the immune system, including lymphocytes, 
dendritic cells and macrophages, in which it has been linked to a variety of functions, such as 
proliferation, apoptosis and differentiation (Fanzo, Hu, Jang, & Pernis, 2003; Marecki & 
Fenton, 2002; Pernis, 2002). Irf4 knockout mice have normal early B cell development but 
profound reduction in serum immunoglobulin concentrations and show incapability to mount 
antibody responses due to a late stage blockage in peripheral B cell maturation that leads to 
the absence of plasma cells, plasmablasts and class-switched B cells (Klein, et al., 2006; 
Mittrucker, et al., 1997). Recently, the Irf4 gene has been demonstrated to have a biphasic 
expression pattern: it is expressed in immature B cells in the bone marrow (Lu, et al., 2003), 
absent from proliferating germinal center centroblasts and then re-expressed in a 
subpopulation of centrocytes in the germinal center and in plasma cells (Falini et al., 2000). 
Extending these studies, the evidences provided here introduce the notion that natural 
genetic variation at the Irf4 gene impacts in its expression levels, being a major factor in the 
quantitative control of terminal B cell differentiation and, consequently, of natural IgM 
secretion. 
It is plausible that a differential effect of Irf4 alleles could explain, at least in part, the 
observed differences in frequency of IgM secreting cells and IgM serum concentration when 
we compared the C57BL/6 and BALB/c mouse strains. It is reported that the coding region of 
the Irf4 gene in C57BL/6 and BALB/c mice shows no sequence differences except for a 
synonymous point mutation in the exon 6 (NCBI entries with accession numbers 
AAA75309.1 and AAA75283.1). On the other hand, regulatory elements have been 
described in the human Irf4 gene encompassing the 5 kb upstream the Irf4 coding region 
(Nishiya, Yamamoto, Imaizumi, Kohno, & Matsuyama, 2004). However, we have sequenced 
4763 bp upstream the translational starting site of the Irf4 gene and did not find sequence 
differences between C57BL/6 and BALB/c mice. Thus, it is possible that the allelic variation 
controlling the observed differences in RNA expression lies in yet unidentified Irf4 gene 
regulatory regions. In fact, the functional conformation of the Irf4 promoter region suggests 
that its expression is strictly regulated in the chromatin context (Nishiya, et al., 2004). 
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Detailed functional studies of the control region of the mouse Irf4 gene would be needed to 
enable a systematic analysis of the differential expression of the C57BL/6 and BALB/c Irf4 
alleles. 
This work highlighted a region on mouse chromosome 13 that contains genetic factor(s) 
involved in the circuitry of the serum immunoglobulin homeostasis and led us to hypothesize 
that allelic variation in Irf4 gene may control the homeostasis of serum IgM in the mouse at 
the level of the generation of antibody-producing cells. These findings may motivate human 
studies on the genetic control of IgM and natural antibody levels in normal individuals and in 
the context of Ig deficiencies and inflammatory autoimmune diseases, particularly focused on 
genes mapping in the region ortholog to IgMSC1, including the Irf4 gene. 
 
 
MATERIALS AND METHODS 
 
Mice 
The mouse strains used in this study included the C57BL/6 and BALB/c as well as mice from 
the genetic crosses F1 (C57BL/6 X BALB/c) and F2 (C57BL/6 X BALB/c). All mice were 
females between 6 and 8 months of age, bred and maintained in conventional housing 
facilities at the Instituto Gulbenkian de Ciência. F1 (C57BL/6 X BALB/c) mice were used to 
generate an F2 (C57BL/6 X BALB/c) progeny of 136 animals. 
 
Genotyping 
Genomic DNA was extracted from mouse tails with standard digestion/ precipitation 
methods. The F2 generation was genotyped using 100 microsatellite DNA markers, 
polymorphic for the parental strains. Markers were chosen according to their chromosomal 
position as given by the Broad Institute for genome research (USA), to cover uniformly the 
whole mouse genome at an average density of 20 cM. The genotypes for each locus were 
determined by DNA marker amplification using conventional PCR techniques. Amplification 
products were analyzed in 4% agarose gels (Cambrex BioScience, East Rutherford, NJ, 
USA) with ethidium bromide (Sigma-Aldrich, St Louis, MO, USA) and the allele size was 
determined using the Eagle Eye® II video system (Stratagene, San Diego, CA, USA).  Each 
individual of the F2 progeny was typed for each marker as homozygous for one or the other 




IgM serum concentration 
Standard indirect ELISA was used to quantify total IgM concentrations in mouse sera. Briefly, 
flat-bottomed 96-well ELISA plates were coated overnight at 4ºC, with goat anti-mouse-IgM-
UNLB human adsorbed antibody (Southern Biotech. Birmingham, AL, USA) diluted in coating 
buffer (0.05M Na2CO3). The plates were washed with PBS, blocked with PBS-gelatin 1% and 
incubated at 37ºC for 60 minutes. After washing, eight serial dilutions of sera to be tested 
(starting at 1:90 and using 1:3 dilution steps) were incubated for 60 minutes at 37ºC and 
washed. Bound seric IgM was detected by the peroxidase-conjugated goat anti-mouse IgM-
HRP human adsorbed antibody (Southern Biotech.) diluted in PBS-Gelatin 1%-Tween 
0.075% (1:4000), revealed with the substrate o-phenylenediamine (Calbiochem, Gibbstown, 
NJ, USA) and H2O2 and the OD read at 490 nm. The concentrations of IgM antibody in the 
samples were calculated against standard curves obtained with purified monoclonal IgM 
(mouse-IgM UNLB, clone 11E10, Southern Biotech.) tested in the same microtitre plate. 
 
Genetic analysis 
Quantitative trait locus analysis was performed by using the normal model in the R/QTL 
software (Broman, Wu, Sen, & Churchill, 2003). This program calculates logarithm of odds 
(LOD scores) over intervals between linked markers, generating likelihood plots of genetic 
association with the phenotype across the genotyped chromosomal regions. The genome-
wide statistical significance of the results was empirically determined by performing 
permutation tests (Lander & Kruglyak, 1995) and the QTL confidence interval was calculated 
using the Bayesian method of R/QTL (Broman & Sen, 2009). 
 
IgM-secreting cells    
The number of IgM-secreting cells was determined by ELISA-Spot-Assay (ESA). The plates 
were coated overnight at 4ºC with goat anti-mouse IgM-human adsorbed (Southern 
Biotech.), diluted in coating buffer (0.05M Na2CO3) and the plates saturated with PBS 
containing 1% gelatin. Serial three-fold dilutions of total splenocytes (starting with 106 cells), 
spleen purified B-cells (starting with 3x106 cells) or sorted peritoneal cavity B cells (starting 
with 7,5*103 cells) were performed in RPMI 1640 medium supplemented with 10% heat 
inactivated fetal calf serum (FCS), 2 mM L-glutamine, 10 mM HEPES (pH 7.4), 50 mM 2-
mercaptoethanol, 100 U penicillin and 100 mg/ml streptomycin (all from Life Technologies, 
N.Y. USA). Cell dilutions were added and the plates were sealed and incubated overnight at 
37ºC in a humidified 5% CO2 atmosphere. Non-adherent cells were thereafter removed by 
flicking the plate followed by lysis with 0.1% Tween-20 in water. After extensive washing with 
PBS containing 0.05% Tween-20 the plates were incubated with goat anti-mouse IgM-AP 
conjugated antibody (Southern Biotech.), washed again and revealed with BCIP-AMP 
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substrate (2.3 mM of 5-bromo-4-chloro-3-indolyl phosphate diluted in 2-amino-2-methyl-1-
propanol buffer, Sigma-Aldrich). After incubation overnight at 4ºC and washing three times 
with distilled water, the traces of IgM-secreting cells were revealed as blue spots and 
counted. 
 
B cell purification 
Splenocyte suspensions were prepared by straining of the spleens through a nylon mesh 
and peritoneal cavity cell suspensions were obtained from peritoneal lavage with 7 ml of PBS 
supplemented with 2% FCS. Purified B cells, with an average purity of 98%, were obtained 
from splenocyte and peritoneal cavity cell suspensions through high speed cell sorting 
(MoFlo, Cytomation Inc., Fort Collins, CO, USA), after labeling with FITC-anti-mouse CD19 
(clone 1D3, BD Biosciences, California, USA). 
 
RNA isolation and Real-Time PCR 
Total RNA from sorted splenic and peritoneal B cells was obtained using an RNeasy Mini Kit 
(Qiagen, Hilden, Germany), following the manufacturer´s protocol for animal cells. RNA was 
converted to cDNA (Transcriptor First Strand cDNA Synthesis Kit, Roche, Mannheim, 
Germany) using random hexamer primers. Irf4 (Mm0051634-m1) expression was quantified 
using TaqMan Gene Expression Assays from ABI with TaqMan Universal PCR master mix. 
The gene expression quantification reactions were performed in an ABI Prism 7900HT 
system. Relative quantification of Irf4 (Mm0051634-m1) in each real-time PCR reaction was 
obtained after normalization for GAPDH expression measured in the same PCR reaction and 
used the 2-CT analysis method (Livak & Schmittgen, 2001). 
 
Statistical analysis 
Statistical significant differences in serum IgM concentration, B cell number, IgM secreting 
cell number and Irf4 relative expression were estimated by student’s t-test. Differences with 
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The non-obese diabetic mouse (NOD) is widely used as a model to study human type 1 
diabetes (T1D). In the NOD mouse T1D is a T cell mediated autoimmune disease of complex 
etiology in which B cells play an essential role.  One of the major unresolved issues in T1D is 
the genetic and/or environmental factors that trigger the autoimmune reaction. In the NOD 
mouse, as in humans, autoantibodies to pancreatic islets are present at early ages and are 
highly correlated to diabetes progression, but their etiological role has long been disputed. 
NOD autoantibodies have the characteristics of a natural repertoire and B1 cells, the main 
natural antibody producers, exhibit functional differences in this strain that could have 
consequences for disease determination. Using a genetic approach, we propose to test if the 
NOD natural autoantibody repertoire includes innate reactivities that participate in diabetes 
pathogenesis by promoting insulitis initiation. 
 







Type 1 diabetes (T1D) is well established as a multifactorial disease with an initial insulitis 
phase that involves dendritic cells, macrophages, CD4+ T cells, CD8+ T cells and B cells 
(Yang & Santamaria, 2003) followed by a diabetic phase where onset of disease is caused by 
selective and progressive autoimmune destruction of the insulin-secreting -cells in the 
pancreas (Bach, 1994). However, the mechanisms underlying the loss of tolerance to specific 
self-antigens are unknown. In diabetic patients and in non-obese-diabetic (NOD) mice T1D 
develops spontaneously, is pathogenically similar (Castano & Eisenbarth, 1990) and is under 
complex genetic control (Ghosh et al., 1993). Environmental factors have also been 
demonstrated to have a modulatory role in T1D progression (Bach, 1994) and could act as 
disease triggers in humans while in NOD laboratory mice, bred and maintained in controlled 
housing conditions, genetically determined factors should assume a major role as initiators of 
the autoimmune process. 
It has been shown that absence of B cells prevents diabetes in the NOD mouse (Akashi et al., 
1997) but the roles that B cells may play in the NOD autoimmune reaction cascade are not 
fully understood. B cell receptor specificity (Hulbert, Riseili, Rojas, & Thomas, 2001) and B 
cell antigen-presenting function have been demonstrated to play a part in disease 
development (Wong et al., 2004), but other functional aberrations or distortions in the 
development of B cell repertoires could have implications for pathogenesis in this strain.  
Autoantibodies have served historically as the sine qua non evidence to indicate the 
involvement of B cells in autoimmune diseases. They provide diagnostic and prognostic 
criteria, play a requisite role in disease pathogenesis and serve as surrogate markers for 
disease activity (Martin & Chan, 2004). For most autoimmune diseases, however, the 
mechanistic relationship between pathogenic B cells, their products and clinical 
manifestations remains elusive.  
NOD mice produce various islet -cell specific autoantibodies although it is still a subject of 
debate whether they contribute to T1D development (Inoue et al., 2007). Currently, 
autoantibodies are looked at as being T1D biomarkers, secondary to the occurring pathogenic 
process, but their presence largely precedes disease and is highly correlated with its 
progression (Bingley et al., 1997; Bonifacio et al., 2001). In addition, maternal antibodies have 
been proven to be important for T1D development in the NOD progeny (Greeley et al., 2002), 
thus it is likely that their role is being underestimated. 
It has been demonstrated that the NOD B cell compartment is highly active and that early 
detected autoantibodies have the characteristics of a natural repertoire (Thomas, Kendall, & 
Mitchell, 2002). Natural antibodies are spontaneously secreted by B1 cells, characterized by 
the expression of the CD5 molecule (Herzenberg, 2000), by the capacity for self-renewal and 
by the preferential localization in the peritoneal and pleural cavities (Dorshkind & Montecino-
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Rodriguez, 2007). These antibodies belong mainly to the IgM isotype, are encoded by 
germline genes and are polyreactive, being implicated in a variety of functions including 
immunoregulation, homeostasis and repertoire selection (Coutinho, Kazatchkine, & 
Avrameas, 1995), and also in autoimmunity (Thomas, et al., 2002). 
Previous studies showed that in a transgenic mouse model some insulin specific B cells 
evade the mechanisms of tolerance induction by entering a B1-like compartment in the 
peritoneal cavity (Rojas, Hulbert, & Thomas, 2001), and that B cells secreting anti-insulin with 
structural characteristics of natural autoantibodies exist in human T1D, evoking the 
contribution that B1 cells may have to the autoimmune process (Ichiyoshi, Zhou, & Casali, 
1995). The suggestion of a role for B1 cells in T1D pathogenesis arose once more in a recent 
report showing their presence in the pancreatic infiltrates of NOD mice and a delayed onset of 
disease upon its specific elimination from the peritoneal cavity. In this study, the protection 
from diabetes correlated with the maintenance of B-cell tolerance, measured as the 
concentration of insulin-specific IgG in the sera (Kendall, Woodward, Hulbert, & Thomas, 
2004).  
It has been argued that the large pool of natural autoantibodies in the NOD mouse may fuel 
the autoimmune process if appropriate T-cell help is available (Thomas, et al., 2002) and the 
idea that natural IgM of certain specificities, most probably genetically determined, may have 
a role as pathogenic initiators of insulitis and T1D autoimmune pathogenesis through 
increased antigen presentation, direct islet injury or complement activation, is sustained by 
several lines of evidence described in the following paragraphs. 
 
Natural autoantibodies as initiators of autoantigen presentation to T cells 
1) The majority of B lymphocytes and macrophages constitutively express Fc/ receptors that 
allow phagocytosis of IgM-antigen complexes and facilitate subsequent antigen processing 
and presentation (Shibuya et al., 2000). In agreement, mice deficient in the secretory form of 
IgM exhibit delayed development of T cell dependent humoral responses (Ehrenstein, O'Keefe, 
Davies, & Neuberger, 1998), suggesting that the uptake of IgM-antigen complexes through 
Fc/ receptors plays an essential role in the priming of helper T lymphocytes (Shibuya, et al., 
2000), which is a critical step in the autoimmune process evolving in the NOD mouse. 
2) Fc- receptor deficient NOD mice have decreased incidence of insulitis and diabetes, 
independently of autoantibody levels. In this scenario, it is inferred that activating Fc- 
receptors augment autoantigen presentation leading to the activation of autoreactive T cells 
(Inoue, et al., 2007). Most likely Fc- receptors interaction with IgG containing immune 
complexes occurs only after the initiation of the autoimmune reaction and could serve as an 
autoimmunity amplification mechanism. This leaves open the possibility that a similar process 
of antigen presentation to T cells could take place at the initial steps of disease process, 
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before IgG presence in the system, through IgM-antigen interaction with Fc/ receptors on 
antigen presenting cells. 
3) B cell surface Ig can also mediate an increased loading onto MHC molecules as a result of 
an augment in antigen uptake (Takai, 2002). It has been shown that GAD autoantibodies are 
implicated in GAD presentation to T-cells, thus antibody specificities are likely modulators of 
the T cell epitopes made available by antigen-presenting cells (Reijonen, Daniels, Lernmark, & 
Nepom, 2000). This may represent a mechanism of revealing otherwise cryptic T cell 
determinants to which tolerance has not been established and may be relevant in the drive 
toward high affinity antibodies. Autoantibody specificity and titers may therefore alter the focus 
of the T cell response over time, contributing to the initiation and perpetuation of autoimmunity 
in T1D (Takai, 2002). 
 
Natural autoantibodies as pancreatic islet injurers 
1) Prior to the first appearance of insulitis NOD mice are sensitized to islet-cell associated 
antigens and a small percentage of -cells have autoantibody bound to their surface. 
Additionally, sera collected from these animals contain autoantibodies that bind to -cells of 
both T1D-prone and T1D-resistant mice. Autoantibodies binding to pancreatic -cells in this 
strain are predominantly of the IgM isotype (Jaume, Parry, Madec, Sonderstrup, & 
Baekkeskov, 2002), therefore an early humoral response may be involved in -cell targeting, 
the initiation of insulitis and subsequent disease development. 
2) Natural autoantibodies bound to pancreatic islet antigens can trigger the complement 
system mediated inflammation (Shieh, Cornelius, Winter, & Peck, 1993), which may 
contribute to the observed deregulation in the NOD mouse immune system and modulate T1D 
development. 
Moreover Fc-receptor activation can regulate immune-cell responses such as B cell 
proliferation (Shieh, et al., 1993). Thus, at early times, IgM-antigen interaction with Fc/ 
receptors could have an autocrine effect on B cell populations leading to expansion of B cells 
bearing autoreactive specificities and facilitating the autoimmunity process. 
 
NOD mice display defects at the level of the B1 cell compartment that may contribute 
to IDDM pathogeny 
Early-detected autoantibodies in the NOD mouse show characteristics of a natural repertoire 
(Thomas, et al., 2002), suggesting a genetic determination of the specificities of the major 
contributors for natural autoantibody production in this strain, namely non-anergic B cells and 
autoreactive B1 cells. Despite the multitude of factors that have been suggested to participate 
in the T1D pathogenesis it has been difficult to identify those that are involved in the very first 
steps of the autoimmune reaction. Here, we propose that soluble islet-specific natural 
antibodies promote disease either by enhancing professional antigen presentation of islets 
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antigens or by directly causing the initial tissue damage and islet cell antigens release. In this 
context, the genetically specified pre-insulitic IgM antibody repertoire would have a role in the 
initiation of T1D pathogenesis.  
To address this hypothesis we initiated the characterization of the NOD and the C57BL/6 
strains B cell compartment at the populational and functional levels at early ages, when 
insulitis is still incipient. We did not find in the NOD mouse B2 cell population abnormalities 
that could be easily correlated to the described pattern of autoreactivity, but NOD mice show 
alterations at the level of the B1 cell compartment that can be contributing to its increased 
natural autoreactivity and involved in T1D pathogenic process. Flow cytometry analysis of 
stained splenocyte and peritoneal cell suspensions revealed that B1 cells are 
overrepresented in the NOD spleen (Figure V.1) and ELISPOT ASSAY (ESA) 
characterization of purified B1 cells in these locations showed that peritoneal cavity NOD B1 
cells have an increased capacity for natural IgM secretion (Fig V.2). Importantly no such 
alterations were observed in the B1 cell population in the spleen (data not shown).  
 
 
Figure V.1 Percentage of B1 cells within B cells in the spleen at 4 weeks of age  
 







Figure V.2 Proportion of IgM secreting B1 cells in the peritoneal cavity relative to the 
NOD strain, at 4 weeks of age  
 
The bars represent the mean and standard deviation of three separate experiments of groups of ten 
animals, assayed in triplicates. 
 
 
Insulin and Glutamate Decarboxylase (GAD) have been validated as main autoantigens 
associated with T1D in humans and in the NOD mouse (Bonifacio, et al., 2001), being the 
GAD67 isoform highly expressed in the NOD pancreas (Pleau, Esling, Van Acker, & 
Dardenne, 1996) and its overexpression connected to increased insulitis and diabetes 
development (Kim et al., 2002). Interestingly, when looking for B1 secretion of autoantigen-
binding natural IgM by ESA, we found that peritoneal cavity NOD B1 cells are more prone to 
spontaneously secrete IgM that recognizes insulin and GAD67 than C57BL/6 B1 cells (Figure 
V.3). This property was exclusive of B1 cells in this location, since the homologous population 
in the spleen was unable to recognize such antigens (data not shown). These results are 
consistent with a study that suggests that unique features of the peritoneal cavity 
microenvironment may foster natural autoantibody production by B1 cells in transgenic 
systems (Rojas, et al., 2001). Therefore, we propose that before disease onset the NOD B1 
cell compartment is overrepresented in the spleen and is over-activated in the peritoneal 
cavity where it generates a repertoire of antibody specificities biased to the recognition of T1D 
related antigens. As previously discussed, such alterations could have implications to disease 
process initiation and to the autoimmune reaction amplification. 
To further test the hypothesis that the NOD repertoire of natural antibodies has particularities 
that may be involved in the progression to T1D, we measured the NOD and C57BL/6 early 
reactivity patterns of serum IgM against a large antigen collection. Using peptide chip arrays 
and principal component analysis, we found that particular specificities discriminate these 
strains reactivity profile (data not shown). Although these findings require further investigation 
they are consistent with our hypothesis. 
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Figure V.3 Percentage of IgM secreting B1 cells able to recognize type 1 diabetes 
related autoantigens (Insulin, GAD67) in the peritoneal cavity, at 4 weeks of age  
 
The bars represent the mean and standard deviation of one representative experiment of groups of ten 
animals, assayed in triplicates. 
 
 
Genetic control of B1 cell autoreactivity in the NOD mouse  
The pathogenic role of autoantibodies in T1D is controversial and many abnormalities 
observed in the NOD mouse B cell compartment are hard to link to T1D pathogenesis on the 
basis of correlations with other immunological parameters. We are particularly interested in 
understanding the role that B1 cells, as natural autoantibody producers, may have in T1D 
progression. We are addressing this question by using a genetic approach that will allow us to 
establish the connection between abnormalities in the B1 cell compartment, generation of 
autoantibodies and diabetogenesis in the NOD mouse. One possibility is to test whether 
already described insulin-dependent-diabetic loci (Idd) control the development and functional 
activation of autoreactive B1 cells, whose natural autoantibodies would have a role in initiating 
the pancreatic -cell destruction, ultimately leading to overt T1D (Figure V.4). Following this 
approach we are currently characterizing the NOD natural IgM autoreactive pattern and 
analyzing several NOD congenic strains, aiming to map these phenotypes within established 
congenic regions. 
This approach will help clarify the role of autoantibodies in the murine T1D and in particular 
to distinguish germline encoded pathogenic specificities from the effects of epitope spreading 
induced by the disease progression. The demonstration of a role for B1 cells and natural 
autoantibodies in the development of T1D, through the dissection of its genetic control, may 
contribute to develop strategies that block disease progression in the NOD mouse and 




Figure V.4 The presence of autoreactive natural antibodies, due to the genetically 
determined development and functional activation of autoreactive B1 cells, may 
initiate the pancreatic -cell autoimmune reaction (1) and fuel the autoimmune process 
through complement system activation (2), increased antigen presentation (3) and 





Due to the length of this paper, we are unable to summarize all of the cutting edge issues 
that surround this research.  For this reason, we refer to the following recent literature on this 
subject (Bresson & von Herrath, 2007; Knip & Siljander, 2008; Marino & Grey, 2008; 
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Chapter VI. Article III: Innate stimulation of B1a cells enhances the autoreactive IgM 
repertoire in the NOD mouse: implications for type 1 diabetes  
 
 
INNATE STIMULATION OF B1a CELLS ENHANCES THE AUTOREACTIVE IgM 
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Aims/Hypothesis: We sought to determine whether the presence of natural autoreactive 
antibodies of B1a cell origin would play a role in type 1 diabetes (T1D) initiation. 
Methods: We have compared IgM repertoires and B1a cell compartments in NOD and 
C57BL/6 mice. Serum IgM autoreactivity profiles were determined by ELISA and the 
secretory properties and activation status of B1a cells were characterized by ELISPOT 
Assay and flow cytometry. B1a cells response to innate activation was analyzed by gene 
expression assays, ELISA and 3H-thymidine incorporation. The effect of IgM produced by 
NOD B1a cells on NOD.SCID beta cells was examined in co-cultures: IgM binding was 
measured by flow cytometry and Real-Time PCR was used to study oxidative stress 
responses. 
Results: NOD displayed increased levels of serum anti-insulin-IgM that were independent of 
the H2 locus, that were maintained up to pre-diabetic stages, and that correlated with the 
NOD B1a cells secretion profile. NOD B1a cells were naturally more activated, expressed 
higher levels of Toll-Like-Receptors (TLR) and responded to TLR stimulation in vitro with 
higher proliferation and increased capacity to secrete anti-T1D related IgM, but produced 
lower amounts of IL10. Spontaneously secreted IgM of NOD B1a cells origin was able to 
bind to pancreatic beta cells in vitro and induced iNOS expression in islet cultures. 
Conclusions/interpretation: NOD B1a cells revealed lower innate activation threshold for 
secretion of autoreactive IgM capable to trigger oxidative stress responses upon binding to 
pancreatic beta cells and providing an early pathogenesis mechanism in murine T1D. 
 
Keywords: NOD, type 1 diabetes, autoreactive IgM, B1a cells, Toll-like-receptor, pancreatic 
beta cell, oxidative stress. 
 
Abbreviations: AAb: autoantibodies, AAg: autoantigens, BCR: B cell receptor, IA-2: islet cell 
antigen 512,  iNOS: inducible nitric oxide synthase, LPS: Lipopolysaccharide, NAbs: natural 
antibodies, PCA: Principal Component Analysis, SLE: systemic lupus erythematosus, SPF: 








The urgency to identify the subtle factors contributing to Type 1 Diabetes (T1D) onset and 
progression is compelled by recent European statistics indicating that the number of new 
cases of T1D in children under the age of five is increasing by more than 5% each year and 
predicting the doubling of T1D incidence in this age group, by 2020 (Patterson, Dahlquist, 
Gyurus, Green, & Soltesz, 2009). Diabetic patients and non-obese-diabetic (NOD) mice 
share the spontaneous pathogenic events of T1D development (Castano & Eisenbarth, 
1990) in which autoreactive cytotoxic T cells selectively destroy insulin secreting beta cells 
within the pancreatic islets of Langerhans (Bach, 1994). Nevertheless, studies on NOD mice 
devoid of B cells have shown that this lymphocyte population is necessary in the diabetic 
autoimmune process (Serreze et al., 1996) and it is widely accepted that islet-related 
autoantibodies (AAb) represent the earliest manifestations of diabetogenesis both in pre-
diabetic patients and in NOD mice (Leslie, Lipsky, & Notkins, 2001). These autoreactive 
immunoglobulins, of the IgG isotype, recognize beta cell antigens and are believed to be 
bystander products of the disease resulting from an ongoing autoimmune process (Leslie, et 
al., 2001). Thus, in the stage of cytotoxic beta cell destruction, B cells would be highly 
exposed to beta cell related autoantigens (AAg) leading to preferential activation of B cells 
with autoreactive potential. In fact, NOD BCR specificity and B cell antigen presentation 
capacity to T cells are determinant factors in T1D progression (Hulbert, Riseili, Rojas, & 
Thomas, 2001; Noorchashm et al., 1999). It is believed that long-sustained autoreactive T-B 
cell interactions condition the repertoire of AAb typical of pre-diabetic patients, where the 
beta cell destruction is already in progress, though clinical signs are not yet present. 
Importantly, B-cell–null NOD mice that express a transgene encoding a mutant heavy chain 
immunoglobulin on the cell surface but cannot secrete antibodies only partially restored T1D 
suggesting that circulating antibodies could play a role in the disease (Wong et al., 2004). 
Here, we revisited the role of autoantibodies in T1D pathogenesis under the contention that 
the early presence of AAb against beta cell antigens can have implications for T1D 
pathogenesis. Insulitis consists of the infiltration of pancreatic islets of Langerhans by 
mononuclear cells and is the hallmark of T1D initiation. In NOD mice the first insulitic events 
start around 3-5 weeks of age but clinical signs of diabetes, due to massive beta cell loss, 
arise only from 12 weeks onwards (Yang & Santamaria, 2003). It has been previously shown 
that NOD, but not C57BL/6 non-diabetic controls, have antibodies bound to beta cells before 
development of insulitis. Interestingly, these antibodies are mainly of the IgM isotype (Shieh, 
Cornelius, Winter, & Peck, 1993) and thus unlikely to originate in germinal center reactions. 
Consistently, young NOD mice have a pronounced repertoire of IgM AAb (Thomas, Kendall, 
& Mitchell, 2002). Most of the antibodies of the IgM isotype are spontaneously secreted by 
B1a cells in the absence of exogenous stimuli or T cell help (Casali & Schettino, 1996). The 
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B1a cells are part of the B1 cell subset of lymphocytes that are mainly found in the peritoneal 
and pleural cavities and at lower levels in the spleen. These B1 cells express low levels of 
B220 and are subdivided into B1a and B1b subsets based on the presence or absence of the 
CD5 molecule on their surface, respectively. B1a cells are mostly of fetal origin, do not 
undergo class switching and affinity maturation and spontaneously secrete natural AAb 
(Herzenberg, 2000). On the other hand, B1b cells are generated mainly during neonatal life 
in the bone marrow (Stall, Wells, & Lam, 1996) and are involved in the earliest specific 
reaction against pathogens (Martin, Oliver, & Kearney, 2001; Ochsenbein et al., 1999). The 
CD5 expression on B1a cells is known to downmodulate responses to BCR mediated 
signaling while favoring IL10 secretion (Bikah, Carey, Ciallella, Tarakhovsky, & Bondada, 
1996; Gary-Gouy et al., 2002). Interestingly, the B1 cells activation status is influenced by gut 
microflora modifications (Alam et al., 2011; Alam et al., 2010) and innate stimulation through 
toll-like receptors (TLRs) can induce their proliferative and antibody secretion capacities 
(Genestier et al., 2007). Thus, B1 can be considered as bridging cells between innate and 
adaptive immunity.  
Importantly, B1a cells have recently been proven to be necessary for insulitis onset in a 
transgenic model in which disease is mediated by T cells recognizing pancreatic beta cell 
antigens (Ryan et al., 2010). Also, in the 125Tg mouse, B1a cells prevailed as anti-insulin 
IgM secretors while B2 cells with the same specificity were anergized (Rojas et al., 2001). 
Further, B1a cells are increased in the peripheral blood of T1D patients (Gyarmati, Szekeres-
Bartho, Fischer, & Soltesz, 1999) and have been suggested to play a role in the NOD 
autoimmune process (Kendall, Woodward, Hulbert, & Thomas, 2004). 
 We have previously hypothesized that NAbs of NOD B1a cell origin could promote the 
initiation of insulitis (Corte-Real, Duarte, Tavares, & Penha-Goncalves, 2009). However, the 
link between B1a cell properties, autoreactive IgM profile and autoimmune process triggering 
has never been established for T1D. Here, we dissect this intricate chain of events by 
analyzing the autoreactive repertoire of NOD IgM, by uncovering the B cell sub-populations 
contributing to its secretion and by examining the impact of these immunoglobulins on NOD 






C57BL/6, NOD, NOD.SCID, C57BL/6.H2g7 and NOD.H2b mice were bred and maintained in 
SPF facilities at the Instituto Gulbenkian de Ciência. All mice used were females with 1 to 12 
weeks of age. NOD female insulitis was unapparent at 3 weeks. Experimental protocols were 
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approved by the competent Portuguese authority (Direcção Geral de Veterinária) and are in 
accordance with international regulations (U.S. Department of Health and Human Service, 
Office of Extramural Research, National Institutes of Health, Office of Laboratory Animal 
Welfare, 1985). 
 
ELISA and ELISPOT assays 
ELISA was used to quantify total IgM and anti-insulin IgM concentrations in mouse sera. 
Total IgM, IgM with reactivity to a pool of T1D related AAg and IL10 levels were measured in 
cell culture supernatants after TLR stimulation. Briefly, ELISA plates (Nunc) were coated with 
IgM, insulin only (Sigma) or a T1D AAg pool of insulin, IA-2 (GenWay Biotech), GAD65 and 
GAD67 (United States Biologicals). Bound seric IgM was detected by goat-anti-mouse-IgM-
Alkaline-Phosphatase (AP) conjugated antibody (Southern Biotech.) revealed with sigma 
phosphatase substrate and optical densities read in a spectrophotometer at 405 nm. IgM 
concentrations were calculated against standard curves obtained with either purified 
monoclonal IgM (clone 11E10, Southern Biotech.) or anti-insulin IgM kindly provided by JW 
Thomas (Thomas, Kralick, & Ewulonu, 1997). IL10 concentration was determined with a 
mouse IL-10 ELISA MAX™ Deluxe kit (Biolegend) according to manufacturer’s instructions.  
The number of B cells secreting IgM with reactivity to the previously described T1D AAg 
pool, to thyroiditis associated AAg (thyroglobulin and thyroperoxidase), to the sialitis related 
AAg muscarinic-3-receptor, to Systemic Lupus Erythematosus (SLE) associated AAg (ds-
DNA, ss-DNA and histone) or to AAg typically recognized by B1a cells (phosphatidylcholine, 
phosphorylcholine and dextran) (Baumgarth, Tung, & Herzenberg, 2005) were determined as 
described elsewhere (Corte-Real et al., 2009). Briefly, cell dilutions were performed in RPMI 
1640 complete medium with 1% BSA and incubated overnight at 37ºC. Cells were removed 
by washing with 0.1% Tween-20 and plates were incubated with goat anti-mouse IgM-AP 
conjugated antibody and revealed with BCIP-AMP substrate (2.3 mM of 5-bromo-4-chloro-3-
indolyl phosphate diluted in 2-amino-2-methyl-1-propanol buffer, Sigma).  
 
Cell analysis and purification 
Single cell suspensions were prepared from spleen and from peritoneal cavity lavage and 
incubated with anti-mouse-Fc-block/CD16/32 (clone 2.4G2, BD Pharmingen). Peritoneal B1a 
cells were identified as B220+CD5+ cells and B1b+B2 cells as B220+CD5- cells. Splenic B1a 
cells were identified as CD23-IgMhighB220lowCD5+ cells, follicular B lymphocytes as 
CD23+IgMlow and marginal zone B cells as CD23-IgMhighCD21+CD5-. FITC-anti-CD19 (clone 
1D3), FITC-anti-IgM (clone R33.24.12), PE-anti-CD23 (clone B3B4), Percp or PE-anti-CD5 
(clone 53-7.3), APC-anti-CD45R/B220 (clone RA3-6B2), biotinylated or FITC-anti-
CD11b/Mac-1 (clone M1/70), FITC-anti-CD21 (clone 7G6), PE-anti-CD43 (clone S7), 
biotinylated-anti-CD86 (clone GL1), FITC-anti-CD62L (clone Mel14), biotinylated or PE-anti-
70 
 
Syndecan-1 (clone 281-2) and FITC or Percp-Streptavidin antibodies were used for staining. 
Traceable latex beads (Beckman coulter) were added for counting cells. Flow cytometry 
(FACSCaliburTM) with CELLQuest software (Becton Dickinson, Franklin Lakes, NJ, USA) was 
used and data analysis performed with FlowJo software (TreeStar). Peritoneal and splenic B 
cell populations were purified by high speed cell sorting MoFlo (Dako-Cytomation, Berkeley, 
CA, USA) or BD FACSAria III cell sorter (BD Biosciences, Franklin Lakes, NJ, USA). Cell 
purity was higher than 90%.  
 
RNA isolation and Real-Time PCR 
Total RNA from sorted peritoneal cavity B1a cells or from cultured beta cells was obtained 
using a High Pure RNA Isolation Kit (Roche) following the manufacturer’s protocol. RNA was 
converted to cDNA with Transcriptor High Fidelity cDNA Synthesis Kit (Roche). The following 
TaqMan Gene Expression Assays with FAM-reporter (Applied biosystems) were used: Tlr2 
(Mm00442346_m1), Tlr4 (Mm00445274_m1), Tlr6 (Mm02529782_s1), Tlr7 
(Mm00446590_m1), Tlr9 (Mm00446193_m1), Fas (Mm00433237_m1), Nos2 
(Mm01309901_m1), Caspase 3 (Mm01195084_m1) and Ccl2 (Mm00441242_m1). Gene 
expression quantification was performed in ABI Prism 7900HT (Applied Byosistems, Foster 
City, CA, USA). Relative quantification in each real-time PCR reaction was obtained after 
normalization for mouse GAPDH (VIC/MGB probe)  expression using the 2-CT analysis 
method (Livak & Schmittgen, 2001).  
 
Lipopolysaccharide stimulation 
Purified peritoneal B1a cells were cultured in RPMI 1640 complete medium with or without 1-
5 g/ml of purified LPS and supernatants were taken for antibody and IL10 quantification by 
ELISA at day 3 of culture. For proliferation analysis cells were pulsed in the last 6 h of 
culture, harvested and 3H-thymidine (Perkin Elmer) incorporation was measured. Expression 
of activation markers after one day of stimulation was assessed on pooled duplicates using 
biotinylated-anti-CD69 (clone H1.2F3), biotinylated-anti-CD86 (clone GL1), Alexa488-anti-
CD25 (clone PC 61) and Percp-Streptavidin. 
 
In vitro transwell cultures  
Islets of Langerhans were isolated from the pancreas of 9 weeks old NOD.SCID females by 
collagenase type V digestion (1.4 mg/ml, Sigma) followed by hand picking under a 
stereomicroscope. Islets were subsequently dissociated into single cell suspensions by 
simultaneous mechanical and dispase enzymatic treatment (5 mg/ml, Roche). Freshly 
dissociated cells were cultured at 1*105 cells per well in Ham’s F-10-glutamax medium 
(Gibco) supplemented with 10 mM glucose (Sigma), 0,5% BSA, 50 M 
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isobutylmethylxanthine (Sigma), 50 units/ml penicillin and 50 g/ml streptomycin (Gibco). 24 
hours after, sorted peritoneal cavity B1a cells (5*105) or follicular splenic B cells (5*105) were 
added in transwells (0,4 µm pore size, Millipore). After 24h of co-culture beta cells were 
either collected for flow cytometry analysis or processed for RNA isolation. Alexa647-anti-
IgM (clone R33.24.12) was used for staining of bound IgM on beta cells. Negative controls 
consisted of beta cells with lymphocyte medium only in the transwell.  
 
Statistical analysis 
Statistics were estimated by either Kruskal-Wallis or unpaired student’s t-test as specified in 
each figure legend. Two-tailed tests with 95% of confidence interval where used and 





High anti-insulin IgM level in the NOD mouse is independent of T cell autoreactivity 
To ascertain whether the NOD natural AAb repertoire was specifically directed to islet-related 
antigens, we quantified the serum concentration of total IgM and of anti-insulin IgM in NOD 
and C57BL/6 mice from 3 to 12 weeks of age. Although no differences were found in total 
IgM levels (Figure VI.1a), significantly increased levels of IgM with reactivity towards insulin 
were found in NOD mice (Figure VI.1b). Importantly, these values were stable between 6-12 
weeks indicating that they were not influenced by the progression of the disease in the NOD 
mice. This suggests that the insulin-IgM autoreactivity is a T-cell independent, intrinsic 
characteristic of the NOD natural IgM repertoire.  In support, we have analysed the profile of 
anti-insulin IgM secretion in C57BL/6.H2g7 mice, whose genetic background is similar to that 
of the C57BL/6 parental strain but contains a MHC locus of NOD origin, and in its reciprocal 
NOD.H2b congenic strain that is protected from T1D. The levels of anti-insulin IgM were 
significantly increased in the NOD.H2b compared to C57BL/6.H2g7 controls (Figure VI.1c). 
No differences were found in total IgM concentration (data not shown).  
Additionally, we have analyzed the global pattern of natural IgM reactivity by comparing the 
capacity of NOD and C57BL/6 serum IgM to recognize AAg present in NOD protein extracts 
and inferred that not only were there different patterns of IgM autoreactivity but also that 
global IgM reactivity was higher in NOD compared to C57BL/6 mice (Supplementary Figure 
VI.1).  We have also measured the serum levels of anti-insulin IgG in NOD and C57BL/6 
mice. As expected, the reactivity profile was quite different from that observed for anti-insulin 
IgM. Although very low to undetectable levels were present in the serum of both strains up to 
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6 weeks, NOD revealed a progressive increase in antibody concentration that was most 
relevant at 12 weeks (Figure VI.1d).  
 
 
Figure VI.1 Antibody IgM reactivity in the NOD is biased towards T1D antigens from 
pre-insulitic ages 
Serum antibody concentration was measured individually by ELISA. Total IgM (a) and anti-insulin IgM 
(b) was assessed in groups of 13 to 47 C57BL/6 or NOD mice at 3 weeks of age and over the interval 
of 6 to 12 weeks of age.  Anti-insulin IgM was determined in groups of 8 to 31 C57BL/6.H2g7 or 
NOD.H2b  mice (c) and  anti-insulin IgG was analyzed  in groups of 14 to 46 C57BL/6 or NOD mice (d) 
at 3, 6 and 12 weeks of age. Average concentrations are shown as horizontal bars.  Anti-insulin IgM (b 
and c) and IgG (d) were different between strains over the 3 to 12 weeks of age interval (p0.0001) in 
Kruskal-Wallis test. NOD anti-insulin IgG concentration significantly increased with time (p0.0001) 
while NOD anti-insulin IgM did not vary in the 6-12 weeks of age in Kruskal-Wallis test.   
 
 
High proportion of NOD peritoneal cavity B1a cells secretes IgM anti-T1D autoantigens 
in absence of patent insulitis  
In search of the cellular source for the altered natural antibodies repertoire in the NOD 
mouse, we quantified the number of B cells secreting IgM that were able to recognize a pool 
of T1D related AAg. We have analysed the peritoneal B1a and B1b+B2 cells and the splenic 
follicular B cells, marginal zone B cells and B1a cells (Figure VI.2a). We observed that 
already at 5 weeks of age the B1a cell peritoneal compartment contained the highest 
population of cells spontaneously secreting IgM with anti-T1D AAg reactivity. Importantly, 
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there were significantly higher numbers of B1a cells secreting IgM with these reactivities in 
the NOD when compared to the C57BL/6 control, which is consistent with the pattern that we 
have found in the serum.  We have detected a low proportion of antibody-secreting cells with 
anti-T1D AAg reactivity in peritoneal B1b+B2 cells, though no differences were observed 
between strains (Figure VI.2a). In the splenic compartment the percentage of cells with these 
properties was either zero or extremely low (Figure VI.2a). 
We next wanted to ascertain whether the observed difference in autoreactivity was restricted 
to T1D associated AAg or whether it could represent a general feature of NOD B1a cells. 
Thus, we have quantified the proportion of B1a cells secreting IgM recognizing either a pool 
of AAg related to autoimmune thyroiditis (Figure VI.2b), the main self-antigen of immune 
mediated sialitis (Figure VI.2c), a pool of antigens that are targets of SLE (Figure VI.2d), or a 
pool of antigens that B1a cells generally recognize (Figure VI.2e). Consistent with the NOD 
polyendocrine phenotype we detected more peritoneal B1a cells secreting IgM that 
recognized thyroiditis and sialitis AAg (Figure VI.2b and VI.2c), although no differences were 
found for the other AAgs tested (Figure VI.2d and VI.2e).  
 
 
Supplementary Figure VI.1 NOD and C57BL/6 mice exhibit distinct profiles of IgM 
autoreactivity  
 
Serum IgM reactivity of 5 C57BL/6 or NOD mice were tested on liver and kidney extracts, over the 4 to 
8 weeks of age interval. The numerical values obtained from the quantification of the immunoreactivity 
profiles were submitted to PCA. First principal component mean scores per strain and time point are 
represented with the respective SD. Group differences were found for the first PCA factor averaged 





Figure VI.2 Higher proportions of autoreactive IgM secreting B1a cells are present in 
the NOD peritoneal cavity  
The percentage of cells spontaneously secreting IgM against: a pool of  insulin+GAD65+GAD67+IA-2 
(a), thyroglobulin and thyroperoxidase (b), muscarinic-3-receptor (c), ds-DNA, ss-DNA and histone (d), 
or phosphatidylcholine, phosphorylcholine and dextran (e) was determined by ELISPOT Assay. 
Peritoneal cavity B1a (a-e) and B1b+B2 cells, splenic follicular B cells (FO), marginal zone B cells 
(Mz)  and splenic B1a cells (a) were purified from pooled samples of groups of 8 to 12 mice between 3 
and 5 weeks of age. The bars represent the average results of triplicates with the respective SD. 
Significant differences between strains were found in (a) (p0.01), in (b) (p0.05) and in (c) (p0.001) 
with unpaired t-student test. Data are representative of three independent experiments. 
 
 
NOD B1a cells are B220bright at 1 week of age  
Subsequently, we have analysed whether the differences in AAb secretion patterns between 
NOD and C57BL/6 could be attributed to disturbances in the peritoneal cavity B1a cell 
compartment.  We observed that although the proportion and numbers of peritoneal B cells 
did not differ between mouse strains, striking differences in the B1a surface phenotype could 
be observed (Figure VI.3a-VI.3c) with NOD cells expressing higher levels of B220 already at 














Figure VI.3 NOD peritoneal cavity B1a cells are B220 high  
Peritoneal cavity B1a and B1b+B2 cell subpopulations were analyzed by flow cytometry in NOD and 
C57BL/6 mice. B220 and CD5 expression was evaluated within CD19
+
 B cells and representative dot 
plots are shown (a) as well as a representative histogram of typical B220 expression intensity (d). The 
individual percentages of B1a and B1b+B2 cells with respective mean values for 5 C57BL/6 or NOD 
mice with 3 weeks of age are represented (b-c) as well as the B220  mean fluorescent intensity (MFI) 
individual values from the same samples (e). Strain differences were found for B220 MFI levels (e) 




To understand the origin of this NOD distinctive feature, we have performed a time course 
analysis of B1a cells both in the peritoneal cavity and in the spleen in comparison to 
C57BL/6. We found identical kinetics and no differences in the number of B1a cells in the 
peritoneal cavity (Figure VI.4a). In the spleen, the B1a cell numbers were relatively similar, 
except at 1 and at 12 weeks where NOD had respectively slightly less or more B1a cells in 
comparison to C57BL/6 (Figure VI.4b). Interestingly, the NOD B1a cells both in peritoneal 
cavity and in the spleen consistently presented increased levels of B220 molecules on their 
surface, detected as early as at 1 week of age (Figure VI.4c and VI.4d). In the peritoneal 
cavity, B220 intensity decreased with aging, though the strain difference persisted (Figure 
VI.4c). Intriguingly, the B220 levels were higher in NOD mouse spleen around 2 weeks 





Figure VI.4 Ontogenic distribution of B1a cells in the spleen and peritoneal cavity  
The number of peritoneal cavity  (a) and splenic (b) B1a cells and the B220 MFI within the same 
populations (c and d respectively) were determined by flow cytometry at 1, 2, 4 and 12 weeks of age. 
The average results for 4 to 9 C57BL/6 or NOD mice are represented with the respective SD. 
Differences were found for NOD and C57BL/6 B1a cells B220 MFI for all analyzed ages (p0.05) in 
unpaired t-student test. B1a numbers were identical between strains except at 1 (p0.05) and 12 
weeks (p0.01) in the spleen in unpaired t-student test. Data are representative of 2 to 4 independent 
experiments for each time point. 
 
 
Peritoneal cavity NOD B1a cells display increased expression of surface activation 
molecules 
We hypothesized that the greatest expression of the B220 molecule on NOD B1a cells could 
be linked to increased basal activation. Indeed, we observed that at 3 weeks NOD B1a cells 
showed decreased proportion of CD43high expression as compared to C57BL/6 (Figure 
VI.5a). Also, NOD B1a cells expressed lower amounts of CD62L and showed enhanced 
expression of the co-stimulatory molecule CD86 (Figure VI.5b and VI.5c). Thus, the surface 
phenotype of NOD B1a cells corroborates with the observed increased activation state at 
pre-insulitic stages. In addition, 4 to 9% of B1a cells expressed Syndecan-1, indicating that 
some of these cells share the antibody secretion phenotype of plasma cells (Figure VI.5d). 
Interestingly, the proportion of Syndecan-1+ B1a cells was consistently larger in the NOD 





Figure VI.5 NOD peritoneal cavity B1a cells are naturally more activated  
 
Peritoneal cavity B1a cells were analyzed in 5 C57BL/6 or NOD mice, with 3 weeks of age. The 
expression of CD43 (a), CD62L (b), CD86 (c) and Syndecan-1 (d-e) was assessed by flow cytometry. 
Individual percentages and the respective means are represented (a-c, e). A typical Syndecan-1 
expression histogram (d) is shown for each strain and unstained controls. Differences were found in 
the expression of all the referred cell surface activation markers (p0.01) in unpaired t-student test. 
Data are representative of 3 independent experiments.  
 
 
NOD B1a cells secrete increased levels of autoantibodies upon TLR stimulation 
The innate-like properties of B1a cell stimulation prompted us to test whether alterations in 
TLR expression or response to TLR stimuli could condition the secretion profiles observed in 
the NOD B1a compartment. We have quantified TLR 2, 4, 6, 7 and 9 mRNA levels in purified 
peritoneal NOD B1a cells in comparison to C57BL/6 and observed that all these genes were 
expressed more in the NOD mice (Figure VI.6). To identify physiological correlates of these 
gene expression differences we have stimulated sorted B1a cells with purified LPS, a known 
ligand to TLR4, and found no consistent strain differences in CD69, CD86 or CD25 cell 
surface expression, indicating that similar activation levels were obtained (Figure VI.7a-
VI.7c). Despite seeing no differences in total IgM levels within the stimulated B1a cell 
supernatants between NOD and C57BL/6, the concentration of NOD IgM with reactivity to 
islet-related AAg was consistently higher (Figure VI.7d and VI.7e). Accordingly, an increased 
proportion of TLR4 stimulated NOD B1a cells secreted IgM with these specificities 
(Supplementary Figure VI.2a), mimicking the secretion behaviour that we observed ex vivo. 
TLR4 stimulation induced potent secretion of the immunoregulatory cytokine IL10 by B1a 
cells and, in contrast with the observed AAb secretion profile, lower amounts were detected 
in the NOD B1a cell cultures (Figure VI.7f). In addition, after 3 days of stimulation NOD B1a 
cells proliferation was substantially higher than in C57BL/6 (Figure VI.7g). Similar 
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observations were obtained upon TLR9 stimulation (Supplementary Figure VI.2b and VI.2c). 
 
 





























































































































































Purified peritoneal B1a cells were obtained from 15 females with 3 weeks of age, pooled for RNA 
extraction, and TaqMan Gene Expression assays were used to quantify the expression of the 
indicated genes. Relative quantification of these genes was obtained in triplicates, after normalization 
to GAPDH expression. Mean fold-differences to C57BL/6 and the respective SD from a pool of two 
identical experiments are represented. Differences were found for all the studied genes (p0.05) in 


















Figure VI.7 NOD peritoneal cavity B1a cells respond to LPS stimulation in vitro with 
increased proliferation and secretion of autoantibodies  
Purified peritoneal cavity B1a cells were obtained from 16 C57BL/6 or NOD mice with 6 to 10 weeks of 
age and were stimulated with 1 or 5 g/ml of purified LPS. Unstimulated cells were used as negative 
controls. After one day the cells were assayed for activation phenotypes by flow cytometry, namely 
CD69, CD86 and CD25 cell surface expression (a-c). On the third day of culture, supernatants were 
assessed for total IgM (d), anti-T1D AAg IgM (e) and IL10 concentration (f) by ELISA. Proliferation was 
measured by 
3
H-thymidine incorporation (e). The average of duplicate samples is represented with the 
respective SD, except for activation markers analysis where pooled duplicates were used for flow 
cytometry acquisition. Strain differences were found for anti-T1D AAg IgM concentration in 
supernatants of B1a cells stimulated with both 1 and 5 g/ml of LPS (p0.05) for IL10 levels in 
supernatants of B1a cells stimulated with 1 g/ml of LPS (p0.05) and for proliferation after 3 days of 5 




Supplementary Figure VI.2 NOD peritoneal cavity B1a cells innate-like stimulation in 
vitro is consistent with a lower threshold for autoreactive IgM secretion 
Purified peritoneal B1a cells were obtained from 16 C57BL/6 or NOD mice with 6-10 weeks of age and 
cultured with 5g/ml of LPS (a) or 0.5 M of CpG (b-c). Unstimulated cells were used as negative 
controls. Anti-T1D AAg IgM secreting cells were quantified by ESA after 2 days of culture (a, c). The 
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expression of CD69 on CPG stimulated B1a cells was assessed by flow cytometry on the 1
st
 day of 
culture, the bars represent the average of duplicates (C57BL/6) or a single well acquisition (NOD) (b). 
For ESA results the average of triplicate samples is represented. Error bars represent SD.  Strain 
differences were found in (a) (p0.05) and (c) (p0.05) in unpaired t-student test.  
 
 
IgM secreted by NOD B1a cells can bind to pancreatic beta cells in vitro and trigger 
iNOS expression 
To analyze the mechanisms by which IgM of NOD B1a cell origin may contribute to disease, 
we have established in vitro cultures where secreted antibody but not B cells are in contact 
with beta cells. We have purified NOD peritoneal B1a cells and splenic follicular B cells and 
cultured them in transwell with dispersed pancreatic islets of Langerhans from 
immunodeficient NOD.SCID mice (Figure VI.8a). After 24 hours of culture, beta cells were 
analysed for the presence of bound IgM (Figure VI.8b). Beta cells could be distinguished by 
their size, granulosity and autofluorescence in the FL1-H channel (Figure VI.8a and VI.8b). In 
agreement with our analysis of IgM reactivity, beta cells that were co-cultured with sorted 
B1a cells presented IgM bound on their surface. On the other hand, beta cells co-cultured 
with follicular B cells showed only background levels of IgM staining (Figure VI.8b and VI.8c).  
Using the same system we next analyzed the expression levels of genes associated with 
pancreatic beta cell responses to stress. Gene expression analysis revealed upregulation of 
iNOS in islet cells co-cultured with NOD B1a cells when compared to beta cells cultured with 
medium alone (Figure VI.9). No difference was observed in the expression of Fas, Caspase 

























The enriched beta cell population collected from 9 NOD.SCID females, with 9 weeks of age, was co-
cultured in a transwell system with purified peritoneal cavity B1a cells (PC B1a) or splenic follicular B 
cells (SP FO) obtained from 15 NOD females with 7-10 weeks of age. After 24 h, beta cells were 
stained and the presence of bound IgM was analysed by flow cytometry (a). Beta cells cultured in 
transwell with lymphocyte culture medium only were used as negative controls. Representative dot 
plots of the beta cells morphological gate, auto-fluorescence in FL1-H channel and IgM staining are 
represented for each experimental condition (b). The mean and SD of duplicates is shown in (c). Beta 
cells co-cultured with sorted peritoneal B1a cells presented increased levels of IgM bound on their 
surface, in comparison to negative controls or beta cells co-cultured with follicular B cells from the 





Figure VI.9 In vitro autoreactive natural IgM binding in pancreatic beta cells triggers 
iNOS expression 
 Dispersed pancreatic islets of Langerhans obtained from 9 NOD.SCID females, with 9 weeks of age, 
were co-cultured in duplicates in a transwell system with purified peritoneal cavity B1a cells collected 
from 12-14 NOD females with 9-10 weeks of age. After 24 h, beta cells RNA was extracted and 
TaqMan Gene Expression assays were used to quantify the expression of iNOS, Fas, Caspase 3 and 
Ccl2. Relative quantification of these genes was obtained in triplicates of each sample, after 
normalization to GAPDH expression. Average fold-differences with SD from a pool of two identical 
experiments are represented in relation to negative controls, where beta cells were co-cultured with 
lymphocyte medium only. Differences were detected for iNOS expression (p0.05) in unpaired t-





This study demonstrates that NOD B1a cells have an increased responsiveness to innate 
activation and secrete natural antibodies with higher reactivity to T1D associated AAg. 
Importantly, NOD B1a cell-derived IgM is able to bind pancreatic beta cells and trigger iNOS 
expression, a starting point in the beta cell oxidative stress response. Together, these results 
provide supporting evidence to propose that the NOD natural AAb repertoire is biased from 
an early age towards endocrine autoreactivity, thus having the potential to fuel the 
autoimmune beta cell attack prior to the T cell mediated destruction. 
In our time course analysis NOD mice presented increased but stable serum levels of IgM 
with insulin reactivity when compared to C57BL/6. This pattern of natural antibody 
autoreactivity did not correlate with the IgG serum levels that clearly followed the progression 
of the disease in the NOD mouse (Figure VI.1d; Koczwara et al., 2003). The remarkably 
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different trajectories of serum anti-insulin IgG or IgM isotypes highlights their different roles in 
the NOD immune response. While the detection of anti-T1D AAg IgG is widely accepted as 
an early disease marker in clinical practice and is generally considered to be a by-product of 
the T cell mediated destruction of beta cells (Serreze et al., 1998; Yu et al., 2000), 
autoreactive IgM comprises the pool of NAbs, the first antibodies to arise during ontogeny 
produced in the absence of exogenous stimuli (Meffre & Salmon, 2007). Analysis of MHC 
congenic strains (Wicker et al., 1992) showed that, unlike IgG, IgM reactivity observed in the 
NOD is independent of T-cell help and disease progression, and is consistent with the 
hypothesis that an increased autoreactivity in the NOD NAb compartment would contribute to 
the initiation of autoimmunity (Corte-Real, Duarte, et al., 2009). This suggested the possibility 
that IgM reactivities would also be altered in human T1D and we have preliminary evidence 
that common genetic variants (SNPs) in the IgM locus control the levels of anti-GAD serum 
IgM and are associated with disease in a collection of T1D patients (unpublished results). 
These findings strengthen the link between NAbs and T1D pathogenesis and give 
importance to further investigations into the origin of autoreactive IgM. 
We found that B220 expression strikingly distinguished NOD B1a cells in peritoneal cavity 
from as early as 1 week of age, as compared to C57BL/6 and BALB/c (not shown). 
Interestingly, peritoneal B1a cells that develop from adult bone marrow progenitors showed 
increased levels of B220 expression (Esplin, Welner, Zhang, Borghesi, & Kincade, 2009; 
Wardemann, Boehm, Dear, & Carsetti, 2002). Thus, it is possible that bone marrow 
progenitors play a larger role in NOD B1a cells ontogeny, conditioning a higher B220 
expression. Additionally, increased B220 expression is associated with a lower threshold of 
activation (Casola et al., 2004; Jellusova, Wellmann, Amann, Winkler, & Nitschke, 2010) and 
possibly underlies the surface expression profiles of CD43, CD62L and CD86 in NOD 
peritoneal B1a cells. Some of these phenotypes have been previously described on NOD 
B1a cells and associated with increased activation, migration and capacity for T cell co-
stimulation (Alam, Valkonen, Ohls, Tornqvist, & Hanninen, 2010). Interestingly, alterations in 
the NOD microflora have been shown to condition some of the surface B1 cell traits (Alam, et 
al., 2011; Alam, Valkonen, Palagani, et al., 2010). Thus, peritoneal cavity B1a cells are able 
to rapidly respond to external stimuli, namely microbial alterations in the intestine. Our 
observations of higher B220 and TLR expression at an early age and increased proliferation 
upon TLR stimulation, concur to strongly suggest that B1a B220high cells may represent a B1 
cell population in the NOD mouse that colonizes the peritoneal cavity in early ontogeny and 
is exquisitely sensitive to innate stimuli. 
In accordance, NOD B1a TLR stimulation resulted in increased levels of IgM secretion with 
reactivity against T1D AAg while the secretion of IL10 remained lower when compared to 
C57BL/6 B1a cells. Stimulation through TLR has been shown to strongly promote plasma 
cell differentiation in the B1 cell compartment (Genestier, et al., 2007). Interestingly, NOD 
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B1a cells produced similar amounts of total IgM in comparison to C57BL/6 in the presence of 
TLR ligands. This indicates that the NOD B1a cell population harbours an increased 
population of autoreactive cells with increased responsiveness and propensity for plasma cell 
differentiation upon innate stimulation.  This is in agreement with increased numbers of NOD 
B1a cells secreting IgM with reactivity towards endocrine AAg and with the pattern of serum 
anti-insulin IgM. 
Importantly, we did not detect strain differences in the numbers of B1a cells in the pancreatic 
lymph nodes, nor their presence in the pancreas of pre-diabetic NOD mice (data not shown), 
strengthening the hypothesis that the role of NOD B1a cells on T1D onset may be mediated 
by autoreactive IgM (Corte-Real, Duarte, et al., 2009). Accordingly, binding of IgM to beta 
cells has been described in vivo in very young NOD mice (Shieh, et al., 1993). We showed 
here that NOD B1a-derived IgM binds to beta cells in vitro and that the expression of iNOS is 
upregulated in islet cells in contact with NOD B1a derived supernatant, suggesting that IgM 
binding is involved in triggering the beta cell oxidative stress response. On the other hand, 
Fas, Caspase 3 and Ccl2 gene expression were not altered indicating that the pattern of 
gene induction differed from what has been described for cytokine induced beta cell damage 
(Cardozo, Kruhoffer, Leeman, Orntoft, & Eizirik, 2001). This reinforces the notion that the 
effects observed in iNOS expression are due to the binding of autoreactive IgM, a hypothesis 
that requires further confirmation. Whether other immunological components, such as 
complement in the serum, could potentiate the IgM effect and determine the fate of beta cells 
in T1D remains also to be addressed. 
In conclusion, in this study we have linked alterations in the B1a cell population to serum IgM 
autoreactivities and beta cell oxidative stress, strengthening the hypothesis that NAbs are an 
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To evaluate NOD and C57BL/6 mice global serum IgM repertoire we have used a semi-
quantitative immunoblotting technique that allows evaluation of antibody reactivities against 
large panels of antigens and has been described in detail elsewhere (Haury, Grandien, 
Sundblad, Coutinho, & Nobrega, 1994; Nobrega et al., 1993). Briefly, protein extracts were 
prepared from the livers and kidneys of 25 NOD females with average age of 6 weeks. 
Following electrophoresis the separated proteins were transferred onto nitrocellulose 
membranes that where then incubated with serum from 5 C57BL/6 and 5 NOD females from 
4 to 12 weeks of age in miniblot incubation units (Immunetics). Goat anti-mouse IgM-AP 
conjugated secondary antibody (Southern Biotech.) was used and immunoreactivities were 
revealed with nitroblue tetrazolium (NBT) and bromo-chloro-indolylphosphate (BCIP) 
substrates (Promega Corp.). Quantitation of immunoreactivities was performed by 
densitometry in high resolution reflective mode. A second densitometry was performed after 
colloidal gold staining (Protogold, Biocell). The irregularities of the electrophoretic migration 
were corrected by the superimposition of the two stainings and the intensity of reactivity 
development was adjusted to a NOD standard serum, obtained from a pool of 19 females 
with 15 to 21 weeks of age. For all these procedures, specially developed macros using the 
software IGOR (Wavemetrics) were used. The adjusted reactivity profiles were divided into 
sections defined empirically for each protein extract and the intensity of the respective serum 
immunoreactivity was quantified as the mean optical density within these limits. A sample 
profile thus consisted of a list of reactivity measures, one for each section, and was analyzed 
by Principal Component Analysis (PCA). 
 
Innate stimulation  
Purified peritoneal B1a cells were cultured in RPMI 1640 complete medium with or without 
0.5 M CpG (ODN 1826, Invivogen). After one day, cells from duplicate wells were pooled, 
stained with biotinylated-anti-CD69 (clone H1.2F3) followed by FITC-streptavidin and were 
analyzed by flow cytometry. On the second day of culture the cells were collected, counted 
and plated for ESA quantification of anti-T1D AAg IgM secreting cells.  The percentage of 
cells secreting antibodies with these reactivities was also assessed on purified peritoneal 
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Chapter VII. Article IV: p58 surface glycoprotein is downregulated in NOD B1a cells 
and its targeting precipitates type 1 diabetes in the NOD mouse 
 
 
p58 SURFACE GLYCOPROTEIN IS DOWNREGULATED IN NOD B1a CELLS AND ITS 
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Peritoneal cavity B1a cells have been implicated in the type 1 diabetes (T1D) autoimmune 
process in several mouse models and also in humans, though a direct link between 
alterations in the peritoneal cavity compartment and diabetes progression has been hard to 
establish. Recently, we have described that peritoneal B1a cells of the non-obese-diabetic 
(NOD) mouse are naturally more activated and have a lower threshold for innate-like 
stimulation. In line with these findings we here show that p58, a surface glycoprotein that is 
constitutively found on B1a cells and has been correlated to the natural activated state of this 
subpopulation, is expressed at lower levels in the NOD peritoneal B1a cell compartment, 
when compared to non-diabetic prone strains.  After  p58 specific targeting in NOD mice in 
vivo we have observed: (1) down-modulation of IgM expression and increased proliferation of 
peritoneal cavity B1a cells; (2) increased IgM serum levels and; (3) an earlier onset of 
diabetes. We here propose that low p58 expression levels may contribute to a less efficient 
regulation on NOD B1a cells and that p58 targeting could abrogate the existing inhibition of 
proliferation signals, accelerating T1D onset in the NOD. These results reinforce the notion 














Type 1 diabetes (T1D) is a complex genetic autoimmune disease, contributed by various 
immunological alterations, which culminates in the destruction of pancreatic beta cells by 
specific T cell cytotoxicity (Bach, 1994). Although a pathogenic role for beta cell specific 
autoantibodies has never been identified in T1D, their early presence is highly correlated with 
progression to disease. Therefore, we have hypothesized that a genetically determined 
alteration in immunoglobulin reactivity could have implications in the diabetogenesis process 
(Côrte-Real, Duarte, Tavares, & Penha-Gonçalves, 2009). In fact, a germline encoded 
repertoire of autoreactive antibodies is naturally present in the body and is mainly contributed 
by spontaneous IgM secreting peritoneal and splenic B1a cells (Feeney, 1990; Gu, Förster, 
& Rajewsky, 1990; Tlaskalová-Hogenová et al., 1992).  
Extensive studies on B1 cell phenotypes and functions have revealed that they could be 
involved in the development of autoimmune diseases (Duan & Morel, 2006). In particular, we 
have been studying the non-obese-diabetic (NOD) mouse model (Castaño & Eisenbarth, 
1990) to understand the role of peritoneal cavity B1a cells in the development of type 1 
diabetes. Recently, we have correlated alterations in the NOD B1a cell compartment to 
serum IgM autoreactivities and to induction of pancreatic beta cell oxidative stress, which led 
us to propose that NOD B1a cells contribute to diabetes progression through the secretion of 
beta cell autoreactive natural antibodies (Côrte-Real et al., 2009; chapter VI, article III). In 
this later study we have also demonstrated that peritoneal cavity NOD B1a cells display 
increased expression of surface activation molecules and have a lower threshold for innate-
like stimulation (chapter VI, article III). 
The expression of the 58 kD surface glycoprotein designated by p58 (Parkhouse, Santos-
Argumedo, Teixeiral, Henry, & Wawrzynczak, 1992) has been previously associated with the 
naturally activated status of peritoneal B1 cells and has been shown to be constitutively 
expressed in BALB/c B1 cells from the peritoneal cavity and spleen, as well as in splenic 
marginal zone (Mz) B cells (Manjarrez-Orduño, Parkhouse, & Santos-Argumedo, 2003). 
Interestingly, p58 expression levels were only significant in follicular (FO) B cells and T cells 
upon stimulation (Manjarrez-Orduño et al., 2003). Despite that p58 identity and function are 
still unknown, a relevant tool for its study is the anti-p58 monoclonal antibody (NIM-R7). NIM-
R7 has been generated against the cell membranes of the p58 expressing BALB/c-derived B 
cell lymphoma (BCL1) (Parkhouse et al., 1992), a typical B1 cell-derived lymphoma that 
arose spontaneously in the BALB/c strain (Slavin & Strober, 1978) and that is characterized 
by the expression of IgM, CD5 and low levels of B220 on its surface, as well as by the 
spontaneous secretion of IgM (Koganei, Ito, Yamamoto, & Matsumoto, 2005).  Importantly, 
when conjugated to ricin-A, NIM-R7 was able to induce BCL1 cell death in vitro while no 
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effect was observed in resting FO B cells, where lower levels of expression of p58 were 
observed (Manjarrez-Orduño et al., 2003). 
Here, we have characterized the expression of p58 in the NOD mouse and we have found 
that peritoneal cavity B1a cells display p58 downregulation, therefore we have further 
explored the hypothesis that B1a cells activation status is altered in this diabetic prone strain. 
Furthermore, targeting of p58 on NOD peritoneal cavity B1a cells had an impact on B1a cell 
numbers and B1a surface IgM expression at this location, upon total IgM serum levels and 
T1D onset, strengthening the notion that B1a cells may play a role in the autoimmune 
diabetic process.   
 
 
MATERIALS AND METHODS 
 
Mice 
C57BL/6, NOD and BALB/c mice were bred and maintained in specific pathogen free 
housing facilities at the Instituto Gulbenkian de Ciência. All mice used were females varying 
between 3 and 32 weeks of age. NOD female insulitis was unapparent at 3 weeks.  
Experimental protocols were approved by the Direcção Geral de Veterinária of the 
Portuguese Ministry of Agriculture, Rural Development and Fisheries and are in accordance 
with national and international regulations (U.S. Department of Health and Human Service, 
Office of Extramural Research, National Institutes of Health, Office of Laboratory Animal 
Welfare, 1985). 
 
Cell culture and analysis  
BCL1 cells were kindly provided by Dr. John F. Kearney, University of Alabama at 
Birmingham, and maintained in RPMI 1640 complete medium (supplemented with 2% FCS, 
2 mM L-glutamine, 10 mM HEPES, 50 mM 2-mercaptoethanol, 100 U penicillin, 100 mg/ml 
streptomycin, all from Life Technologies, 50 g/ml gentamycin from Sigma and 0.25 g/ml 
fungizone from Invitrogen). Lymphocytes were isolated from peritoneal cavity by peritoneal 
lavage performed with PBS supplemented with 2% FCS or from spleen by straining through 
a nylon mesh. Single cell suspensions were then stained according to standard procedures. 
Fc receptors unspecific binding was prevented by incubating the cells with unlabeled anti-
mouse-Fc-block/CD16/32 (clone 2.4G2, BD Pharmingen).  Peritoneal cavity and splenic B 
cells were identified as CD19+ cells. Peritoneal cavity B cells were divided in sub-populations 
according to the expression of CD11b and CD5: B1a as CD11b+CD5+, B1b as CD11b+CD5-, 
B1c as CD11b-CD5+ and B2 cells as CD11b-CD5- cells. In the spleen, follicular B cells were 
defined as CD23+IgMlow/+, marginal zone B cells as CD23-IgMhighCD21+ and B1a cells were 
95 
 
identified as CD23-IgMhighB220lowCD5+. T cells were defined as CD19-CD5+ in both peritoneal 
cavity and spleen. The antibodies used were Pacific-Blue or Cy5-anti-mouse CD45R/B220 
(clone RA3-6B2), FITC or biotin-anti-mouse-CD11b/Mac-1 (clone M1/70), FITC-anti-mouse-
CD21 (clone 7G6), FITC or A647-anti-mouse-IgM (clone R33.24.12), PE-anti-mouse-
CD23/IgEFcR (clone B3B4), PE or Percp-anti-mouse-CD5/Ly-1 (clone 53-7.3) and PE-Cy7-
anti-mouse-CD19 (clone 1D3). Monoclonal NIM-R7 (anti-p58) antibody (Parkhouse et al., 
1992)  was biotinylated and used for staining. Biotinylated antibodies were revealed by either 
FITC, Percp or APC-Cy7-streptavidin. Traceable latex beads (Beckman coulter Inc.) were 
added for counting cells. Stained cell suspensions were analyzed by flow cytometry either 
with a FACSCaliburTM (Becton Dickinson) or a FACS CYAN ADP (Dako Cytomation) and the 
data was respectively acquired with CELLQuest or Summit software. Analysis was 
performed with FlowJo software (TreeStar Inc.).  
 
Intra-peritoneal injection, blood collection and glycosuria measurement 
For the assessment of NIM-R7 impact on lymphocytes physiology we have performed 4 
intra-peritoneal (IP) injections of 50 g of this antibody diluted in 100 ml of RPMI 1640 (Life 
Technologies) into NOD female mice, starting at 5 weeks of age and with one week intervals. 
Mice were euthanized one week after the last injection and the organs were taken for flow 
cytometry analysis. For the verification of the effect of NIM-R7 on IgM serum levels and on 
T1D development, the same IP injections protocol was started at 3 weeks of age and was 
followed by a further two IP injections with 2 weeks interval. Blood was collected from the 
facial vein at 5, 7, 10 and 13 weeks of age and urinary glucose levels were measured weekly 
from 12 to 32 weeks of age with Diabur 5000 test stripes (Roche). Mice were considered to 
be diabetic after two consecutive positive measures of glycosuria. 
 
ELISA 
Briefly, 96-well ELISA plates (Nunc) were coated overnight at 4ºC with anti-mouse-IgM 
(clone R33.24.12, 2 µg/ml) diluted in coating buffer (0.05 M Na2CO3), and were subsequently 
blocked with PBS-gelatin (1%, powder food grade, Merck) at 37ºC for 1 hour. Then, 1:100 
diluted serum samples were incubated for 1 hour at 37ºC and washed. Bound serum IgM 
was detected by goat anti-mouse-IgM-AP conjugated antibody (Southern Biotech.), the 
plates were developed with sigma phosphatase substrate and optical densities were read in 
a spectrophotometer at 405 nm. The concentrations of IgM antibody in the samples were 
calculated against standard curves obtained with purified monoclonal IgM (clone 11E10, 





Statistical significant differences for the analyzed phenotypes were estimated by unpaired 
student’s t-test. Two-tailed tests with 95% of confidence interval where used and differences 
with p0.05 were considered significant. Differences with p0.05 (*), p<0.01(**) or 





p58 is expressed at high levels on NOD peritoneal cavity B1a cells and splenic B1a 
and marginal zone B cells 
Previous studies have described that, in undisturbed conditions, p58 expression is restricted 
to BALB/c peritoneal cavity B1 cells and splenic B1 and marginal zone B cells, and have 
suggested that p58 may have a role in the lymphocyte activation processes (Manjarrez-
Orduño et al., 2003). In general, the expression of p58 on NOD peritoneal cavity and spleen 
lymphocyte subpopulations was similar to that of BALB/c mice. The expression of p58 in 
NOD peritoneal cavity B1a cells was significantly increased when compared to other 
peritoneal lymphocyte sub-populations (Figure VII.1a and VII.1c). Similarly, in the NOD 
spleen, higher expression levels of p58 were detected in both B1a and marginal zone B cell 






Figure VII.1 p58 is constitutively more expressed on NOD B1a cells both in peritoneal 
cavity and spleen 
 
p58 expression within NOD peritoneal cavity B1a, B1b, B1c, B2 and T cell subpopulations (a) or NOD 
spleen B1a, marginal zone B (Mz), follicular B (FO) and T cell subpopulations (b)  was analyzed by 
flow cytometry in 6 NOD females with 11 to 15 weeks of age. The individual percentages with 
respective mean values are represented for peritoneal cavity (a) and spleen (b) as well as the 
representative histograms of typical p58 expression intensity (c, d). Differences in p58 expression 




p58 is naturally downmodulated in the NOD peritoneal B cell compartment 
Given that p58 could have physiological implications for “naturally activated cells” and that 
NOD B1a cells have a lower threshold for innate-like stimulation (chapter VI, article III), we 
performed a comparative flow cytometry analysis of p58 expression on peritoneal cavity B1a, 
B1b, B1c, B2 and T cells (Figure VII.2) and splenic B1a, Mz B cells, FO B cells and T cell 
sub-populations (Figure VII.3) of NOD and non-diabetic C57BL/6 and BALB/c mouse strains. 
We have verified that, in the peritoneal cavity, p58 is expressed in all the analyzed strains 
mainly in B1a and B1b cells (Figure VII.2a and b) and at very low levels in B1c, B2 and T cell 
sub-populations (Figure VII.2c-VII.2e). Interestingly, p58 expression was lower in all the NOD 
peritoneal cavity B cells subsets, when compared to both C57BL/6 and BALB/c strains 
(Figure VII.2a-VII.2d). No strain differences in p58 expression levels were found for the 
peritoneal cavity T cell population (Figure VII.2e) and curiously, p58 expression within B1a 
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cells was higher in the BALB/c in comparison to the C57BL/6 (Figure VII.2a). In the spleen, 
we have observed that p58 is expressed at high levels in both B1a and marginal zone B cells 
in the three analyzed strains (Figure VII.3a and VII.3b) and, in contrast to what has been 
described (Manjarrez-Orduño et al., 2003), we have found that significant levels of p58 
expression were also detectable in FO B cells for all the strains of mice that we have studied 
(Figure VII.3c). Very low levels of p58 were found in the splenic T cell subpopulation (Figure 
VII.3d). No differences in the p58 expression levels on splenic B1a, FO B cells, Mz B cells or 
T cells were found between NOD, C57BL/6 and BALB/c strains. In conclusion, our results 
show that p58 is generally expressed on mouse B1a and Mz B cells, and that  NOD 
peritoneal B1a cells have lower levels of p58 than their non-diabetic counterparts. 
 
 
Figure VII.2 p58 is expressed at low levels on NOD peritoneal cavity B cell populations 
 
p58 expression within peritoneal cavity B1a (a), B1b (b), B1c (c), B2 (d) and T cell (e) subpopulations 
was analyzed by flow cytometry in 5 C57BL/6, 6 NOD and 5 BALB/c females with 11 to 15 weeks of 
age. The individual percentages with respective mean values are represented. Strain differences in 







Figure VII.3 p58 is constitutively more expressed on splenic B1a and marginal zone B 
cell subpopulations 
 
p58 expression within splenic B1a (a), marginal zone B (Mz) (b), follicular B (FO) (c), and T (d) cell 
subpopulations was analyzed by flow cytometry in 5 C57BL/6, 6 NOD and 5 BALB/c females with 11 
to 15 weeks of age. The individual percentages with respective mean values are represented. No 




p58 specific targeting affects B lymphocyte distribution and IgM expression in the 
peritoneal cavity 
The anti-p58 specific NIM-R7 monoclonal antibody was generated against the membranes of 
BCL1 (Parkhouse et al., 1992) which are believed to have been originated on peritoneal 
cavity B1a cells (Koganei et al., 2005). In fact, we have confirmed by flow cytometry that the 
pattern of cell surface markers expression within the BCL1 cells morphological gate (Figure 
VII.4a) is very similar to that described for B1a cells. Most BCL1 cells were IgM+CD5+ (Figure 







Figure VII.4 BCL1 cells express p58 and have a similar phenotype to peritoneal cavity 
B1a cells 
 









 (c) staining profiles within the BCL1 gate are shown. p58 
expression is represented for BCL1 unstained controls (d) and BCL1 stained cells (e). A histogram of 
typical p58 expression on the same cells is shown (f). 
 
Further, it has been previously shown that BCL1 cells are effectively killed upon treatment 
with NIM-R7 conjugated to ricin-A, while no effect is observed in FO B cells or T cells 
(Manjarrez-Orduño et al., 2003). Given that BCL1 cells have a B1a like phenotype (Koganei 
et al., 2005; and Figure VII.4) and that p58 is constitutively expressed on NOD peritoneal 
B1a cells (Figure VII.1), we decided to test whether p58 targeting in vivo would have an 
impact on the numbers of B1a cells in NOD mice. With this aim, we performed a weekly IP 
injection of 50 g of NIM-R7 for four consecutive weeks, in NOD female mice, starting at 5 
weeks of age, and one week after treatment we assessed the flow cytometry profile and 
numbers of peritoneal cavity lymphocyte sub-populations in comparison with un-manipulated 
mice or RPMI injected controls. Contrary to our expectations, we have observed a dramatic 
increase in the numbers of p58 expressing B1a cells in the NIM-R7 antibody treated group in 
comparison to either un-manipulated mice (6 fold) or RPMI injected mice (3.5 fold) (Figure 
VII.5a). The numbers of B2+B1b cells in the peritoneal cavity have also increased 
enormously upon NIM-R7 treatment (15 fold when compared to un-manipulated mice, 6.5 
fold when compared to RPMI injected controls) (Figure VII.5b). The simple injection of RPMI 
had a slight increasing effect on the number of peritoneal cavity B2+B1b cells in comparison 
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to un-manipulated mice, but this effect was not observed for B1a cells in the same location. T 
cell numbers were not significantly affected in the NIM-R7 antibody injected group and 
splenic lymphocyte subpopulations were unaltered by the NIM-R7 treatment (data not 
shown). Interestingly, there was a  major decrease of surface IgM expression levels on both 
peritoneal B1a and B2 cells in the NIM-R7 treated NOD mice (Figure VII.6), although the 
levels of p58 remained unchanged (data not shown). 
 
 
Figure VII.5 Specific targeting of p58 in vivo affects B lymphocyte distribution in the 
peritoneal cavity 
 
Flow cytometry analysis of NOD peritoneal cavity after one week of intra-peritoneal treatment with 
purified NIM-R7 antibodies was performed. The individual numbers of B1a (a) and B2+B1b (b) cell 
subpopulations for 3 females with 9 weeks of age and the respective mean values are represented for 
non-manipulated mice (nothing), RPMI injected controls (RPMI IP) or the antibody treated group (NIM-








Figure VII.6 Specific targeting of p58 in vivo decreases surface expression of IgM on peritoneal 
cavity B cells 
 
IgM mean fluorescence intensity (MFI) within NOD peritoneal cavity B1a (a) and B2+B1b (b) after one 
week of intra-peritoneal treatment. The individual values obtained for 3 females with 9 weeks of age 
and the respective mean values are represented for non-manipulated mice (nothing), RPMI injected 
controls (RPMI IP) or the antibody treated group (NIM-R7 IP). The representative histograms of typical 
IgM expression intensity (c, d) are presented. Differences in IgM expression levels between groups 
are denoted. Data are representative of two independent experiments. 
 
 
p58 specific targeting induces an increase in serum IgM titers and accelerates NOD 
T1D onset   
B1a cells are the main natural IgM secretors (Casali & Schettino, 1996) and have been 
implicated in the development of several autoimmune syndromes (Duan & Morel, 2006), 
including type 1 diabetes (Alam, Valkonen, Ohls, Törnqvist, & Hänninen, 2010; Ryan et al., 
2010). Our own results suggest that B1a cells could have a pathogenic role in type 1 
diabetes progression in the NOD mouse model, by secreting pancreatic beta cell reactive 
autoantibodies that, upon binding, could initiate beta cell oxidative stress (article III). 
Therefore, we decided to determine if the proliferation of peritoneal cavity B1a cells, and the 
decrease of surface IgM expression levels, induced by the treatment of mice in vivo with 
NIM-R7 IP injection, would be accompanied by an impact on the total serum IgM levels, and 
induction of type 1 diabetes in the NOD mouse. Pre-insulitic NOD females with 3 weeks of 
age (Yang & Santamaria, 2003) were injected IP as described above and then given another 
two extra NIM-R7 IP administrations, 2 weeks apart.  As a control, mice were injected IP with 
RPMI. Significant differences in the total levels of IgM between the two groups of mice were 
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observed at 13 weeks of age (Figure VII.7a) which correlated well with the increase in B1a 
cell number previously shown (Figure VII.5a). Contrary to our expectations, there was no 
difference in the levels of anti-insulin IgM between the two groups of mice over time (data not 
shown).  
Strikingly, the onset of T1D was accelerated in the NIM-R7 IP injected group, where 50% of 
the NOD females developed diabetes by 13 weeks of age (Figure VII.7b). Equal incidence 
values were reached only by 17 weeks of age in the RPMI injected control group. The clear 
correlation of these results suggests a pathogenesis mechanism linking alterations in the 
NOD B1a cell compartment to increased serum IgM levels and early T1D onset.  
 
 
Figure VII.7 Specific targeting of p58 in vivo induces an increased serum IgM titer and 
accelerates NOD T1D onset  
 
Serum IgM concentration was measured individually at 5, 7, 10 and 13 weeks of age in 6 NOD 
females under intra-peritoneal NIM-R7 treatment (NIM-R7 IP) or in 6 NOD female controls where 
RPMI was injected IP (RPMI IP) (a). Urine glucose levels were followed weekly in the previously 
defined groups from 12 weeks of age, and type 1 diabetes incidence is shown (b). Significant 






The physiology of B1 cells, their role in normal immune responses and their implications in 
autoimmunity are not yet completely understood. We and others have described that 
peritoneal NOD B1a cells are altered in comparison to non-diabetic mice (Alam et al., 2010). 
In particular, we have demonstrated that this subset has a lower activation threshold for 
innate-like stimulation in this T1D mouse model (chapter VI, article III). By dissecting p58 
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expression levels in different B1 cell subsets in the NOD, we found that it is expressed 
mostly on B1a cells, while B1 precursors or immature B1 cells contained within the CD11b- 
B1c subset do not express p58. This observation is consistent with previous work which 
showed that p58 is expressed mainly on peritoneal B1a cells, and that this glycoprotein is not 
expressed at early stages of lymphocyte development, as well as it is associated with an 
increased lymphocyte activation status on the BALB/c mouse (Manjarrez-Orduño et al., 
2003). In NOD mice, p58 expression is significantly decreased in the B1a cell compartment 
when compared to C57BL/6 and BALB/c mice. This difference was not observed for splenic 
B1a cells. This finding is puzzling and indicates that p58 function is more complex than 
initially thought, being that low p58 expression levels may contribute to a less efficient 
regulation and to the lower threshold for innate-like stimulation observed in NOD B1a cells.  
Importantly, we have confirmed that p58 is mostly expressed on B1a and Mz B cells across 
mouse strains and constitutes a useful surface marker to define these subsets in cellular 
studies.  Unlike the previous work (Manjarrez-Orduño et al., 2003), we have detected 
significant levels of p58 expression on follicular B cells in the spleen, a difference perhaps 
due to the fact that we have used older mice in our study (11-15 weeks vs newborn to 8 
weeks old). Moreover, we did not morphologically discriminate non-activated from activated 
FO B cells, therefore we cannot exclude that an enriched population of splenic activated B 
cells in older mice is contributing to the observed p58 expression in our follicular B cell 
analysis. 
Treatment with NIM-R7 has been shown to efficiently kill BCL1 cells (Manjarrez-Orduño et 
al., 2003). Since BCL1 cells express p58 and have a B1a-like-nature it was tempting to test 
whether targeting peritoneal cavity NOD B1a cells with NIM-R7 would have an impact on 
their phenotype and survival. Surprisingly, injection of NIM-R7 IP induced a major increase in 
NOD peritoneal B1a cell numbers and not in B1a cell death. This result points once again to 
the intricate function that p58 may have on the physiology of B1a cells. At the same time, 
IgM surface expression on peritoneal B1a cells was greatly decreased upon NIM-R7 
treatment, an observation that suggests that p58 targeting induces maturation towards a 
plasma cell-like, secretory phenotype (Oracki, Walker, Hibbs, Corcoran, & Tarlinton, 2010). 
Further work, for example in vitro, is necessary to confirm if p58 treatment in vivo stimulates 
plasma cell differentiation. Still, these observations suggest that p58 expression could have 
an inhibitory function on NOD B1a cells proliferation and plasma cell differentiation, which 
would be abrogated upon its specific triggering with NIM-R7.  
Phenotypic alterations in NOD B1a cells have been observed and correlated with T1D 
progression, and we have suggested that NOD B1a cells could be contributing to T1D 
pathogenesis through the secretion of beta cell reactive autoantibodies (Côrte-Real et al., 
2009; article III). Here, despite the fact that we did not observe an increase in serum anti-
insulin IgM levels, the total IgM titers in the NIM-R7 IP injected NOD group were augmented, 
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strengthening the hypothesis that targeting p58 in vivo favors the differentiation of B1a cells 
into antibody secreting cells. Furthermore, NIM-R7 administration to NOD females resulted in 
an earlier onset of T1D. Thus, alterations induced in B1a cells correlate with increased IgM 
levels in the serum and acceleration of diabetes, supporting the possibility of a causal 
relationship between B1a cells-originated IgM and diabetogenesis. 
Unfortunately, this treatment in vivo impacts on the p58 cell surface marker whose function is 
still unknown, and so the observed effects may or may not be subsequent to the specific 
alterations observed in the B1a cell subset. Clarification of these aspects warrants further 
investigation on p58 identity and function. 
Nevertheless, these results allow the proposal that p58 down-modulation observed in the 
NOD peritoneal B1a cells compartment could contribute to its described lower threshold of 
innate activation (article III) and could consequently have implications for T1D progression. 
In summary, while further studies are needed to establish the cellular and molecular 
mechanisms underlying diabetes hastening by p58 targeting, we here show that p58 is a 
generalized mouse peritoneal cavity B1a cell surface marker which is down-modulated in the 
NOD B1a cell compartment and that alterations induced in the NOD peritoneal cavity 
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Chapter VIII. General Discussion 
 
1. Irf4 controls serum IgM concentration at the level of antibody secreting cells 
differentiation 
 
In article I published in the context of this PhD thesis we were interested in identifying 
unknown genetic factors controlling the homeostatic levels of IgM secretion and upholding in 
the mouse. We have identified a region on mouse chromosome 13 that contained a locus 
(loci) controlling IgM serum levels. Interestingly, this genomic region, which was designated 
as IgMSC1 (IgM secreting cells locus 1), encompassed the Irf4 gene, a known key player in 
the plasma cell differentiation pathway. Consistently, we detected higher levels of Irf4 
expression in the peritoneal cavity and splenic B cell populations in the BALB/c strain, which 
also showed greater serum levels of IgM and higher numbers of IgM secreting B cells in both 
locations, when compared to the C57BL/6 strain.  
Our study was done in the absence of immunization, so we hypothesized that the serum IgM 
and IgM secreting cells that we were detecting originated mostly from the spontaneous 
secreting B1a cell subpopulation in both the peritoneal cavity and spleen. In fact, we have 
later confirmed that a higher proportion of peritoneal cavity B1a cells spontaneously secreted 
IgM in the BALB/c (Figure VIII.1a). The IgM secreting capacity of the purified peritoneal 
cavity B2+B1b cell pool was not different between C57BL/6 and BALB/c (data not shown). 
Notably, Irf4 expression was also higher in purified peritoneal B1a cells of the BALB/c in 
comparison to the C57BL/6 (Figure VIII.1b). These data strongly suggest that a naturally 
higher expression of Irf4 in BALB/c peritoneal cavity B1a cells contributes to an increased 
capacity to secrete IgM that is collected in the serum, determining the observed increase in 
the circulating levels of natural IgM in this strain.  
Nevertheless, we cannot exclude that splenic marginal zone B cells, as well as activated 
follicular B cells, are also contributing to the observed phenotypes. To test whether the 
contribution of Irf4 to natural antibody concentration in the serum comes mostly from the 
control of B1a cells spontaneous IgM secretion, we would have to assess and compare the 
spontaneous IgM secretory capacities of purified B cell subpopulations in the spleen of 
C57BL/6 and BALB/c, as well as their correlations to Irf4 expression levels in the same cell 
subsets. Further, we would have to confirm if the pattern of IgM secretion and Irf4 expression 
in splenic B1a cells is the same as the one observed in peritoneal cavity B1a cells. Genetic 
confirmation that Irf4 is a main contributor to the control of serum IgM levels in naïve mice 
would require the construction of C57BL/6 and BALB/c congenic strains, reciprocal for the 





Figure VIII.1 Higher proportions of IgM secreting B1a cells in the BALB/c peritoneal 
cavity correlate with greater expression of Irf4 
The proportion of peritoneal cavity B1a cells spontaneously secreting IgM was determined by 
ELISPOT Assay (a) and the expression of Irf4 was measured by Taqman Gene Expression Assay in 
the same cell subset (b). Peritoneal cavity B1a cells were purified from groups of 5 mice with 8 weeks 
of age. In (a) the bars represent the average results of triplicates with the respective standard 
deviation (SD). In (b) the relative quantification of Irf4 was obtained in triplicates, after normalization to 
GAPDH expression, and the SD from a pool of two identical experiments is depicted.  Mean fold-
differences to the C57BL/6 are shown. Significant differences between strains were found (p0.01) 
with unpaired t-student test. Data are representative of two independent experiments. 
 
 
IRF4, BLIMP1 and XBP1 are accepted to be the main transcription factors responsible for 
plasma cell differentiation and antibody secretion upon B cell stimulation (Figure I.1). 
However, the control mechanism of natural IgM secretion by B1a cells, in the absence of 
immunization, is still contradictory and not completely understood. In the absence of external 
stimuli, Irf4 upregulation in mice that lack Mitf activity results in the differentiation of B cells 
into plasma cells and in the production of IgM, but not IgG (L. Lin et al., 2004). Further, 
although having a normal development of peritoneal B1a cells, Irf4-/- mice have a 99% 
reduction in circulating IgM (Mittrücker et al., 1997) and a recent study has shown that Irf4 
controls the amount of IgM secreted by individual splenic B1a cells, while the individual low 
IgM secretion capacity of peritoneal cavity B1a cells remains unaltered in Irf4-/- mice 
(Holodick et al., 2010). These results indicate that accumulation of serum immunoglobulin M 
on wild type mice depends mostly on Irf4 dependent high secretion by splenic B1a cells and 
less on the low secreting homologous population in the peritoneal cavity. However, and 
although we have purified B cells as a bulk in both the peritoneal cavity and spleen, our 
results in C57BL/6 and BALB/c wild type mice point to a much higher percentage of naturally 
secreting IgM secreting cells within the peritoneal cavity. 
A few years ago, the studies from the Rothstein laboratory have reported undetectable 
expression levels of Prdm1 (the gene encoding BLIMP1), as well as Xbp1, in spontaneous 
secreting peritoneal cavity B1a cells, suggesting at that time that this subpopulation could 
use a non-classical pathway to produce immunoglobulins (Tumang, Francés, Yeo, & 
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Rothstein, 2005). In contrast, more recent studies from both the Calame (Savitsky & Calame, 
2006) and the Tarlinton groups (Fairfax et al., 2007) have demonstrated that, even if 
expressed at lower levels when compared with LPS stimulated conventional B2 cells, B1a 
cells require BLIMP1 in order to fully develop into antibody secreting plasma cells and to 
secrete IgM at normal levels. Furthermore, Rag2-/- blastocysts (which give rise to mice 
lacking endogenous B cells, serum Ig and T cells) when reconstituted with Xbp1-/- embryonic 
stem cells gave origin to mice with normal B (including peritoneal cavity B1a) and T cell 
subsets, yet with minimal immunoglobulin production of any isotype (Reimold et al., 2001). 
Thus, the prevailing hypothesis is that spontaneously IgM secreting B1a cells use the same 
regulatory mechanisms for immunoglobulin secretion as plasma cells resulting from the 
mitogen stimulation of B2 cells, but as B1a cells secrete less immunoglobulin per cell, they 
may require lower amounts of Prmd1 and Xbp1 mRNA and protein (Savitsky & Calame, 
2006). 
Importantly, the Nutt group has proven that when Rag1-/- mice (which are also deficient in 
endogenous B cells, T cells and serum Ig) were reconstituted with fetal liver cells mutant for 
the Prdm1 gene, they lacked a defined plasma cell compartment, yet showed low but 
detectable amounts of all immunoglobulin isotypes (0.1%–10% compared to wild type 
controls), demonstrating the existence of a BLIMP1 independent initial stage of antibody 
secretion. Notably, upon stimulation, Xbp1 was detected and Pax5 downregulated, but Irf4 
expression levels did not increase on BLIMP1 mutant B cells, suggesting that the early steps 
of antibody secreting cell differentiation may occur independently of BLIMP1 and IRF4 
(Kallies et al., 2007). These findings are consistent with the observation that low levels of IgM 
secretion by B1a cells in both the peritoneal cavity and spleen can be maintained in the 
absence of Irf4 in the Irf4-/- mouse (Holodick et al., 2010). Thus, in wild type mice, the 
upregulation of Irf4 can initiate the classical cascade of plasma cell differentiation (Figure I.1) 
and allow antibody secreting cells to use their full potential to produce immunoglobulins.  
It is well established that by repressing Bcl6 and Pax5, the expression of Irf4 and Prdm1 
ensures that after plasma cell development is induced, B cells cannot return to an earlier 
developmental stage. However, the terminally differentiated state of plasma cells may be 
reversed under special conditions, as when BCL6 is expressed by plasmacytomas that 
consequently lose their immunoglobulin secretion capacities (Fujita et al., 2004). Although 
sharing the capacity of antibody secretion, B1a cells have particular properties, as the one of 
self-renewal (Förster & Rajewsky, 1987), that clearly distinguish them from classical plasma 
cells. Thus, it is possible that in B1a cells the combination of low expression levels of 
transcription factors, that are essential for immunoglobulin secretion, keep these cells in an 
intermediate stage of a continuum differentiation program that leads to terminal plasma cell 
differentiation in classically stimulated B2 cells. Additionally, it is possible that in B1a cells 
further differentiation to a terminal plasma cell state is blocked through yet unknown 
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mechanisms. Our results clearly suggest that, in natural conditions, higher expression levels 
of Irf4 imbalances the B1a cell compartment to a more efficient secretory function.  
 
 
2. NOD mice have increased levels of natural autoantibodies with the potential to 
induce pancreatic beta-cell damage  
 
Natural antibodies are mostly produced by B1a cells, which link the innate and the adaptive 
immune system, and are also involved in several autoimmune processes, including type 1 
diabetes (Gyarmati et al., 1999; Kendall, Woodward, Hulbert, & Thomas, 2004; Ryan et al., 
2010). In fact, natural IgM plays a relevant role as immune protector, scavenger of apoptotic 
cells/debris and preventer of autoimmunity (Ehrenstein et al., 1998). Furthermore, germline 
encoded IgM of B1a cell origin has been shown to bind to human carcinoma cells and to 
directly control their proliferation through the induction of apoptosis, playing a crucial part in 
immunosurveillance against malignant cells (Brändlein et al., 2003). Thus, it is also 
reasonable to predict that the coupling of autoreactive IgM to self-antigens could provide a 
mechanism in the induction of target cell killing. Moreover, in an autoimmune context, IgM 
binding could result in the activation of the complement cascade contributing to an 
autoantigen-driven destructive response (Brown et al., 2002; Fearon & Locksley, 1996; Klaus 
et al., 1980; Pepys, 1972). 
In article II of this thesis, we firstly set-out the hypothesis that in the framework of type 1 
diabetes, natural IgM could serve as an autoimmunity trigger of beta cell injury. In fact, it has 
been reported that NOD mice pancreatic beta-cells have IgM bound to their surface prior to 
the appearance of insulitis (Shieh et al., 1993). Further, in article III, we have clearly 
demonstrated that young NOD mice have higher serum levels of IgM with insulin reactivity 
when compared to C57BL/6.  Significantly, stable titres of anti-insulin-IgM are maintained in 
time, and do not increase even in pre-diabetic NOD mice, where the destructive anti-beta cell 
autoimmune process is already ongoing. In addition, the analysis of MHC congenic strains 
(Wicker et al., 1992) showed that IgM reactivity observed in the NOD is independent of T cell 
help and disease progression. These findings are consistent with the hypothesis proposed 
on article II that increased autoreactivity in the NOD natural antibody compartment is set 
prior to pancreatic autoimmunity onset, and could contribute to the initiation of autoimmunity.  
An increased concentration of circulating serum IgM with the ability to recognize pancreatic 
islet antigens could determine their direct binding on beta cells. This could directly mediate 
cell damage or trigger the activation of the complement system and the establishment of a 
beta cell-directed adaptive immune response, contributing to enhanced immuno-
deregulations in the NOD mouse and to the development of T1D. Furthermore, IgM–
autoantigen interaction with Fcα/μ receptors on macrophages and B cells could determine a 
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more efficient autoantigen presentation capacity to autoreactive T cells or have an autocrine 
effect on beta cell reactive B cell populations, facilitating the autoimmunity process (Côrte-
Real, Duarte, Tavares, & Penha-Gonçalves, 2009).  
Importantly, in the work presented in article III of this thesis, we were able to demonstrate in 
vitro that the binding of natural IgM per se induces oxidative stress on pancreatic beta cells, 
as measured by the upregulation of iNOS expression. This indicates that autoreactive IgM 
has a role in promoting beta cell damage and is possibly contributing to T1D initiation. 
Further investigation is required to understand whether the early presence of beta cell 
reactive natural IgM has additional implications for the diabetogenic process occurring in the 
NOD. 
Interestingly, as also shown in article III, the patterns observed for natural antibody and IgG 
autoreactivity in the NOD serum were not identical.  While NOD anti-insulin IgM remained 
constant in time, the concentration of IgG with the same specificity clearly followed the 
progression of disease. Significantly, and contradicting the established notion that elevated 
beta cell reactive IgG is merely a by-product of the T cell mediated destruction of beta cells, 
a recent study from the Vinuesa laboratory has shown that anti-islet immunoglobulins of the 
IgG isotype can enhance the expansion of islet-reactive CD4+ T cells in an Fc-Receptor 
(FcR)-mediated manner, and cooperate with inherited defects in thymic and peripheral CD4+ 
T cell tolerance, contributing to type 1 diabetes progression (Silva et al., 2011). These 
authors studied TCR+HEL+ transgenic mice carrying a point mutation in the Roquin gene 
(Roquinsan). The mutated Roquin gene exacerbates the expression of the inducible T-cell 
costimulator (ICOS) on follicular helper T (TFh) cells, with profound effects on cell function 
and immune tolerance. Consequently, Roquinsan/san mice spontaneously develop germinal 
center reactions, IgG autoantibodies and systemic autoimmunity (D. Yu et al., 2007; 
Linterman et al. 2009; Vinuesa et al., 2005). TCR+HEL+ transgenic mice have an increased 
frequency of islet-reactive CD4+ T cells. The HEL transgene encodes HEL under the insulin 
gene promoter, and mirrors the pattern of insulin expression, with high expression in islet 
beta cells and Aire dependent expression in thymic medullary epithelial cells (Akkaraju et al., 
1997; Liston et al., 2004). The T cell receptor (TCR) transgene encodes a TCR which 
recognizes a dominant HEL peptide presented by MHC-II (Ho, Cooke, Goodnow, & Davis, 
1994). Nevertheless, the presence of immune tolerance mechanisms in the T cell 
compartment prevents type 1 diabetes development in 80% of TCR+HEL+ transgenic animals 
in a non-diabetic background (Akkaraju et al., 1997; Lesage et al., 2002; Silva et al., 2011). 
On the other hand, the Roquinsan mutation dramatically increases the progression to T1D in 
TCR+HEL+ mice, such that 100% develop diabetes by 8 weeks of age (Silva et al., 2011). 
These authors have clearly shown that the autoreactive B cells present in 
Roquinsan/sanTCR+HEL+ mice have a role in T1D progression by secreting high titers of anti-
HEL IgG autoantibodies. In this system, anti-HEL IgG enhances the antigen presenting 
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capacity of FcR expressing cells, mediating the activation of islet-reactive CD4+ T cells. 
Importantly, the presence of anti-HEL IgG antibodies in HEL+ single transgenic mice was 
insufficient to precipitate diabetes, arguing against a direct antibody-mediated destruction of 
beta cells (Silva et al., 2011).  
A role for autoreactive IgG in type 1 diabetes development has previously been proposed in 
studies of NOD mouse embryos implanted in non-diabetic surrogate mothers (Greeley et al., 
2002; Kagohashi et al., 2005). Despite that the incidence of diabetes was reduced in NOD 
mice born from non-diabetic prone mothers, it was never clarified if the observed maternal 
effects reflected the absence of transmission of anti-islet autoantibodies or other factors, 
such as an altered colonization of the offspring by microbial commensals, which is known to 
influence T1D incidence in NOD mice (Wen et al., 2008). The Vinuesa laboratory has 
complemented these findings by demonstrating that spontaneously produced, maternally 
transmitted or passively transferred anti-islet IgG autoantibodies can overcome thymic and 
peripheral tolerance mechanisms in the TCR+HEL+ transgenic mouse model and trigger 
CD4+ T cell mediated autoimmune diabetes in an FcR-dependent manner (Silva et al., 
2011). Further evidence supporting that this mechanism mediates a pathogenic role for 
autoantibodies comes from a report where NOD mice lacking FcR were shown to be 
protected from diabetes (Inoue et al., 2007). Also, passive transfer of rabbit or mouse IgG 
against islet-expressed ovalbumin (OVA) was shown to enhance activation of transferred 
naïve OVA specific CD8+ T cells, break tolerance and promote T1D in RIP-mOVA mice, 
which express OVA as a self-antigen in the thymus and in pancreatic beta cells. The transfer 
of anti-OVA IgG alone, to the same mouse recipients, had no effect on beta cells physiology 
(Harbers et al., 2007).  
Although the presence of anti-islet autoantibodies is the best current predictor of human T1D, 
the role of B cells and autoantibodies in still poorly understood in diabetic people (Achenbach 
et al., 2004; L. Yu et al., 2000; Naserke, Bonifacio, & Ziegler, 2001; Reijonen, Daniels, 
Lernmark, & Nepom, 2000; Ziegler, Hummel, Schenker, & Bonifacio, 1999). Observational 
studies of subjects with either mothers or fathers with type 1 diabetes have revealed 
paradoxical protection associated with transmission of anti-islet autoantibodies (Harjutsalo, 
Reunanen, & Tuomilehto, 2006; Koczwara, Bonifacio, & Ziegler, 2004; Pociot, Nørgaard, 
Hobolth, Andersen, & Nerup, 1993; Warram, Krolewski, Gottlieb, & Kahn, 1984). These 
maternal effects in humans are still largely unexplored. Importantly, as well as the human 
population, the pathogenesis of human type 1 diabetes is likely to be heterogeneous, hence 
it is conceivable that the diabetes-promoting role of B cells and anti-islet antibodies may not 
be uniform nor easy to untangle.  
The extraordinarily divergent paths of serum anti-insulin IgG and IgM isotypes that we have 
described for the NOD mouse (article III), an inbred mouse model of type 1 diabetes, 
highlight the different roles that these antibodies may play in the autoimmune response. 
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Therefore, diverging from what has been generally accepted, enough evidence exists that 
autoreactive antibodies of both the IgM and IgG isotypes have a part in the initiation and 
maintenance of the diabetic autoimmune process. 
 
 
3. NOD B1a cells secrete beta cell reactive natural autoantibodies, fueling the 
autoimmune process in type 1 diabetes 
 
B1a cells develop through a process of positive selection based on the BCR reactivity and 
are the predominant natural IgM secretors. Thus, membrane bound and secreted IgM of B1a 
cell origin are naturally autoreactive (Casali & Notkins, 1989; Hardy et al., 1994; Kantor & 
Herzenberg, 1993). In healthy individuals, strict regulation of B1a cells immunoglobulin 
secretion assures that this autoimmune predisposition is restrained, nevertheless B1a cells 
have been involved in autoimmune conditions like type 1 diabetes (Kendall, Woodward, 
Hulbert, & Thomas, 2004; Ryan et al., 2010).  
Importantly, in the work published in articles II and III, we provide the first evidence that when 
insulitis is still incipient, NOD B1a cells spontaneously secrete IgM whose specificities 
contributes to the increased pattern of antibody autoreactivity observed in the serum of this 
strain, in comparison to non-autoimmune controls. Moreover, our early characterization of 
the B1a cell compartment in the NOD and C57BL/6 strains revealed that peritoneal cavity 
B1a cells in the NOD are naturally more activated and have a diminished threshold for 
innate-like stimulation, compared to its homolog population in the non-diabetic-prone strain. 
In fact, in resting conditions, NOD peritoneal cavity B1a cells have a profile of B220, CD43, 
CD62L and CD86 expression that is associated with an increased activation status (Casola 
et al., 2004; Jellusova et al., 2010). In addition, NOD peritoneal cavity B1a cells had naturally 
higher levels of TLR2, TLR4, TLR6, TLR7 and TLR9 expression and responded to TLR 
stimulation with increased proliferation, augmented secretion of IgM with reactivity against 
type 1 diabetes autoantigens and lower production of IL10, when compared to C57BL/6 B1a 
cells. Intriguingly, equivalent amounts of total IgM were secreted upon TLR stimulation of 
either C57BL/6 or NOD B1a cells. Therefore, the NOD B1a cell population must be enriched 
for autoreactive cells with increased responsiveness and propensity for plasma cell 
differentiation upon innate-like stimulation (Figure VIII.2).  Accordingly, in resting conditions 
NOD mice have more B1a cells in the peritoneal cavity that secrete IgM towards T1D 






Figure VIII.2 Autoreactive NOD B1a cells have a lower threshold for innate like 
stimulation 
 
Representative image of peritoneal cavity B1a cells IgM secretion patttern in non-diabetic prone mice 
in comparison to the NOD strain. Autoreactive NOD B1a cells naturally express higher levels of TLR4 
and TLR9 and respond to LPS and CpG stimulation with an increased capacity to secrete natural 
autoreactive IgM. Induction (); Inhibition: (    ). 
 
 
Alterations in microflora have been shown to condition some of the surface B1a cell traits 
(Alam et al., 2011; Alam, Valkonen, Palagani, et al., 2010) and type 1 diabetes progression 
in the NOD mouse (Alam et al., 2011; Kriegel et al., 2011). Nevertheless, further 
investigation is required to understand whether endogenous TLR ligands or the external 
stimulation of TLR, provided for example by microbial alterations in the intestine, is essential 
for the establishment and maintenance of the secretory properties of NOD peritoneal cavity 
B1a cells and for the shaping of the serum IgM autoreactive repertoire. 
It has also been established, in the article III of this thesis, that natural IgM derived from NOD 
B1a cell is able to bind to pancreatic beta cells and trigger the beta cell oxidative stress 
response in vitro. Together, the results discussed in articles II and III provide supporting 
evidence to propose that from early ages, the repertoire of natural antibodies spontaneously 
secreted by NOD peritoneal cavity B1a cells is skewed towards endocrine auto-reactivity and 





4. Peritoneal cavity NOD B1a cells triggering precipitates T1D in the NOD mouse 
 
It is now clear that peritoneal cavity NOD B1a cells are altered in comparison to non-diabetic 
mice with potential implications for the diabetogenic process. Consistently, in article IV, we 
demonstrate that p58 surface glycoprotein expression, which has been correlated to the 
natural activated state of this subpopulation (Manjarrez-Orduño, Parkhouse, & Santos-
Argumedo, 2003), is lower in the NOD peritoneal cavity B1a cell compartment when 
compared to C57BL/6 and BALB/c non-diabetic prone strains. Moreover, p58 specific 
targeting in NOD mice in vivo induces the down-modulation of IgM on peritoneal cavity B1a 
cells and the proliferation of this cell subset. Consistently with a more efficient differentiation 
to a plasma cell-like phenotype, p58 targeted NOD mice have an increased concentration of 
circulating IgM, and most relevantly, these features correlate with an earlier onset of diabetes 
in this strain.  
The identity and function of p58 and its implications for B1a cells physiology in health and 
autoimmunity are still unknown and require further investigation. Nevertheless, the results of 
article IV suggest that lower expression levels of p58 on NOD B1a cells contribute to a less 
efficient regulation of this cell compartment, and that p58 targeting promotes the proliferation 
of NOD B1a cells and their differentiation to IgM secreting plasma cells, accelerating the 
onset of type 1 diabetes in the NOD. These results reinforce the initial hypothesis that 
peritoneal cavity B1a cells have an initial role on the autoimmune diabetogenesis process. 
Anti-CD20 and anti-CD22 monoclonal antibody (mAb) therapy, which specifically deplete the 
B cell compartment in treated animals, have shown significant promise in disease prevention 
and reversal in young NOD mice (Fiorina et al., 2008; Hu et al., 2007; Xiu et al., 2008). 
Furthermore, the construction of transgenic NOD mice in which B cells express human CD20 
(hCD20/NOD mice) has allowed the analysis of the therapeutic effects of B cell depletion 
using the murine anti-CD20 monoclonal antibody (2H7), which targets the same epitope as 
rituximab, the only B cell targeted drug approved for use in humans (Bour-Jordan & 
Bluestone, 2007; Hu et al., 2007). The first B cell depleting trials with rituximab in type 1 
diabetes patients have reported responsiveness to therapy, broadly comparable with anti-
CD3 monoclonal antibody treatment, highlighting an important role for B cells or antibodies in 
type 1 diabetes in humans (Pescovitz et al., 2009). Rituximab is highly effective in depleting 
recirculating and memory B cells and causes a rapid decrease in autoantibodies in a number 
of autoimmune diseases such as RA and SLE (Leandro & de la Torre, 2009). However, the 
effect of Rituximab on anti-islet antibodies has not yet been described in T1D patients 
(Pescovitz et al., 2009). 
The B cell-activating factor (BAFF, BLyS) is a critical survival promoting factor for which 
peripheral B cells compete (Lesley et al., 2004; Thien et al., 2004). Consistently with the anti-
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CD20 results, long-term anti-BLyS mAb therapy in NOD mice resulted in selective depletion 
of marginal zone and follicular B cells, correlating with a significant delay in autoimmune 
diabetes onset, and reduced anti-insulin IgG titers (Zekavat et al., 2008). Thus, anti-BLyS 
mAb therapy could be an alternative promising approach for the treatment of T1D in 
susceptible individuals.  
It has been previously shown that BCL1 cells are effectively killed upon treatment with NIM-
R7 conjugated to ricin-A, while no effect is observed in FO B cells or T cells (Manjarrez-
Orduño et al., 2003). As shown in article IV BCL1 cells have a B1a like phenotype and p58 is 
constitutively expressed on NOD peritoneal B1a cells. Thus, our initial expectation was that 
in vivo NIM-R7 intra-peritoneal treatment would deplete NOD peritoneal cavity B1a cells. The 
induction of B1a cell proliferation, plasma cell differentiation and T1D precipitation has 
allowed us to infer the importance of peritoneal B1a cells in type 1 diabetes development. 
Nevertheless, future studies aiming to specifically deplete this cell subset would allow us to 
verify if T1D development in the NOD mouse would be prevented in the absence of B1a 

















Chapter IX. General Conclusion and Future Perspectives 
 
The studies presented in this thesis provide evidence that: 
- Natural IgM secretion in the mouse is regulated by the transcription factor Irf4 which, in 
natural conditions, controls the number of spontaneous antibody secreting cells both in the 
peritoneal cavity and in the spleen; 
- Peritoneal cavity B1a cells of the NOD mouse naturally secrete IgM with high reactivity 
towards pancreatic beta cells, which are able to bind to their target autoantigens and induce 
beta cell oxidative stress; 
- The peritoneal cavity B1a cell compartment in the NOD mouse is enriched for autoreactive 
cells which are remarkably activated in resting conditions and respond vigorously to innate-
like stimulation; 
-  The induction of proliferation and antibody secretion specifically on peritoneal cavity NOD 
B1a cells anticipates the onset of type 1 diabetes. 
In conclusion, this thesis has contributed to the study of genetic factors controlling natural 
IgM secretion and to the elucidation of the early pathogenic steps of type 1 diabetes. 
Essentially, these studies have established that alterations in the NOD peritoneal cavity B1a 
cell subset are responsible for the existence of an autoreactive repertoire of serum IgM, 
which can induce beta cell oxidative stress, strongly suggesting that natural autoantibodies 
are an early factor in type 1 diabetes pathogenesis evolving in the NOD mouse. 
The work here detailed has shed light on the mysterious field of B1a cells physiology in 
health and disease. Nevertheless, some questions remain unanswered and require further 
investigation: (1) The study of Irf4 expression and spontaneous IgM secretion on the splenic 
B1a cell compartment, the construction of C57BL/6 and BALB/c congenic strains, reciprocal 
for the Irf4 locus, as well as knocking-in the BALB/c Irf4 allele into the C57BL/6 genetic 
background, will allow us to better understand the role of Irf4 in the control of serum IgM 
levels in naïve mice. (2) The several pathways by which anti-pancreatic beta cell IgM could 
determine the initiation of T1D remain largely unexplored.  It will be important to understand if 
the induction of oxidative stress responses on beta cells, upon IgM binding, has 
consequences on beta cell viability in the NOD mouse. The role of NOD natural IgM on the 
activation of the complement system and on the enhancement of the autoantigen 
presentation capacity to autoreactive T cells needs further clarification. Likewise, the 
potential autocrine effect of natural IgM autoantibodies on NOD beta cell reactive B cell 
populations remains to be established. (3) Further studies will help to understand whether 
endogenous or exogenous TLR ligands contribute to the establishment and maintenance of 
the secretory properties of NOD peritoneal cavity B1a cells, and for the shaping of the serum 
IgM autoreactive repertoire. (4) The identification of p58 as well as in vitro targeting of p58 on 
purified peritoneal cavity B1a cells will allow us to better comprehend the function of this 
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glycoprotein and its implication on B1a cells physiology. (5) Although complex, future work 
aiming to specifically reconstitute B1a cell populations in NOD.Igµ.null mice and to 
specifically deplete the B1a cell subset in NOD mice will allow us to verify the requirement of 
B1a cells and natural IgM in T1D development.  
The demonstration of a role for B1a cells, and natural autoantibodies, in the development of 
type 1 diabetes may contribute to the development of strategies that block disease 
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